{"Title": ["Alexion: Subcutaneous ULTOMIRIS Shows PK-based Non-inferiority In Phase 3 Study", "Alexion Pharma To Present At Bank Of America Virtual Conference; Webcast At 2:00 PM ET", "Alexion Pharma To Present At BofA Virtual Napa Biotech Conference; Webcast At 2:00 PM ET", "Got $2,000? Smart Investors Are Buying These Stocks Hand Over Fist.", "These 3 Value Stocks Are Absurdly Cheap Right Now", "Got $1,000? These Value Stocks Are Begging to Be Bought.", "BBH's Underlying Holdings Could Mean 11% Gain Potential", "Tuesday Sector Laggards: Healthcare, Technology & Communications", "Alexion: Subcutaneous ULTOMIRIS Shows PK-based Non-inferiority In Phase 3 Study", "BUZZ-U.S. STOCKS ON THE MOVE-Virgin Galactic, Baozun, HollyFrontier", "3 Top Stocks That Will Make You Richer in June (and Beyond)", "Thursday Sector Leaders: Utilities, Healthcare", "Nasdaq Today: Why Alexion and Workday Stock Are Soaring", "BUZZ-U.S. STOCKS ON THE MOVE-ARCA Biopharma, Aerpio Pharma, Triumph Group", "Notable Thursday Option Activity: KHC, ALXN, FDX", "BUZZ-U.S. STOCKS ON THE MOVE-Blue Hat, ARCA Biopharma, Aerpio Pharma", "BUZZ-U.S. STOCKS ON THE MOVE-Raytheon, Planet Fitness, Lands End", "Stock Alert: Alexion Pharma Up 7%", "Here's Why argenx Stock Is Soaring Today", "IBB, ILMN, SGEN, ALXN: ETF Inflow Alert", "Is Arrowhead Pharmaceuticals a Buy?", "BUZZ-U.S. STOCKS ON THE MOVE-L Brands, Akorn, Aurora Cannabis", "BUZZ-U.S. STOCKS ON THE MOVE-Akorn, L Brands, Aurora Cannabis", "3 Healthcare Stocks With Sustainable Competitive Advantages", "S&P 500 Movers: HPQ, DLTR", "Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be", "Notable ETF Outflow Detected - IBB, ILMN, ALXN, INCY", "BUZZ-U.S. STOCKS ON THE MOVE-Helius Medical, Datadog, Novavax", "ALXN Makes Bullish Cross Above Critical Moving Average", "BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Novavax, Cymabay Therapeutics", "Activist investor Elliott pushes Alexion Pharma to sell itself", "Elliott again pushes Alexion Pharma to explore a sale", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 5/17/2020", "Analysts Anticipate IYH Will Reach $237", "Alexion Pharmaceuticals Inc (ALXN) Q1 2020 Earnings Call Transcript", "Alexion Pharmaceuticals Beats Earnings Estimates but Cuts Guidance", "Alexion Pharma Updates 2020 Financial Guidance - Quick Facts", "Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates", "BUZZ-U.S. STOCKS ON THE MOVE-Oil and gas stocks, banks, Tesla, tankers", "Why Portola Pharmaceuticals Is Skyrocketing Today", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 5/8/2020", "Alexion Will Buy Portola Pharmaceuticals for $1.4 Billion", "Nasdaq 100 Movers: ALXN, SWKS", "Stock Alert: Alexion Pharma Loses 5% After Portola Acquisition News", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "Alexion diversifies treatment portfolio with $1.41 bln Portola deal", "Alexion Pharma To Acquire Portola - Quick Facts", "Alexion to buy Portola Pharmaceuticals in $1.41 bln deal", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals", "Alexion Pharma: CHMP Adopts Positive Opinion For ULTOMIRIS", "Noteworthy ETF Inflows: FTCS, NEM, TTWO, ALXN", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "Have $300? Then Open a Position in These Top Stocks", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "Alexion Pharmaceuticals to Initiate Phase 3 Study for Ultomiris as a Potential Coronavirus Treatment", "Alexion to buy Portola Pharmaceuticals in $1.41 bln deal", "BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma", "BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group", "Alexion Pharmaceuticals (ALXN) Shares Cross Above 200 DMA", "Nasdaq 100 Movers: WDC, NFLX", "Alexion to study rare blood-disorder drug in severe COVID-19 patients", "Alexion to study rare blood-disorder drug in severe COVID-19 patients", "Alexion Pharma To Launch Clinical Trial To Evaluate ULTOMIRIS - Quick Facts", "Monday Sector Leaders: Healthcare, Technology & Communications", "Validea's Top Five Healthcare Stocks Based On David Dreman - 4/19/2020", "2 Top Small-Cap Stocks to Buy Right Now", "3 Value Stocks to Buy With Your $1,200 Stimulus Check That Can Make You Rich", "Is Alexion Pharmaceuticals a Buy?", "Thursday Sector Laggards: Energy, Healthcare", "Thursday's ETF Movers: REM, FBT", "Analysts Anticipate 24% Gains Ahead For The Holdings of BBH", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 4/19/2020", "Validea's Top Five Healthcare Stocks Based On David Dreman - 4/19/2020", "Should You Buy These 3 Dirt-Cheap Stocks?", "5 Healthcare Stocks That Haven't Been This Cheap in at Least 10 Years", "Coronavirus Stock Market Crash: 3 Stocks You Need to Own", "3 No-Brainer Coronavirus Bear Market Buys", "Nasdaq 100 Movers: UAL, NTAP", "Have $1,000? Then Buy These Top Stocks Right Now", "Interesting ALXN Put And Call Options For November 20th", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 3/15/2020", "First Week of ALXN May 1st Options Trading", "Health Care Sector Update for 03/06/2020: STIM, OPK, ALXN, JNJ, PFE, ABT, MRK, AMGN", "The Implied Analyst 12-Month Target For SPHB", "Alexion Pharma To Present At Cowen Health Care Conference; Webcast At 9:20 AM ET", "S&P 500 Analyst Moves: ALXN", "First Week of ALXN April 17th Options Trading", "Validea's Top Five Healthcare Stocks Based On David Dreman - 3/15/2020", "Validea's Top Five Healthcare Stocks Based On David Dreman - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On John Neff - 2/16/2020", "Validea Peter Lynch Strategy Daily Upgrade Report - 2/11/2020", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/6/2020", "Is Apellis Pharmaceuticals a Buy?", "Add Up The Pieces: IUS Could Be Worth $30", "Relative Strength Alert For Alexion Pharmaceuticals", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 2/16/2020", "Alexion Pharmaceuticals Inc (ALXN) Q4 2019 Earnings Call Transcript", "3 Top Biotech Stocks to Buy Right Now", "Alexion Pharmaceuticals Guides FY20 Below Analysts' Estimates - Quick Facts", "Alexion Pharmaceuticals Inc. Q4 adjusted earnings Beat Estimates", "Alexion Pharmaceuticals Q4 19 Earnings Conference Call At 7:30 AM ET", "5 'Strong Buy' Biotech Stocks to Buy for 2020", "Health Care Sector Update for 01/27/2020: INO, ALXN, ACHN, RDY, JNJ, PFE, ABT, MRK, AMGN", "Noteworthy Thursday Option Activity: ALXN, JPM, TPR", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 1/19/2020", "2 Biotechs Battling Immune Diseases", "3 Healthcare Stocks That Are Coming Back to Life", "Nasdaq 100 Movers: ALXN, AAL", "Alexion Pharma To Present At J.P Morgan Conference; Webcast At 10:30 AM ET", "11 S&P 500 Stocks That Could Soar 20% or More in 2020", "Why Has Vertex Pharmaceuticals' Stock Gained 30% In The Last Quarter?", "6 Industries That Are Historically Cheap, Even With the Stock Market at an All-Time High", "Noteworthy Tuesday Option Activity: ALXN, ANTM, QCOM", "Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study", "These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen", "4 No-Brainer Large-Cap Stocks to Own in 2020", "Look Under The Hood: PJP Has 11% Upside", "Interesting ALXN Put And Call Options For August 2020", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 12/27/2019", "Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today", "Here's Why Dicerna Pharmaceuticals Is Falling Today", "Nasdaq 100 Movers: ALXN, MYL", "Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 12/15/2019", "Are These Biotech Companies Buyout Candidates? Deal Or No Deal?", "Friday Sector Leaders: Energy, Healthcare", "Friday's ETF with Unusual Volume: IWY", "3 Biotech Stocks to Buy as the Sector Heats Up", "Thursday Sector Laggards: Energy, Healthcare", "Noteworthy Thursday Option Activity: HD, SHW, ALXN", "S&P 500 Movers: ALXN, TSCO", "Nasdaq 100 Movers: ALXN, DLTR", "How The Pieces Add Up: PJP Targets $70", "Noteworthy Monday Option Activity: ALXN, DPZ, LMT", "Billionaire Ray Dalio Snaps Up These 3 \u201cStrong Buy\u201d Stocks", "Alexion Rejects Elliott Recommendation - Quick Facts", "Thursday Sector Laggards: Energy, Healthcare", "Noteworthy Thursday Option Activity: HD, SHW, ALXN", "S&P 500 Movers: ALXN, TSCO", "Nasdaq 100 Movers: ALXN, DLTR", "How The Pieces Add Up: PJP Targets $70", "Noteworthy Monday Option Activity: ALXN, DPZ, LMT", "Billionaire Ray Dalio Snaps Up These 3 \u201cStrong Buy\u201d Stocks", "3 Healthcare Stocks With Heightened Expectations", "Health Care Sector Update for 10/23/2019: PDLI,ALXN,TMO,HEXO,HEXO.TO", "Noteworthy Wednesday Option Activity: ADI, MMM, ALXN", "Health Care Sector Update for 10/23/2019: ALXN,TMO,HEXO", "Alexion Pharmaceuticals Inc (ALXN) Q3 2019 Earnings Call Transcript", "Nasdaq 100 Movers: TXN, ALXN", "Alexion Pharmaceuticals Q3 19 Earnings Conference Call At 8:00 AM ET", "5 Top Healthcare ETFs", "3 Healthcare Stocks With Heightened Expectations", "First Week of December 20th Options Trading For Alexion Pharmaceuticals (ALXN)", "BridgeBio Calls Off Its Acquisition Offer for Eidos Therapeutics", "Why Achillion Pharmaceuticals, Tech Data, and First Majestic Silver Jumped Today", "Why Achillion Pharmaceuticals Stock Is Skyrocketing Today", "Alexion Pharma To Acquire Achillion Pharma For About $930 Mln Cash", "Monday Sector Leaders: Healthcare, Financial", "Alexion Pharma Raises 2019 Outlook", "Will The Pace of M&A Pick Up Following The Biotech Sector\u2019s Pounding?", "MITO Empowered, FPRX Cuts Another 70 Jobs, Second Death In Legionnaires Outbreak", "Here's Why Stealth BioTherapeutics Rocketed Higher Today", "Oversold Conditions For Alexion Pharmaceuticals (ALXN)", "Biotech Stocks Facing FDA Decision In October 2019", "November 8th Options Now Available For Alexion Pharmaceuticals (ALXN)", "Why Achillion Pharmaceuticals Stock Is Jumping Today", "Noteworthy Monday Option Activity: ALXN, CHRW, ALGN", "Thursday Sector Leaders: Healthcare, Utilities", "Nasdaq 100 Movers: ADBE, KLAC", "PBE, GILD, ALXN, INCY: Large Outflows Detected at ETF", "Interesting ALXN Put And Call Options For January 2022", "Nasdaq 100 Movers: MELI, ALXN", "Friday Sector Leaders: Services, Healthcare", "ALXN September 2020 Options Begin Trading", "First Week of ALXN May 2020 Options Trading", "October 11th Options Now Available For Alexion Pharmaceuticals (ALXN)", "Nasdaq 100 Movers: WYNN, LRCX", "Why American Outdoor Brands, Innovative Industrial Properties, and Alexion Pharmaceuticals Slumped Today", "Friday Sector Laggards: Services, Healthcare", "Notable Friday Option Activity: GS, COST, ALXN", "Nasdaq 100 Movers: ULTA, TSLA", "Nasdaq 100 Movers: ADSK, INCY", "Here's Why Alexion Pharmaceuticals Dropped 11% in August", "October 11th Options Now Available For Alexion Pharmaceuticals (ALXN)", "Nasdaq 100 Movers: ALXN, AMD", "Should Amgen Finally Buy Alexion Pharmaceuticals?", "3 Reasons Why Amgen Could Actually Acquire Alexion", "Health Care Sector Update for 08/23/2019: ALXN, SEEL, GSK, JNJ, PFE, ABT, MRK, AMGN", "ALXN & Takeover Rumors, AMGN's JASMINE Blooms, CLSD Sees The Writing On The Wall", "Interesting ALXN Put And Call Options For October 18th", "Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win", "Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals", "Momenta Continues Its Transition", "Notable Friday Option Activity: NTAP, IBM, ALXN", "We Did The Math SPHB Can Go To $49", "S&P 500 Analyst Moves: ALXN", "Alexion Gets Positive Opinion From CHMP For SOLIRIS For Treatment Of NMOSD", "Notable Thursday Option Activity: ALXN, UHS, VLO", "ALXN September 27th Options Begin Trading", "Alexion Pharmaceuticals Inc (ALXN) Q2 2019 Earnings Call Transcript", "Nasdaq 100 Movers: ALXN, TXN", "Alexion Boosts FY19 Outlook - Quick Facts", "Alexion Pharmaceuticals Inc. Q2 adjusted earnings Beat Estimates", "First Week of ALXN September 20th Options Trading", "3 Biotech Stocks That Could Double Your Money", "3 Top Biotech Stocks to Buy for the 2nd Half of 2019", "Alexion Pharmaceuticals Tops Expectations in Q2", "Interesting ALXN Put And Call Options For August 23rd", "How to Invest in Biotech Stocks", "3 Top Biotech Stocks to Add to Your Watchlist", "Look Under The Hood: MGC Has 10% Upside", "First Week of ALXN February 2020 Options Trading", "Noteworthy Thursday Option Activity: ALXN, CVS, XOM", "3 Cheap Drug Stocks You Can Buy Right Now", "Monday Sector Laggards: Healthcare, Technology & Communications", "Interesting ALXN Put And Call Options For August 23rd", "10 Stocks to Buy That Could Be Takeover Targets", "3 Drug Stocks That Could Win From Key FDA Approvals in June", "Alexion Pharmaceuticals Enters Oversold Territory (ALXN)", "11 Biotech Stocks to Put on Your Radar Soon", "First Week of July 19th Options Trading For Alexion Pharmaceuticals (ALXN)", "3 Big Biotech Stocks That Warren Buffett Might Like", "Thursday Sector Laggards: Healthcare, Utilities", "ALXN August 2nd Options Begin Trading", "3 Top Biotech Stocks to Buy Right Now", "Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big", "S&P 500 Analyst Moves: ALXN", "Alexion Pharmaceuticals Inc (ALXN) Q1 2019 Earnings Call Transcript", "Alexion Pharmaceuticals Fires on All Cylinders in Q1", "Alexion Pharma Raises 2018 Guidance; Q1 Profit Beats Estimates - Quick Facts", "Biotech Stocks Facing FDA Decision In June 2019", "ALXN Makes Notable Cross Below Critical Moving Average", "3 Top Biotech Stocks to Buy Right Now", "Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big", "S&P 500 Analyst Moves: ALXN", "Alexion Pharmaceuticals Inc (ALXN) Q1 2019 Earnings Call Transcript", "Alexion Pharmaceuticals Fires on All Cylinders in Q1", "Alexion Pharma Raises 2018 Guidance; Q1 Profit Beats Estimates - Quick Facts", "Biotech Stocks Facing FDA Decision In June 2019", "ALXN Crosses Below Key Moving Average Level", "Wednesday Sector Laggards: Healthcare, Materials", "Notable Wednesday Option Activity: ALXN, SWKS, ABT", "Interesting ALXN Put And Call Options For May 31st", "Market Close Report: NASDAQ Composite index closes at 7,996.08 down -4.15 points", "Wednesday Sector Laggards: Healthcare, Materials", "Notable Wednesday Option Activity: ALXN, SWKS, ABT", "Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates", "Drugmakers pay $123 million to resolve U.S. charity kickback probe", "Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up", "Economic & Earnings Data Deluge", "Q4 Earnings Soldier on Gamely: GOOGL, CLX & More", "U.S. STOCKS ON THE MOVE-Papa John's, Ultimate Software, Match, Aemetis, Evolus", "Here's Why Alexion Pharmaceuticals Gained 26.3% in January", "Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates", "The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion", "Earnings Reaction History: Alexion Pharmaceuticals, Inc., 36.4% Follow-Through Indicator, 5.2% Sensitive", "Alexion Pharmaceuticals (ALXN) Q4 2018 Earnings Conference Call Transcript", "Pre-Market Earnings Report for February 4, 2019 : SYY, ALXN, CLX, ON, AMG, BSAC, SAIA, MTSC, JOUT, UFI, LPG, NSSC", "Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?", "Close Update: Stocks Extend Fed-Fueled Rally, End January With Sizable Gains", "Alexion's Ultomiris Meets Primary Endpoint in aHUS Study", "First Week of ALXN March 15th Options Trading", "Alexion Pharmaceuticals Q4 18 Earnings Conference Call At 8:00 AM ET", "Health Care Sector Update for 01/28/2019: ABBV,ALXN,TRVN,ARAY", "Health Care Sector Update for 01/28/2019: ALXN,TRVN,ARAY", "New Drugs Approved In December", "Why Sarepta Therapeutics Stock Is Starting to Shine Again", "Why Alexion Pharmaceuticals Stock Fell 21% in December", "4 Biotechs That Are Potential Buyouts Post Celgene Deal", "February 2019 Options Now Available For Alexion Pharmaceuticals (ALXN)", "Alexion Pharma Says Phase 3 Study Of ULTOMIRIS Meets Primary Objective", "Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder", "Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija", "Alexion Pharma Announces FDA Approval Of ULTOMIRIS", "Alexion wins early U.S. approval for rare blood disorder drug", "U.S. FDA approves Alexion Pharma's rare blood disorder drug", "U.S. FDA approves Alexion Pharma's blood disorder drug", "Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead", "Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure", "Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 6,332.99", "Alexion Pharmaceuticals Enters Oversold Territory", "Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint", "Alexion Pharmaceuticals Becomes Oversold (ALXN)", "Achillion Reports Positive Interim Data on Factor D Inhibitors", "Why Achillion Pharmaceuticals Is Cratering Again Today", "Noteworthy Tuesday Option Activity: IBM, AZO, ALXN", "Allakos (ALLK) Catches Eye: Stock Jumps 6.5%", "Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 6,332.99", "Alexion Pharmaceuticals Enters Oversold Territory", "Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher", "Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher", "5 Top Drug/Biotech Merger & Acquisition Targets for 2019", "Here's Why Ra Pharmaceuticals Inc. Is Soaring Today", "Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis", "AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals", "The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen", "4 Biotech Stocks Investors Can Add to Their Portfolio in 2019", "Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher", "Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%", "Nasdaq 100 Movers: ALXN, ADBE", "Aileron Inks Collaboration Deal With Pfizer for Cancer Combo", "Eyenovia Initiates Phase III Study for Mydriasis Candidate", "Inovio (INO) to Receive Milestone Payment From AstraZeneca", "Global Blood Therapeutics' Voxelotor on Faster Approval Path", "Amgen's BiTE Immunotherapies Show Promise in Early Studies", "FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate", "Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%", "Nasdaq 100 Movers: ALXN, ADBE", "Aileron Inks Collaboration Deal With Pfizer for Cancer Combo", "Eyenovia Initiates Phase III Study for Mydriasis Candidate", "Inovio (INO) to Receive Milestone Payment From AstraZeneca", "Bullish Two Hundred Day Moving Average Cross - ALXN", "Keryx (KERX) Looks Good: Stock Adds 7.2% in Session", "10 Stocks That Are Screaming Buys Right Now", "Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint", "Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher", "Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension", "Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session", "Acorda Down More Than 30% in the Past 3 Months: Here's Why", "Health Care Sector Update for 11/06/2018: XNCR,MOR,MYL,AVNS", "Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates", "Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down", "ALXN Crosses Above Key Moving Average Level", "Biotech ETFs in Focus on String of Q3 Earnings Beat", "Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?", "Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal", "Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?", "Alexion Pharmaceuticals (ALXN) Tops Q3 Earnings Estimates", "Earnings Reaction History: Alexion Pharmaceuticals, Inc., 33.3% Follow-Through Indicator, 4.4% Sensitive", "Health Care Sector Update for 10/24/2018: MDT,TMO,LH,ALXN", "Health Care Sector Update for 10/24/2018: BGNE,TMO,ALXN,LH", "Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript", "Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT", "Pre-Market Earnings Report for October 24, 2018 : T, BA, TMO, UPS, GD, NOC, BSX, NSC, ITW, ALXN, SIRI, APH", "Health Care Sector Update for 10/24/2018: LH, ALXN, TMO, JNJ, PFE, ABT, MRK, AMGN", "Alexion Pharmaceuticals (ALXN) Tops Q3 Earnings Estimates", "Earnings Reaction History: Alexion Pharmaceuticals, Inc., 33.3% Follow-Through Indicator, 4.4% Sensitive", "Health Care Sector Update for 10/24/2018: MDT,TMO,LH,ALXN", "Notable Two Hundred Day Moving Average Cross - ALXN", "Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs", "3 Biotech Stocks With Virtual Monopolies", "Word On The Street: 3 Stocks For A Killer Q4", "Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?", "Nasdaq 100 Movers: TSLA, NVDA", "Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion", "Company News For Sep 27, 2018", "S&P 500 Movers: CTAS, SCG", "Nasdaq 100 Movers: CTAS, ALXN", "Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars", "Market Close Report: NASDAQ Composite index closes at 7,990.37 down -17.10 points", "5 Top Healthcare Mutual Funds to Buy in October", "Nasdaq 100 Movers: TSLA, NVDA", "Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion", "Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher", "Alexion's Soliris Successful in Phase III Study for NMOSD", "Nasdaq 100 Movers: CMCSA, ALXN", "S&P 500 Movers: CMCSA, EW", "Market Close Report: NASDAQ Composite index closes at 7,993.25 up 6.29 points", "Health Care Sector Update for 09/26/2018: SYK,ALXN,TLRY,FIRE.V,ANAB", "10 Stocks That Are Screaming Buys Right Now", "Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco", "Alexion's BLA for ALXN1210 Gets Priority Review From FDA", "Health Care Sector Update for 08/20/2018: AMRX, ALXN, ALSN, THC, LCI", "Health Care Sector Update for 08/20/2018: ASLN,ALXN", "QQXT's Underlying Holdings Imply 13% Gain Potential", "Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More", "Notable Thursday Option Activity: CVX, ALXN, FOXA", "Biotech ETFs in Focus on String of Q2 Earnings Beat", "Oversold Conditions For Alexion Pharmaceuticals (ALXN)", "Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels", "5 Stocks Trading Near 52-Week High With More Upside in Store", "5 Stocks Trading Near 52-Week High With More Upside in Store", "Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up", "Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates", "Alexion Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ALXN", "Biotech ETFs in Focus on String of Q2 Earnings Beat", "Oversold Conditions For Alexion Pharmaceuticals (ALXN)", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?", "Karyopharm Initiates NDA Submission Process for Selinexor", "J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)", "J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales", "Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates", "Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More", "6 Stocks to Buy for Trade War Protection", "J&J's (JNJ) Phase III Study for Invokana Halted Earlier", "How The Pieces Add Up: BBH Headed For $146", "Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population", "ALXN August 31st Options Begin Trading", "Achillion's 3rd Factor D Inhibitor Enters Clinical Studies", "J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)", "Roche's Flu Drug Meets Primary Endpoint in Phase III Study", "Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert", "J&J's (JNJ) Phase III Study for Invokana Halted Earlier", "Alexion (ALXN) Submits Application for ALXN1210 with FDA", "Alexion Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALXN", "Analysts Anticipate IYH Will Reach $205", "10 Stocks That Are Screaming Buys Right Now", "10 Stocks That Are Screaming Buys Right Now", "Alexion-Complement Pharma Tie Up to Treat Neuro Disorders", "Notable Tuesday Option Activity: CHTR, ALXN, FBHS", "Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod", "Notable Tuesday Option Activity: ALXN, BLK, AZO", "Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report?", "Health Care Sector Update for 05/25/2018: EVFM, RMTI, ALXN", "Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod", "Health Care Sector Update for 05/25/2018: ALXN,RMTI", "Look Under The Hood: QQXT Has 16% Upside", "10 Stocks That Are Screaming Buys Right Now", "7 Money-Making Stocks to Buy Now", "Noteworthy Tuesday Option Activity: ALXN, USAT, FDX", "Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO", "Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1", "Health Care Sector Update for 05/25/2018: BMRN,RMTI,ALXN,EVFM", "Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%", "7 Stocks Goldman Sachs Thinks Are Set to Rip Higher", "US Stocks Edge Higher on Positive Economic Data, Tech Gains", "Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up", "Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates", "Market Close Report: NASDAQ Composite index closes at 7,118.68 up 114.94 points", "Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today", "3 Top Healthcare Stocks to Buy Right Now", "Health Care Sector Update for 04/26/2018: ALXN,AXSM,ABBV,BMY", "Noteworthy Thursday Option Activity: MA, ALXN, MHK", "Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX", "What's in the Cards for BioMarin (BMRN) in Q1 Earnings?", "Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season", "Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Here's Why Alexion Pharmaceuticals Is Surging Today", "What's in Store for Biogen (BIIB) This Earnings Season?", "Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics", "Pharma M&A Active This Week: 4 Potential Buyout Targets", "Alexion (ALXN) to Acquire Wilson Therapeutics for $855M", "Add Up The Parts: SPYX Could Be Worth $74", "Health Care Sector Update for 04/11/2018: ALXN, HSDT, BIOL, TXMD", "Health Care Sector Update for 04/11/2018: CBAY,ALXN,TXMD,BIOL", "Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?", "What's in Store for Biogen (BIIB) This Earnings Season?", "Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics", "Pharma M&A Active This Week: 4 Potential Buyout Targets", "Nasdaq 100 Movers: FB, MSFT", "Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene", "Alexion (ALXN) Gains On Positive Date From Lead Candidate", "US Stocks Extend Gains Amid Strong Earnings Reports, Rising Oil Prices", "Health Care Sector Update for 04/11/2018: ALXN,TXMD,BIOL", "Nasdaq 100 Movers: MELI, ALXN", "Morning Movers: Sears Soars, Dollar General Gains, Alexion Rallies", "Pre-Market Most Active for Mar 15, 2018 : ALXN, PTI, AQUA, BABA, SBGL, QQQ, HGV, ERIC, MU, HMY, XT, DG", "Health Care Sector Update for 03/15/2018: RCUS,ALXN,SNY,BIVV,ABLX,SLDB", "Notable Thursday Option Activity: ALXN, WYN, MON", "Health Care Sector Update for 03/15/2018: ALXN,SNY,BIVV,ABLX,SLDB", "Why Alexion Pharmaceuticals, Inc. Stock Is Soaring Today", "S&P 500 Movers: QRVO, ALXN", "Nasdaq 100 Movers: MELI, ALXN", "Morning Movers: Sears Soars, Dollar General Gains, Alexion Rallies", "Pre-Market Most Active for Mar 15, 2018 : ALXN, PTI, AQUA, BABA, SBGL, QQQ, HGV, ERIC, MU, HMY, XT, DG", "Is Omeros Corporation a Buy on the Dip?", "IBB, REGN, VRTX, ALXN: Large Outflows Detected at ETF", "Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost", "Health Care Sector Update for 03/15/2018: ALXN", "After Hours Most Active for Feb 16, 2018 : P, GE, ALXN, BAC, TWTR, DAKT, TLRD, FOXA, S, MU, CAR, QQQ", "The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi", "Noteworthy Thursday Option Activity: AMTD, ALXN, NOC", "NASDAQ Composite Index closes up 31.55 points for the week, rising for the 4th straight day", "Nasdaq 100 Movers: ULTA, MELI", "S&P 500 Movers: ULTA, CSRA", "Market Close Report: NASDAQ Composite index closes at 6,981.96 up 107.47 points", "3 Strong Buy Stocks with Big Revenue Drivers", "Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4", "Teva Tumbles, Twitter Soars as Market Seeks Direction", "Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates", "Earnings Reaction History: Alexion Pharmaceuticals, Inc., 36.4% Follow-Through Indicator, 3.2% Sensitive", "REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?", "Why Earnings Season Could Be Great for Alexion Pharmaceuticals (ALXN)", "Pre-Market Earnings Report for February 8, 2018 : PM, CVS, TMUS, BCE, REGN, TRI, YUM, ALXN, K, TSN, TU, WLTW", "3 ETFs to Watch on Biotech Earnings", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "What's in the Cards for Teva (TEVA) This Earnings Season?", "Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?", "Allergan (AGN) to Report Q4 Earnings: What's in the Cards?", "Will Gilead (GILD) Disappoint Investors in Q4 Earnings?", "Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?", "What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?", "5 Biotech Stocks Set to Trump Estimates This Earnings Season", "Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?", "Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?", "Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?", "The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck", "Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?", "What's in the Cards for Varian Medical (VAR) in Q1 Earnings?", "What's in the Cards for Biogen (BIIB) This Earnings Season?", "ALXN Makes Notable Cross Below Critical Moving Average", "This News Explains Halozyme Therapeutics' Double-Digit Drop Today", "The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex", "ALXN March 2nd Options Begin Trading", "Can Biotech Keep Last Year's Momentum Alive in 2018?", "S&P 500 Analyst Moves: ALXN", "Implied FBT Analyst Target Price: $151", "10 Strong Buy Stocks From 2017\u2019s Best Analysts", "Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?", "Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?", "Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition'", "Alexion's (ALXN) Soliris Label Expansion Approved in Japan", "Health Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS", "Morning Movers: Apple Sinks, Under Armour Slips, Alexion Rises", "First Week of August 2018 Options Trading For Alexion Pharmaceuticals (ALXN)", "Orbimed Advisors Llc Buys Clementia Pharmaceuticals Inc, Aetna Inc, Universal Health Services ...", "Omeros Inks Agreement With FDA for OMS721 Phase III Trial", "Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?", "4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018", "Why This Biotech Could See 30% Upside In The Second Quarter", "Nasdaq 100 Movers: VIAB, ALXN", "S&P 500 Movers: COO, ALXN", "Market Close Report: NASDAQ Composite index closes at 6,840.08 up 27.24 points", "Health Care Sector Update for 12/08/2017: VTGN,ALXN,COO", "Achillion's Renal Disease Candidate Gets Orphan Drug Status", "5 Cheap Biotech Stocks to Snag on the Bounce", "Health Care Sector Update for 12/08/2017: ALXN,SAGE,COO", "Health Care Sector Update for 12/07/2017: MYO, ENTL, SYK, ALXN, HALO", "Nasdaq 100 Movers: CTRP, VIAB", "S&P 500 Movers: HRB, VIAB", "Analysts Predict 22% Upside For PBE", "Health Care Sector Update for 12/07/2017: SCMP,ENTL,SYK,ALXN", "Friday Sector Leaders: Energy, Healthcare", "Why Ra Pharmaceuticals, Inc. Got Hammered Today", "Why Omeros Corporation Is the Best Buy in Biotech Right Now", "Alexion (ALXN) Down 14.6% Since Earnings Report: Can It Rebound?", "Notable Monday Option Activity: UAL, FB, ALXN", "Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3", "3 Big Stock Charts for Wednesday: Alexion Pharmaceuticals, Inc., Alliance Data Systems Corporation and Snap-on Incorporated", "Achillion (ACHN) Shares Down as J&J Announces Stake Sale", "Why Alexion Pharmacteuicals Sank 8.9% in November", "The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October", "Implied FBT Analyst Target Price: $156", "Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus", "Health Care Sector Update for 11/03/2017: ALXN", "Nasdaq 100 Movers: QCOM, MDLZ", "3 ETFs to Watch on Biotech Earnings", "Oversold Conditions For Alexion Pharmaceuticals (ALXN)", "Tech Tumbles and Oil Boils", "The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October", "Implied FBT Analyst Target Price: $156", "Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus", "Health Care Sector Update for 11/03/2017: ALXN", "Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod", "Alexion Rises On 'Best-Case Scenario' FDA Approval For Muscle Disease", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Celgene Results Called 'Alarming,' As Alexion, Bristol Mixed", "Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up", "5 Biotech Stocks That Are Getting Battered Too Hard for Comfort", "Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up", "Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More", "Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug", "Notable Tuesday Option Activity: ACN, NVDA, ALXN", "Nasdaq 100 Movers: BIIB, HAS", "Morning Movers: More Cuts For GE\u2026and More Earnings Than You Can Shake a Stick At", "Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock?", "Seeking Alpha Editors' Picks Daily - October 11, 2017", "Analysts Predict 10% Upside For The Holdings of QQQ", "The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO", "3 Biotech and Pharma Stocks with Key FDA Catalysts this October", "Clovis Oncology Scores Relative Strength Rating Upgrade", "Rhenman & Partners Asset Management AB Buys Arena Pharmaceuticals Inc, Vertex ...", "Intercept (ICPT) Provides Safety Guidelines For Ocaliva", "Stocks To Watch: Prothena Sees Relative Strength Rating Jump To 81", "Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating", "Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark", "Stocks Flashing Renewed Technical Strength: Innoviva", "Notable Wednesday Option Activity: ALXN, MON, CME", "Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal", "4 'Strong Buy' Stocks From Best-Performing Analysts", "Global Blood Therapeutic Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Acceleron Pharma Trying To Close In On Key Technical Measure", "Acorda Therapeutics Getting Closer To Key Technical Measure", "Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer", "The Medicines Co. Continues to Focus on Pipeline Development", "Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions", "Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher", "3 Biotech Stocks With Major Catalysts in October", "Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up", "Karyopharm's Liposarcoma Candidate Superior in Phase II Study", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session", "Ardsley Advisory Partners Buys Alexion Pharmaceuticals Inc, New Residential Investment Corp, ...", "Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why", "Teva/Nuvelution to Speed Up Development of Austedo in US", "Epizyme (EPZM) Looks Good: Stock Adds 7.8% in Session", "Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day", "ProQR's Genetic Disorder Candidate Gets Orphan Drug Status", "Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia", "Pluristem's Ischemia Candidate Gets Fast Track Designation", "Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher", "Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2%", "Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU", "J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU", "Novartis Poised to Grow on Oncology Portfolio & Biosimilars", "ProQR's Genetic Disorder Candidate Gets Orphan Drug Status", "Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia", "Pluristem's Ischemia Candidate Gets Fast Track Designation", "Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher", "IBB, BIIB, REGN, ALXN: ETF Inflow Alert", "Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study", "Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%", "Why Alexion Pharmaceuticals (ALXN) Could Beat Earnings Estimates Again", "Alexion (ALXN) Reports Interim Results for Soliris Study", "4 Biotech Stocks That Show Promise on Sustainable Growth", "Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data", "Roche (RHHBY) Announces Data on Respiratory Drug Esbriet", "Alexion to Restructure Operations, to Lower Headcount by 20%", "Achillion's HCV Partnership with J&J Terminated, Stock Falls", "AstraZeneca's Asthma Candidate Shows Promising Results", "Glaxo's Shingles Candidate Gets Positive FDA Committee Vote", "Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable", "5 Top-Ranked Biotech Stocks to Buy Right Now", "AstraZeneca's Lung Cancer Study Data Promising, Shares Spike", "Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints", "Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth", "4 Biotech Stocks to Improve Your Portfolio\u2019s Health", "AstraZeneca's COPD Candidate Duaklir Reports Positive Data", "Nasdaq 100 Movers: ALXN, PAYX", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Cellect Biotechnology (APOP) Soars: Stock Adds 10.2% in Session", "ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA", "VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences", "Morning Movers: U.S. Steel Jumps on Merrill Upgrade; United Technologies Drops on Rockwell Collins Acquisition", "Biotech Stocks Back in Favor: Will the Rally Continue?", "Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Cellect Biotechnology (APOP) Soars: Stock Adds 10.2% in Session", "5 Winning Stocks to Beat September Blues", "AMAG's Filing for Feraheme's Label Expansion Accepted by FDA", "Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia", "Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion", "How The Parts Add Up: QQQ Headed For $158", "4 Biotech Stocks to Improve Your Portfolio's Health", "XBI, EXEL, ALXN, VRTX: ETF Inflow Alert", "Juno Therapeutics (JUNO) Soars: Stock Adds 20.1% in Session", "Advanced Accelerator Gets Action Date for Lutathera from FDA", "Novo Nordisk's Tresiba Gets Canadian Nod", "Kamada (KMDA) Gets FDA Approval for Rabies Vaccine", "Traders buy calls on Alexion Pharma", "Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.", "BioMarin's Pegvaliase BLA Granted Priority Review by the FDA", "Intra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session", "Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%", "Immunomedics (IMMU) Catches Eye: Stock Up 5.1%", "Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe", "Noteworthy ETF Inflows: XBI, EXEL, ALXN, VRTX", "Immunomedics' Progress in Phase II Cancer Study Encouraging", "Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...", "Array BioPharma (ARRY) Looks Good: Stock Adds 5.9% in Session", "Alexion's (ALXN) Soliris' Label Expansion Approved in Europe", "Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session", "Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)", "Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher", "Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session", "Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...", "Seattle Genetics' Adcetris Granted Priority Review by FDA", "4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings", "Alexion's (ALXN) Soliris' Label Expansion Approved in Europe", "Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session", "Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)", "Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher", "3 'Strong Buy' Biotech Stocks You Should Watch", "Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%", "XBI, EXEL, ALXN, CLVS: ETF Outflow Alert", "Novo Nordisk's Semaglutide Shows Remarkable Results in Study", "Implied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options", "Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus", "Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up", "Why Achillion Pharmaceuticals Is Shooting 25% Higher Today", "Forget Bayer, Buy These 3 Drug Stocks Instead", "Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session", "The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July", "Forget Teva (TEVA), Buy These 4 Drug Stocks Instead", "3 ETFs to Watch Out for on Biotech Earnings", "Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View", "Alexion (ALXN) Tops Q2 Earnings, Sales; Shares Up", "XBI, CLVS, EXEL, ALXN: ETF Outflow Alert", "Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN", "Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season", "Noteworthy Wednesday Option Activity: HBI, EA, ALXN", "New Strong Buy Stocks for August 2nd", "What's in the Cards for Exelixis (EXEL) in Q2 Earnings?", "Is Celgene (CELG) Poised For a Beat This Earnings Season?", "Are Options Traders Betting on a Big Move in Alexion Pharmaceuticals (ALXN) Stock?", "S&P 500 Analyst Moves: ALXN", "Is a Beat in Store for Alexion (ALXN) this Earnings Season?", "Is Gilead (GILD) Poised for a Beat This Earnings Season?", "Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs", "Can Intercept (ICPT) Beat Estimates this Earnings Season?", "XBI, CLVS, EXEL, ALXN: Large Inflows Detected at ETF", "5 Top Multibagger Biotech Stocks to Buy in the 2nd Half", "Spiros Segalas Commentary on Alexion Pharmaceuticals", "3 Stocks With Huge Business Advantages", "Alexion Reportedly Being Investigated by HHS, Shares Slip", "3 Hot Biotech Stocks Ready for the Sector\u2019s Next Breakout", "Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN", "Wall Street\u2019s 5 Hottest Biotech Stocks Right Now", "3 Best-Performing Stocks in June", "Analysts Anticipate QQQ Will Reach $151", "2 Fastest Growing Biotech Stocks", "SPDR S&P Biotech ETF Experiences Big Inflow", "Here's Why Ra Pharmaceuticals Inc. Tumbled as Much as 32% Today", "3 Top Stocks on Sale This Summer", "Top Stock Reports for Oracle, Allergan & Abbott", "3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals", "Monday 6/19 Insider Buying Report: ALXN, AKAM", "Weekly Top Insider Buys Highlight for the Week of June 16", "Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...", "Company News for June 15, 2017", "Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug", "Biogen Loses Top Executive Again, CFO Clancy to Join Alexion", "Omeros (OMER) Lead Candidate Gets Breakthrough Designation", "Bullish Two Hundred Day Moving Average Cross - ALXN", "Monday 6/19 Insider Buying Report: ALXN, AKAM", "Weekly Top Insider Buys Highlight for the Week of June 16", "Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...", "What Happened in the Stock Market Today", "Market Close Report: NASDAQ Composite index closes at 6,194.89 down -25.48 points", "Noteworthy Wednesday Option Activity: STRP, ALXN, SCCO", "Wednesday Sector Leaders: Healthcare, Utilities", "Nasdaq 100 Movers: BIIB, ALXN", "Noteworthy ETF Outflows: PBE, QGEN, IONS, ALXN", "5 Top Stocks for June", "3 Stocks With Vertex Pharmaceuticals-Like Return Potential", "Why Is Alexion (ALXN) Down 23% Since the Last Earnings Report?", "How The Pieces Add Up: EQAL Targets $31", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,205.26.", "After Hours Most Active for May 25, 2017 : HPE, KO, OZRK, JNPR, MSFT, XOM, DFS, ALXN, BMY, CTSH, JD, CMCSA", "9 Biotech Stats That Will Blow You Away", "Company News for May 24, 2017", "Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data", "Back to 2400 Already?", "Here's Why Alexion Pharma (ALXN) Stock is Sinking Today", "Alexion Pharmaceuticals is Now Oversold (ALXN)", "Mid-Day Market Update: Kirkland's Drops After Weak Q1 Results; Helios and Matheson Analytics Shares Surge", "Noteworthy Tuesday Option Activity: ALXN, GOOGL, MGRC", "Nasdaq 100 Movers: ALXN, INTU", "Pre-Market Most Active for May 23, 2017 : VIPS, TSU, SC, NOK, EPC, MOMO, TTWO, AEG, ERIC, QQQ, TLT, ALXN", "Why Herbalife, Alexion Pharmaceuticals, and Brown-Forman Slumped Today", "Market Close Report: NASDAQ Composite index closes at 6,138.71 up 5.09 points", "Mid-Afternoon Market Update: America's Car-Mart Rises On Earnings Beat; Alexion Shares Drop", "Health Care Sector Update for 05/23/2017: ALXN, ETRM, CERS, JNJ, NVS", "Stocks That Fell to 3-Year Lows in the Week of May 19", "Here's Why Omeros Corporation Is Surging Again Today", "Nasdaq 100 Movers: XLNX, MNST", "Pre-Market Most Active for May 23, 2017 : VIPS, TSU, SC, NOK, EPC, MOMO, TTWO, AEG, ERIC, QQQ, TLT, ALXN", "Why Herbalife, Alexion Pharmaceuticals, and Brown-Forman Slumped Today", "Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death", "What Are We Waiting For?", "Monday Sector Laggards: Healthcare, Services", "Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene", "Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal", "S&P 500 Analyst Moves: ALXN", "ALXN Makes Bullish Cross Above Critical Moving Average", "Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View", "Alexion (ALXN) Tops Q1 Earnings, Sales; Shares Up", "Thursday's ETF Movers: XBI, OIH", "Stocks Give an Encore Performance", "Is This Why Akari Therapetuics PLC Is Falling Today?", "5 Healthcare Innovators I'm Still Buying", "Friday Sector Laggards: Healthcare, Consumer Products", "Peek Under The Hood: IYH Has 11% Upside", "3 Beaten-Up Healthcare Stocks: Are They Bargains?", "Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed", "The 7 Most Expensive Prescription Drugs in the World", "3 Big Reasons to Be Bullish on Biotech Stocks", "Nasdaq 100 Movers: LILA, ALXN", "Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?", "Friday Sector Laggards: Healthcare, Consumer Products", "Alexion Pharmaceuticals Slid 9.9% in March -- but Why?", "3 Top Growth Stocks Priced at a Bargain This Spring", "Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study", "Here's Why Omeros Corporation Stock Climbed Higher Today", "Omeros: Power in the Pipeline", "Alexion (ALXN) Files for Soliris' Label Expansion in Japan", "Market Close Report: NASDAQ Composite index closes at 5,805.15 down -31.01 points", "Commit To Buy Alexion Pharmaceuticals At $75, Earn 5.1% Using Options", "Alexion Pharmaceuticals Enters Oversold Territory (ALXN)", "Look Under The Hood: BBH Has 12% Upside", "Midday Update: Market Indices Flat But Set to Close The Week Higher", "Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates", "Futures Cautiously Higher Ahead of Production Data", "Alexion (ALXN) Licenses Artubus Technology for Rare Diseases", "Health Care Sector Update for 03/23/2017: ALXN", "Noteworthy Monday Option Activity: ALXN, ANTM, PN", "Nasdaq 100 Movers: TSCO, CTRP", "Alexion's sBLA for Soliris Receives FDA Acknowledgement", "3 Big Stock Charts for Thursday: CA, Inc. (CA), Autodesk, Inc. (ADSK) and Alexion Pharmaceuticals, Inc. (ALXN)", "ALXN Crosses Below Key Moving Average Level", "Is This the Right Time to Invest in Biotech Stocks?", "Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More", "Close Update: Stocks Limp Into Friday's Close But Hang Onto Slim Gains For the Week", "Noteworthy Monday Option Activity: ALXN, ANTM, PN", "Nasdaq 100 Movers: TSCO, CTRP", "Alexion's sBLA for Soliris Receives FDA Acknowledgement", "Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS", "Nasdaq 100 Movers: ALXN, KHC", "Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y", "Alexion (ALXN) Misses on Q4 Earnings and Revenues", "IBB, REGN, ILMN, ALXN: Large Outflows Detected at ETF", "Pre-Market Earnings Report for February 16, 2017 : CHTR, DUK, PCG, WM, ALXN, ZTS, MGM, LH, AEE, ECA, SCG, HII", "Notable Tuesday Option Activity: UPS, ALXN, PEP", "Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?", "S&P 500 Analyst Moves: ALXN", "Nasdaq 100 Movers: BIIB, TSCO", "ALXN Crosses Above Key Moving Average Level", "The Zacks Analyst Blog Highlights: ExxonMobil, Procter & Gamble, Micron, Macy's and Alexion Pharmaceuticals", "Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More", "Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again", "Nasdaq 100 Movers: ALXN, ISRG", "Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,563.65.", "Notable ETF Inflow Detected - IBB, REGN, ALXN, INCY", "Nasdaq 100 Movers: EBAY, ILMN", "Here's Why Alexion Pharmaceuticals, Inc. Stock Gave Up 36% in 2016", "4 Top Biotech Mutual Funds for 2017", "Company News for January 06, 2017", "ALXN Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: WBA, ALXN", "S&P 500 Movers: KSS, ALXN", "Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,487.94.", "Alexion (ALXN): Will the Stock Continue to Suffer in 2017?", "Alexion Blood Disorder Drug Gets Orphan Designation in U.S.", "The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech", "Nasdaq 100 Movers: WDC, NVDA", "Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead", "Are These 3 Stocks the Biggest Comeback Opportunities of 2017?", "Alexion Soliris Fails in Phase II/III Delayed Graft Function Study", "Bad News Bashes Biotech Investors... Again", "Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug", "Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation", "Agree To Purchase Alexion Pharmaceuticals At $75, Earn 9.9% Using Options", "Noteworthy ETF Inflows: IBB, REGN, MYL, ALXN", "Market Close Report: NASDAQ Composite index closes at 5,457.44 up 20.28 points", "Alexion Investors Want Answers", "Nasdaq 100 Movers: NCLH, ALXN", "S&P 500 Movers: JWN, ALXN", "We Did The Math PBE Can Go To $52", "Health Care Sector Update for 12/21/2016: ALXN,GILD,MRUS,INCY,MACK", "Is the Worst Yet to Come for Alexion Pharmaceuticals?", "Nasdaq 100 Movers: ALXN, MYL", "Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,463.83.", "Mid-Day Market Update: Crude Oil Up Over 3%; Ophthotech Shares Tumble After Failed Phase 3 Trial Of Fovista", "Why Alexion Pharmaceuticals, Inc.'s Shareholders Lost $3 Billion Today", "Nasdaq 100 Movers: ALXN, REGN", "Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data", "Is the Worst Yet to Come for Alexion Pharmaceuticals?", "Nasdaq 100 Movers: ALXN, MYL", "Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe", "Health Care Sector Update for 12/12/2016: ALXN,AZN,HON,AKAO,OPHT", "Monday's ETF with Unusual Volume: SPYG", "Mid-Afternoon Market Update: Achaogen Surges On Positive Phase 3 Results; Alexion Shares Slide", "S&P 500 Movers: ALXN, REGN", "Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares Tumble After Failed Drug Trial", "Why Thor Industries, Alexion Pharmaceuticals, and Berry Plastics Jumped Today", "Market Close Report: NASDAQ Composite index closes at 5,379.92 up 11.11 points", "Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola", "3 Beaten-Down Biotech Stocks You Can Buy Right Now", "IBB, REGN, ALXN, VRTX: ETF Inflow Alert", "Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma", "ALXN Makes Bullish Cross Above Critical Moving Average", "Market Close Report: NASDAQ Composite index closes at 5,237.11 up 28.31 points", "Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed", "New Strong Sell Stocks for November 8th", "Biotech ETFs Slumping on Q3 Results", "Nasdaq 100 Movers: LVNTA, BIIB", "S&P 500 Movers: NEM, SYY", "Market Close Report: NASDAQ Composite index closes at 5,166.17 up 119.80 points", "Nasdaq 100 Movers: ALXN, NVDA", "Market Close Report: NASDAQ Composite index closes at 5,237.11 up 28.31 points", "Nasdaq 100 Movers: SYMC, ALXN", "Friday's ETF with Unusual Volume: BBH", "Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay", "New Strong Sell Stocks for November 2nd", "Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More", "3 Big Stock Charts: ConocoPhillips (COP), Western Digital Corp (WDC) and Alexion Pharmaceuticals, Inc. (ALXN)", "Noteworthy Friday Option Activity: OFG, ALXN, SCTY", "Market Close Report: NASDAQ Composite index closes at 5,189.14 down -.96 points", "Nasdaq 100 Movers: ORLY, WDC", "Alexion (ALXN) Misses on Q2 Earnings, Beats Revenues", "Market Close Report: NASDAQ Composite index closes at 5,215.97 down -34.30 points", "Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View", "Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Genetic Stocks to Watch for Earnings on Nov 1: GILD & More", "Alexion (ALXN) Q3 Earnings: Can the Stock Pull a Surprise?", "The Math Shows QUS Can Go To $69", "Nasdaq 100 Movers: WDC, ULTA", "Alexion Presents New Long-Term Phase III Data on Kanuma", "Health Care Sector Update for 10/07/2016: CELG", "3 Growth Stocks to Buy in October", "Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data", "Alexion Graft-Versus-Host Disease Drug Wins Orphan Status", "Market Close Report: NASDAQ Composite index closes at 5,305.75 down -33.77 points", "S&P 500 Analyst Moves: ALXN", "Commit To Buy Alexion Pharmaceuticals At $85, Earn 6.7% Using Options", "Look Under The Hood: IVV Has 11% Upside", "Nasdaq 100 Movers: TSCO, WBA", "Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled", "Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved", "Nasdaq 100 Movers: ALXN, BMRN", "Market Close Report: NASDAQ Composite index closes at 5,305.75 down -33.77 points", "S&P 500 Analyst Moves: ALXN", "New Strong Sell Stocks for August 22nd", "New Strong Sell Stocks for August 15th", "Alnylam Pharmaceuticals, Inc. Cranks Out the Data", "The Implied Analyst 12-Month Target For QQXT", "5 Growth Stocks to Buy in September", "Alexion's GVHD Candidate Gets Orphan Drug Status in the EU", "Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review", "New Strong Sell Stocks for August 22nd", "New Strong Sell Stocks for August 22nd", "New Strong Sell Stocks for August 15th", "Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More", "Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure", "New Strong Sell Stocks for August 5th", "I Just Bought These 4 Fast-Growing Biotech Stocks", "Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly", "Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why", "Why Alexion Pharmaceuticals, Inc. Stock Sank 23.5% in June", "Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing", "Brexit Shouldn't Have Much, If Any, Effect on This Sector", "Health Care Sector Update for 07/07/2016: ALXN", "Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint", "Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold", "S&P 500 Analyst Moves: ALXN", "Nasdaq 100 Movers: NXPI, CMCSA", "How Does Brexit Impact Healthcare Stocks?", "2 Biotech Stocks That Won't Pay a Dividend Anytime Soon, and 1 That Should", "How This Former Market Darling Became an Undervalued Stock", "3 Value Stocks Near 52-Week Lows Worth Buying", "Nasdaq 100 Movers: ENDP, STX", "3 Underdog Stocks We're Watching", "This Week\u2019s 43 Biggest Stock Upgrades and Downgrades", "The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron", "4 Stocks That Crushed the Biotechnology ETF (IBB) This Week", "Company News for June 08, 2016", "Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus", "IBB: The iShares NASDAQ Biotechnology Index (ETF) Is Still a Buy", "Stock Market News for June 16, 2016", "3 Underdog Stocks We're Watching", "S&P 500 Movers: BIIB, WDC", "3 Stocks to Watch on Tuesday: Alexion Pharmaceuticals, Inc. (ALXN), Verizon Communications Inc. (VZ) and FedEx Corporation (FDX)", "Stocks Mixed After Dow Flirts With 18,000", "Tuesday Sector Laggards: Healthcare, Utilities", "Why Alexion Pharmacetuicals Inc. Is Dropping Today", "Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status", "Alexion's Soliris Misses Phase III Primary Efficacy Endpoint", "3 Biotech Stocks to Buy in June", "41 Trades To Make Before May Ends", "Baron Funds Comments on Alexion Pharmaceuticals", "Nasdaq 100 Movers: ALXN, STX", "Analysts Expect 19% Upside For QQXT", "Alnylam Pharmaceuticals, Inc.'s Double-Digit \"Earnings\" Fall", "Nasdaq 100 Movers: SBAC, ALXN", "These Billionaires Just Made a Killing on Celator. Here's What Else They've Been Buying", "Alexion (ALXN) Misses on Q1 Earnings and Revenues", "Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View", "4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG", "Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?", "Tuesday Sector Laggards: Healthcare, Utilities", "IBB, REGN, ILMN, ALXN: ETF Outflow Alert", "Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis", "Biotech ETFs Sink on Mixed Q1 Results", "Alexion (ALXN) Misses on Q1 Earnings and Revenues", "Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View", "4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG", "Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?", "Tuesday Sector Laggards: Healthcare, Utilities", "IBB, REGN, ILMN, ALXN: ETF Outflow Alert", "Do You Own Any Of These Top Sector Funds?", "9 Drugs That Cost Medicare a Fortune", "Surprising Analyst 12-Month Target For SPXT", "S&P 500 Analyst Moves: ALXN", "Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data", "These 3 Biotechs Are Growing Fast -- Which Is the Best Buy Today?", "Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal", "Alexion Pharmaceuticals Inc. in 5 Charts", "Biotech Stock Roundup: PTCT Plunges on \"RTF\" from FDA, Radius Shoots Up on Amgen Data", "Is This Upstart the Biggest Threat to Alexion Pharmaceuticals?", "The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta", "Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma", "Biotech ETFs Slide as Stocks Report Mixed Q4 Results", "The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release", "Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%", "Alexion Misses on Earnings and Revenues in Q4, Gives View", "Alexion (ALXN) Misses on Q4 Earnings and Revenues", "2 Reasons Alexion Pharmaceuticals' Stock Could Rise", "Is Alexion (ALXN) Likely to Disappoint this Earnings Season?", "Will 2016 Be Alexion Pharmaceuticals Inc.'s Best Year Yet?", "Regeneron Pharmaceuticals Inc. Stock: Bargain or Rip-Off?", "Why Ultragenyx Pharmaceuticals Skyrocketed in 2015", "S&P 500 Analyst Moves: ALXN", "Health Care Sector Update for 01/07/2016: GSK, ALXN", "Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals", "Pre-Market Earnings Report for February 3, 2016 : MRK, CMCSA, MDLZ, GM, SO, ADP, ALXN, BDX, EXC, ETN, MPC, BEN", "The Best 3 Biotech Stocks for 2016", "Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences", "Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals", "Alexion (ALXN) Gains after Kanuma Receives FDA Approval", "Nasdaq 100 Movers: SPLS, ALXN", "S&P 500 Movers: HRB, AZO", "Instant Analysis: Alexion Pharmaceuticals Inc Wins an Important FDA Approval", "5 Best Performing Nasdaq Stocks of 2015", "Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved", "3 Biotech Stocks to Buy in December", "ALXN Crosses Above Key Moving Average Level", "These Biotech Stocks May Start Paying Dividends in 2016", "Jim Simons' Largest Adds of the 3rd Quarter", "A Duo of Catalysts Sends Alexion Pharmaceuticals 13% Higher in October", "Biotech Sees Better-than-Expected Earnings: ETFs in Focus", "Noteworthy ETF Outflows: IBB, REGN, BIIB, ALXN", "3 Biotech Stocks to Buy in November", "Alexion Beats on Earnings in Q3 but Misses on Revenues", "Health Care Sector Update for 10/29/2015: REVA, ALXN", "Alexion (ALXN) Beats on Q3 Earnings, Revises Outlook", "Pre-Market Earnings Report for October 29, 2015 : MO, MA, COP, EPD, TWC, MCK, AMT, ALXN, AET, CME, PX, APD", "Alexion (ALXN) to Report Q3 Earnings: What to Expect?", "Bullish Two Hundred Day Moving Average Cross - ALXN", "5 Exciting Biotech Stocks to Buy on November Upswing", "3 Top Stocks to Buy for Your Kids/Grandkids", "Ultragenyx (RARE) Reports Positive Interim Data on UX007", "3 Biotechs Growing Faster Than Apple", "3 Beaten-Down Biotech Stocks to Buy Now", "Stock Market News for October 14, 2015", "Health Care Sector Update for 10/13/2015: LLY, CCL, ALXN", "Alexion (ALXN) Presents Positive 5-Year Data on Strensiq", "Alexion Pharmaceuticals Nabs an Approval, Wall Street Not Impressed", "3 Triple-Digit Biotech Stocks That Are Worth Every Penny", "3 Biotech Stocks That Can Upgrade Your Portfolio", "S&P 500 Analyst Moves: ALXN", "The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA", "Biotech Stock Roundup: Biosimilar Competition for Amgen, Tetraphase Hit By Disappointing Data", "Alexion's Kanuma FDA Action Date Delayed by Three Months", "Alexion Pharmaceuticals, Inc. Scores 2 Regulatory Wins", "Stock Market News for September 28, 2015", "Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)", "Baron Funds Comments on Alexion Pharmaceuticals Inc.", "This Drugmaker's Incredible Run Looks Far From Done", "Omeros' Reveals Positive Data on OMS721 from Phase II", "New Strong Sell Stocks for August 18th", "The 5 Most Expensive Drugs in the World in 2015", "Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary", "Oversold Conditions For Alexion Pharmaceuticals (ALXN)", "Noteworthy ETF Outflows: RSP, CB, CELG, ALXN", "Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook - Tale of the Tape", "Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog", "Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog", "Pre-Market Earnings Report for July 30, 2015 : PG, MDLZ, COP, CL, EPD, TWC, OXY, TEVA, ALXN, ADP, CI, VLO", "Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog", "Biotech IPO Boom Gaining Thrust With NantKwest Debut", "Health Care Sector Update for 07/31/2015: ALXN, NLNK, UHS", "Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog", "QLD, ALXN, AAL, AMGN: ETF Outflow Alert", "How Rare-Disease Drugmaker Alexion Pharmaceuticals Found Its Groove in June", "The Zacks Analyst Blog Highlights: Vertex, Biogen, Applied Genetic, Gilead and Alexion - Press Releases", "Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog", "Alexion Hypophosphatasia Drug Strensiq Approved in Japan - Analyst Blog", "The Competitive Advantage of the Best Biotech Stocks", "ALXN September 4th Options Begin Trading", "Andreas Halvorsen Increases Stake in Esperion Therapeutics", "Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog", "Nasdaq 100 Movers: MU, AVGO", "New Strong Sell Stocks for June 12th - Tale of the Tape", "Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog", "Nasdaq 100 Movers: REGN, NFLX", "S&P 500 Analyst Moves: ALXN", "Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog", "New Strong Sell Stocks for June 5th - Tale of the Tape", "Is It Too Late to Invest in Health Care?", "Biotech Stock Roundup: ImmunoGen Soars on ASCO Data, Amgen Collaborates with Roche - Analyst Blog", "New Strong Sell Stocks for June 2nd - Tale of the Tape", "QLD, ALXN, AAL, ADI: ETF Outflow Alert", "Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog", "New Strong Sell Stocks for May 26th - Tale of the Tape", "New Strong Sell Stocks for June 9th - Tale of the Tape", "Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog", "ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary", "Will Suitors Line Up to Buy These Biotech Stocks Next?", "Investors Just Doubled Their Money on This Stock", "Alexion Pharmaceuticals, Inc. (ALXN) in Focus: Stock Jumps 5.1% - Tale of the Tape", "Alexion to Buy Synageva for $8.4B: Alexion Down, Synageva Up - Analyst Blog", "Midday Update: Yellen Spooks Wall Street With Comments on Stock Valuations", "Why I'm Buying Sarepta Therapeutics Stock", "S&P 500 Movers: ALXN, WU", "Nasdaq 100 Movers: ALXN, EXPD", "Futures Rebound on Gains in Europe, Billion Dollar Biotech Deal", "Close Update: Stocks Lower On Yellen Valuation Warning", "Health Care Sector Update for 05/06/2015: FATE,JUNO,GEVA,ALXN,ARDX", "Health Care Sector Update for 05/06/2015: PTBI, GEVA, ARDX, ALXN", "ETF Preview: Broad Market ETFs Gain in Line With Futures; Crude Oil, Biotech Funds Among Most Active", "Why Shares of Synageva BioPharma Corp. Skyrocketed Today", "Alexion Misses Q1 Earnings Estimates, Keeps 2015 Outlook - Analyst Blog", "Alexion (ALXN) Misses on Q1 Earnings, Maintains Outlook - Tale of the Tape", "QLD, ALXN, AAL, ADI: Large Outflows Detected at ETF", "Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog", "Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog", "Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog", "10 Largest Companies by Market Cap in Biotech", "10 Most Profitable Businesses in Biotech", "Tuesday's ETF with Unusual Volume: FTC", "Following Gilead Sciences, Inc., Which Biotech Will Pay a Dividend Next?", "ProShares Ultra QQQ Experiences Big Outflow", "Stock Market News for March 26, 2015 - Market News", "ALXN Makes Notable Cross Below Critical Moving Average", "Can This Biotech Stock Go from Good to Great?", "Commit To Buy Alexion Pharmaceuticals At $145, Earn 11% Using Options", "Nasdaq 100 Movers: CTXS, NFLX", "Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog", "S&P 500 Analyst Moves: ALXN", "Alexion Pharmaceuticals Takes Over #13 Spot From Tyson Foods", "Insiders Buy the Holdings of FBT ETF", "Alexion's Soliris' Label May be Updated upon EC Approval - Analyst Blog", "TQQQ, ATVI, AKAM, ALXN: ETF Outflow Alert", "Nasdaq 100 Movers: ALXN, AVGO", "3 Biotech Stocks Wall Street Loves", "Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary", "Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 5.8% - Tale of the Tape", "Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog", "Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog", "Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog", "Zacks Rank #1 Additions for Thursday - Tale of the Tape", "Health Care Sector Update for 01/29/2015: ABT, CAH, ALXN", "Stock Market News for February 10, 2015 - Market News", "Alexion (ALXN) Misses on Q4 Earnings, Appoints New CEO - Tale of the Tape", "Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog", "Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog", "Salix Financial Results Need Correcting: Audit Committee - Analyst Blog", "Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog", "Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog", "The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog", "Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4% - Tale of the Tape", "Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog", "Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog", "Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape", "Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape", "BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog", "Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog", "Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog", "Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog", "Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog", "Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog", "Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog", "Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog", "Applied Genetic Technologies (AGTC) in Focus: Stock Rises 6.6% - Tale of the Tape", "AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8% - Tale of the Tape", "Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog", "Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog", "Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog", "Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog", "Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog", "BioDelivery Sciences International (BDSI) in Focus: Stock Up 5% - Tale of the Tape", "Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog", "Illumina Unveils 3 NGS Systems, Modifies Business Strategy - Analyst Blog", "OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog", "State of the Union Address Investing Idea: Precision Medicine", "Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst Blog", "Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog", "Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst Blog", "BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog", "Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal - Analyst Blog", "Galena Biopharma (GALE) Jumps: Stock Rises 9.1% - Tale of the Tape", "Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst Blog", "Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog", "Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst Blog", "Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst Blog", "Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst Blog", "Bristol-Myers Opdivo Study Stopped on Favorable Data - Analyst Blog", "Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst Blog", "Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog", "Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog", "Pharmacyclics Reports Preliminary Results and 2015 Outlook - Analyst Blog", "Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog", "Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst Blog", "3 Biotech Stocks Focused on Curing Ultra-Rare Diseases", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "S&P 500 Movers: ADM, MWV", "Nasdaq 100 Movers: BIIB, TSCO", "Alexion Reports Disappointing Phase II Data on Soliris - Analyst Blog", "Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog", "Alexion Seeks FDA Approval for its Hypophosphatasia Drug - Analyst Blog", "S&P 500 Movers: RIG, CELG", "The Market's 10 Best Stocks", "Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog", "3 Companies Growing Faster Than MannKind Corporation", "Alexion Announces New Share Repurchase Program of $500M - Analyst Blog", "Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog", "Nasdaq 100 Movers: MU, GMCR", "Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog", "Stock Market News for December 03, 2014 - Market News", "Valeant's Onexton Gel Gets FDA Approval for Acne - Analyst Blog", "Health Care Sector Update for 11/28/2014: ALXN, NVS, DVAX", "Alexion's Soliris Gets Final Positive NICE Recommendation - Analyst Blog", "Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan - Analyst Blog", "Stock Market News for November 19, 2014 - Market News", "Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY", "ETF Outlook: First Trust Amex Biotech Index Fund ETF (FBT)", "Is This Trend Making Gilead Sciences, Inc. Worry?", "Why Alexion Pharmaceuticals (ALXN) Could Be an Impressive Growth Stock - Tale of the Tape", "Top Funds Buy Ulta Beauty, Alexion, Avago", "Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog", "The 5 Most Expensive Drugs in the World", "Company News for October 24, 2014 - Corporate Summary", "Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus - Analyst Blog", "Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? - Analyst Blog", "Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog", "Sector Update: Health-care Stocks Lower Pre-Bell", "Sector Update: Health Care", "Nasdaq 100 Movers: TSLA, VRTX", "The 5 Richest States in America", "Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog", "Pre-Market Earnings Report for October 23, 2014 : CMCSA, UNP, MMM, CELG, LLY, OXY, CAT, GM, ALXN, PCP, RTN, POT", "Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape", "Proshares UltraPro QQQ Experiences Big Inflow", "Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog", "Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog", "Noteworthy ETF Inflows: TQQQ, ATVI, AKAM, ALXN", "3 Hot Ways to Play the Biotechnology Bonanza", "Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status - Analyst Blog", "Stock Market News for October 06, 2014 - Market News", "IBB, CELG, BIIB, ALXN: ETF Outflow Alert", "Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog", "Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog", "Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog", "Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog", "Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog", "Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog", "Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS - Analyst Blog", "Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog", "NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog", "Noteworthy ETF Inflows: TQQQ, ATVI, AKAM, ALXN", "Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog", "Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog", "Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog", "Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog", "VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog", "Nasdaq 100 Movers: MNST, DLTR", "Biotech ETF Price Swings May Signal Need For Caution", "Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog", "Will Alexion Pharmaceuticals (ALXN) Miss This Earnings Season? - Analyst Blog", "Pre-Market Earnings Report for July 24, 2014 : MMM, UNP, BMY, LLY, CELG, F, CAT, GM, PCP, ALXN, POT, RTN", "Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog", "Nasdaq 100 Movers: NFLX, WYNN", "Aegerion Q2 Loss Narrower than Expected, 2014 View Retained - Analyst Blog", "Nasdaq 100 Movers: MNST, DLTR", "Biotech ETF Price Swings May Signal Need For Caution", "Alexion Pharma Looks To Life Beyond Its Blockbuster", "Friday's ETF with Unusual Volume: MTUM", "RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog", "Nasdaq 100 Movers: WFM, DISH", "Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog", "bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape", "Insmed Soars on Arikayce's Breakthrough Designation - Analyst Blog", "Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog", "Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog", "J&J's Velcade in Focus at the European Hematology Association - Analyst Blog", "Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog", "Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog", "Shire to Conduct Trials on Vyvanse on FDA's Request - Analyst Blog", "Valeant Launches Hostile Bid for Allergan - Analyst Blog", "Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog", "Roche's HPV Test Approved in Canada - Analyst Blog", "Encouraging Long-Term Data on Celgene's Otezla - Analyst Blog", "Bayer Looking to Expand Eylea's Label - Analyst Blog", "Allergan Rejects Valeant's Proposal Yet Again - Analyst Blog", "PDL BioPharma Views Lower Q2 Revenues - Analyst Blog", "Alkermes Progresses with its Late Stage Candidate - Analyst Blog", "AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Analyst Blog", "Immunomedics' IMMU-132 Gets Orphan Drug Status - Analyst Blog", "Valeant's Jublia Approved in the U.S. - Analyst Blog", "Dendreon's CEO Departs at Critical Juncture - Analyst Blog", "Agios Initiates Trial on AG-348 - Analyst Blog", "GW Pharma Gets Fast-Track Designation for Epidiolex - Analyst Blog", "Pipeline Progress at GlaxoSmithKline - Analyst Blog", "MannKind Hits 52-Week High - Analyst Blog", "NPS Pharma's Natpara Likely to be Reviewed in September - Analyst Blog", "Positive Phase IIb Data from Jazz Pharma - Analyst Blog", "Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog", "Positive Data on Vertex Pharma's Kalydeco - Analyst Blog", "Bayer Looking to Expand Adempas Label - Analyst Blog", "Incyte Gains on Positive Jakafi Data - Analyst Blog", "Data on Bristol-Myers' Yervoy - Analyst Blog", "Valeant Relentless on Acquiring Allergan - Analyst Blog", "Nasdaq 100 Movers: ROST, ILMN", "Valeant Ups Offer for Allergan - Analyst Blog", "Intercept's Obeticholic Acid Gets Fast Track Status - Analyst Blog", "BioMarin's Pipeline Advances - Analyst Blog", "Valeant Selling Product Rights to Nestle - Analyst Blog", "PTC Therapeutics Up on Positive CHMP Opinion - Analyst Blog", "Pipeline Progress at RedHill Biopharma - Analyst Blog", "NPS Pharma on Shire's Radar? - Analyst Blog", "Sarepta to Acquire Manufacturing Facility - Analyst Blog", "Data on Insmed's Arikayce - Analyst Blog", "Celgene Inks Licensing Deal with AADi - Analyst Blog", "Intercept Sinks on Cholesterol Issue - Analyst Blog", "Dendreon Up on Provenge Data - Analyst Blog", "AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog", "Endocyte/Merck Withdraw EU Regulatory Filings - Analyst Blog", "ZIOPHARM Presents Encouraging Data - Analyst Blog", "Sarepta to Acquire Manufacturing Facility - Analyst Blog", "Update on Glaxo's Darapladib - Analyst Blog", "Merck KGaA Beats on Q1 Earnings - Analyst Blog", "Wider-than-Expected Q1 Loss at MannKind - Analyst Blog", "Repros' Q1 Loss In Line with Expectations - Analyst Blog", "Osiris Therapeutics Q1 Loss Narrower-Than-Expected - Analyst Blog", "Glaxo-Genmab's Arzerra Disappoints - Analyst Blog", "Insys in Focus on Subsys Worries - Analyst Blog", "Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog", "Shares Continue to fall on Emergent BioSolutions' Wider Loss - Analyst Blog", "Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog", "Dendreon Falls on Q1 Loss - Analyst Blog", "Spectrum Pharma Up on Q1 Earnings - Analyst Blog", "Wider-Than-expected Loss at NPS Pharma, Shares Down - Analyst Blog", "Abbott's Promising Data on RADICAL Platform - Analyst Blog", "Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog", "XOMA Posts Wider Q1 Loss - Analyst Blog", "Anacor Reports Wider-than-Expected Q1 Loss - Analyst Blog", "Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog", "Narrower-than-Expected Loss at AVEO - Analyst Blog", "Avanir Loss In Line with Ests, Revs Up - Analyst Blog", "J&J /Gilead HCV Combo Drug Filed - Analyst Blog", "Medivation Q1 Loss Wider Than Expected - Analyst Blog", "Regeneron Beats on Earnings, Revenues in Q1 - Analyst Blog", "Split Update Overshadows Wider Q1 Loss at Theravance - Analyst Blog", "Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog", "Isis Pharma's Q1 Loss Widens - Analyst Blog", "Wider-than-Expected Loss at Aegerion - Analyst Blog", "Acorda Misses on Earnings, Beats Revs - Analyst Blog", "Nasdaq 100 Movers: DISCA, GMCR", "Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog", "Wider-than-Expected Loss at Auxilium - Analyst Blog", "VIVUS Reports Narrower-than-Expected Loss - Analyst Blog", "Marginal Earnings Beat at Zoetis, View Maintained - Analyst Blog", "Regeneron Inks Ophthalmology Deal - Analyst Blog", "Vical Narrows Q1 Loss - Analyst Blog", "Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog", "Earnings Beat at Pharmacyclics, Guidance Pulls Down Stock - Analyst Blog", "Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog", "Wider-than-Expected Loss at Auxilium - Analyst Blog", "VIVUS Reports Narrower-than-Expected Loss - Analyst Blog", "Geron Reports In-Line Q1 Loss - Analyst Blog", "Endocyte Shares Sink on DSMB Recommendation - Analyst Blog", "Acorda Down on Plumiaz CRL - Analyst Blog", "Novo Nordisk Beats Earnings Ests, Misses Revs - Analyst Blog", "Wider-than-Expected Q1 Loss at Incyte - Analyst Blog", "Celldex's Q1 Loss Widens - Analyst Blog", "Shire Beats on Earnings in Q1 - Analyst Blog", "Affymetrix Q1 Earnings Beat Ests by a Penny - Analyst Blog", "3 Biotech Beats this Earnings Season - Earnings ESP", "Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog", "OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog", "Synageva's Q1 Loss Narrower than Expected - Analyst Blog", "CRL for The Medicines Co.'s Cangrelor - Analyst Blog", "Loss at BioMarin Narrower Than Expected - Analyst Blog", "Bristol-Myers Beats Earnings in Q1, Misses on Sales - Analyst Blog", "Bayer Gains on Q1 Earnings - Analyst Blog", "Zacks Rank #1 Additions for Tuesday - Tale of the Tape", "OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog", "Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog", "Hyperion Set to Acquire Andromeda - Analyst Blog", "Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog", "Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog", "Emergent's BioThrax Gets Orphan Drug Status - Analyst Blog", "Alexion Posts Strong Earnings in Q1 - Analyst Blog", "Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog", "Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog", "Pre-Market Earnings Report for April 24, 2014 : VZ, MMM, MO, UPS, LLY, CAT, CELG, GM, TWC, FCX, RTN, ALXN", "Keep an Eye on these 3 Biotech Stocks - Earnings ESP", "Alexion Likely to Keep Earnings Streak Alive - Analyst Blog", "Company News for April 25, 2014 - Corporate Summary", "Emergent's BioThrax Gets Orphan Drug Status - Analyst Blog", "Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog", "Good News for BioMarin - Analyst Blog", "FDA Nod for Merck's Grastek - Analyst Blog", "Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog", "Pipeline Progress at Coronado Biosciences - Analyst Blog", "Synageva Heading For Big Disappointment", "Positive Data on Biogen/Sobi's Eloctate - Analyst Blog", "Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape", "Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape", "Update on BioLineRx's BL-8040 - Analyst Blog", "Encouraging Results on Gilead's Sovaldi - Analyst Blog", "S&P 500 Movers: BBBY, HPQ", "Nasdaq 100 Movers: BBBY, CHRW", "Positive Results on Intercept Pharma's OCA - Analyst Blog", "Halozyme Falls on Phase II Study Halt - Analyst Blog", "Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog", "FDA Target Date for Gilead's HCV Candidate - Analyst Blog", "RadNet Touches New 52-Week High - Analyst Blog", "MannKind Slips on Afrezza Approval Delay - Analyst Blog", "Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape", "Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape", "3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog", "EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog", "Encouraging Pre-Clinical Data from Celldex - Analyst Blog", "Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog", "Pipeline Update from Idenix - Analyst Blog", "FDA News Lifts Dyax Slightly - Analyst Blog", "Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog", "Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape", "Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape", "The Medicines Co's Fibrocaps Under U.S. Review - Analyst Blog", "Glaxo and Amgen Terminate Agreement - Analyst Blog", "Noteworthy ETF Inflows: IBB, AMGN, BIIB, ALXN", "Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape", "Bayer Initiates Xofigo Combination Study - Analyst Blog", "Encouraging Results on Gilead's Sovaldi - Analyst Blog", "Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape", "Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape", "Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape", "Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape", "Exact Sciences (EXAS) Jumps: Stock Adds 10.2% in Session - Tale of the Tape", "EC Approves Roche/Halozyme's MabThera SC - Analyst Blog", "Glaxo Presents Darapladib Data - Analyst Blog", "Idera Soars on Phase II Drug Data - Analyst Blog", "MannKind Down on FDA's Briefing Document - Analyst Blog", "Celladon (CLDN) Jumps: Stock Up 5.9% - Tale of the Tape", "Gilead's HCV Candidate Under Review in the EU - Analyst Blog", "BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog", "Inovio Pharmaceuticals, Inc. (INO) Worth Watching: Stock Surges 12.7% - Tale of the Tape", "Insmed Incorporated saw its shares rise more than 7% in the session. - Tale of the Tape", "MEI Pharma, Inc. (MEIP) in Focus: Stock up 12.1% - Tale of the Tape", "Integra LifeSciences Introduces Wound Matrix - Analyst Blog", "CVS Caremark Receives FEP contract - Analyst Blog", "FDA Nod for Biogen's Alprolix - Analyst Blog", "China Cord Blood Corporation (CO) Soars: Stock Up 5.7% - Tale of the Tape", "Exelixis' Cometriq Approved in the EU - Analyst Blog", "Insmed Down on Disappointing Arikayce Results - Analyst Blog", "Nektar Rises on FDA Notification (revised) - Analyst Blog", "Retrophin (RTRX) Catches Eye: Stock Moves 7.9% Higher - Tale of the Tape", "What Falling Estimates & Price Mean for Kythera (KYTH) - Tale of the Tape", "Time to Focus on Alexion (ALXN) for Strong Earnings Growth Potential - Tale of the Tape", "Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog", "Update on Celgene's Product Portfolio - Analyst Blog", "IYH, MDT, BAX, ALXN: ETF Outflow Alert", "AstraZeneca's Forxiga Approved in Japan - Analyst Blog", "Positive CHMP Opinion for Novo Nordisk's Drugs - Analyst Blog", "Japan Approves Medivation/Astellas' Xtandi - Analyst Blog", "Nasdaq 100 Movers: WFM, ALXN", "S&P 500 Movers: ALXN, FRX", "Galectin Therapeutics, Inc. (GALT) in Focus: Stock Moves Up 8.84% - Tale of the Tape", "Breakthrough Therapy Status for Pfizer's Drug - Analyst Blog", "AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape", "Gilead Down on Sovaldi Price Issue - Analyst Blog", "Are Biotech Stocks Oversold? - Analyst Blog", "Trial Protocol Submission Lifts Heat Biologics - Analyst Blog", "Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape", "Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% - Tale of the Tape", "Nasdaq 100 Movers: ALXN, SYMC", "Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% - Tale of the Tape", "Qiagen's QuantiFERON-TB Test Now in China - Analyst Blog", "Glaxo's MAGE-A3 Candidate Disappoints Again - Analyst Blog", "Good News for Johnson & Johnson - Analyst Blog", "AVEO Regains AV-203 Rights from Biogen - Analyst Blog", "Favorable Data for Myriad Genetics - Analyst Blog", "Positive Data on Novo Nordisk's N8-GP - Analyst Blog", "Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% - Tale of the Tape", "Prothena Surges on Clinical Data Hopes - Analyst Blog", "Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape", "Synthetic Biologics Inc. (SYN) in Focus: Stock up 9.5% - Tale of the Tape", "Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape", "Sequenom (SQNM) Soars: Stock Rises 6.4% - Tale of the Tape", "Why ANI Pharmaceuticals (ANIP) Has a Bright Short-Term Future? - Tale of the Tape", "Oncothyreon Inc. (ONTY) in Focus: Stock up 6.1% - Tale of the Tape", "Update from Celgene - Analyst Blog", "Horizon Pharma to Buy Vidara, Shares Rise - Analyst Blog", "OncoMed's Q4 Loss Narrows - Analyst Blog", "Fate Reports In-Line Loss in Q4 - Analyst Blog", "Nasdaq 100 Movers: ALXN, NVDA", "Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog", "Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape", "Nektar Rises on FDA Notification - Analyst Blog", "Genomic Health Unveils Oncotype DX Data - Analyst Blog", "Prosensa Rises on Encouraging Data - Analyst Blog", "Novo Nordisk Extends Diabetes Operations - Analyst Blog", "Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog", "Biogen Faces Delay in FDA Action Date - Analyst Blog", "Bristol-Myers, Five Prime Join Forces, Shares up - Analyst Blog", "Horizon Pharma (HZNP) Jumps: Stock Rises 5.6% - Tale of the Tape", "Narrower-Than-Expected Loss at Relypsa - Analyst Blog", "Idenix Files Lawsuit vs. Gilead Again - Analyst Blog", "Glaxo/Theravance Update on COPD Drugs - Analyst Blog", "Milestone Payment for Ligand Pharma - Analyst Blog", "Repros Provides Proellex Update - Analyst Blog", "Pipeline Update from BioDelivery Sciences - Analyst Blog", "Intercept Sees Weakness in Earnings Result - Analyst Blog", "Amgen Scores Again with PCSK9 Inhibitor - Analyst Blog", "Biogen to be added to S&P100 - Analyst Blog", "Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the Tape", "Update on Glaxo's Pipeline - Analyst Blog", "Raptor Pharma Posts Wider-Than-Expected Q4 Loss - Analyst Blog", "Progenics Q4 Loss Narrower Than Expected - Analyst Blog", "Revenues Decline at Discovery Labs in Q4, Shares Down - Analyst Blog", "Narrower-than-Expected Q4 Loss at Repros - Analyst Blog", "Vanda Pharmaceuticals (VNDA) Soars: Stock Adds 9.6% in Session - Tale of the Tape", "AVEO Q4 Loss Narrower than Expected - Analyst Blog", "Update on Bayer's Adempas - Analyst Blog", "Fate Therapeutics' Prohema in Phase II Study - Analyst Blog", "AstraZeneca to Sell Cheshire Research Site - Analyst Blog", "Acura Pharmaceuticals, Inc. (ACUR) in Focus: Stock Moves 7.7% Higher - Tale of the Tape", "Bright Outlook at Bayer - Analyst Blog", "Geron Plunges on FDA Clinical Hold - Analyst Blog", "Bright Outlook at Ligand - Analyst Blog", "PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog", "Insmed (INSM) Looks Good: Stock Adds 5.9% in Session - Tale of the Tape", "Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog", "Enzymotec Ltd. (ENZY) in Focus: Stock Up 5.2% - Tale of the Tape", "Bayer/Amgen's Nexavar Fails in Late-Stage Study - Analyst Blog", "Glaxo Strengthens Indian Presence - Analyst Blog", "Phase I Data on Rexahn's Supinoxin - Analyst Blog", "Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog", "Stock Market News for March 11, 2014 - Market News", "IWR, ACT, ALXN, DAL: Large Inflows Detected at ETF", "Focus on Regulus' Pipeline - Analyst Blog", "Kythera Regains ATX-101 from Bayer - Analyst Blog", "Regado Rises on REG1 Fast Track Designation - Analyst Blog", "Alexion Lifts 2014 View, Shares Up - Analyst Blog", "Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop", "Biogen Upgraded to Strong Buy - Analyst Blog", "Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%", "IGI, Laboratories, Inc. (IG) in Focus: Stock up 11.7% - Tale of the Tape", "Sector Update: Health Care", "Sector Update: Healthcare Shares Flat to Higher Pre-Market; Alexion Up 3% on Fiscal 2014 Guidance", "Strength Seen in Ohr Pharmaceutical, Inc. (OHRP) Stock Shoots 22% - Tale of the Tape", "Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally", "Monday's ETF Movers: XLV, GXC", "S&P 500 Movers: CLF, FMC", "Nasdaq 100 Movers: VOD, ALXN", "Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog", "Spectrum Pharma Posts Lower Y/Y Q4 Earnings - Analyst Blog", "Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape", "Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape", "Pipeline Progress at Alkermes - Analyst Blog", "Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape", "Osiris Misses on Q4 Earnings - Analyst Blog", "Regulatory Update on Cubist Pharma's Tedizolid - Analyst Blog", "Sangamo Soars on Positive Data - Analyst Blog", "Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog", "Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog", "Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape", "PDL BioPharma Misses on Q4 Earnings - Analyst Blog", "Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape", "OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog", "Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock up 8.9% - Tale of the Tape", "Update on Alexion's Soliris - Analyst Blog", "Update on Bayer/Regeneron's Eylea - Analyst Blog", "Theravance to Split in Q2 - Analyst Blog", "Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog", "Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog", "Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape", "Top Mutual Funds Add To Health Care, Leisure And Banks", "Isis Pharma Slips on Wider-Than-Expected Q4 Loss - Analyst Blog", "Promising Data on Merck Allergy Drug - Analyst Blog", "Bayer Up on Higher Q4 Earnings - Analyst Blog", "Are These Biotechs Part of Your Portfolio? - Analyst Blog", "Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape", "Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog", "EU Review for The Medicines Co.'s Oritavancin - Analyst Blog", "Biogen Keeps Momentum Going With MS Drug Tecfidera", "Earnings Decline YoY at Alkermes - Analyst Blog", "Noteworthy ETF Inflows: IWP, ACT, ALXN, CCI", "Idenix Q4 Loss Narrower-Than-Expected - Analyst Blog", "Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog", "Mylan Beats on Q4 Earnings & Revenues - Analyst Blog", "Infinity Pharma Rises on Narrower-than-Expected Loss - Analyst Blog", "Oncothyreon Inc. (ONTY) in Focus: Stock up 9.3% - Tale of the Tape", "FDA Clears AstraZeneca's Myalept - Analyst Blog", "No Looking Back for Regeneron's Eylea - Analyst Blog", "Arena Posts Wider Loss, Misses Ests - Analyst Blog", "Idenix Q4 Loss Narrower-Than-Expected - Analyst Blog", "Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog", "Orphan Drug for Alexion's Soliris in EU - Analyst Blog", "Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog", "Encouraging News from Pfizer - Analyst Blog", "FDA Designation for Bristol-Myers Candidate - Analyst Blog", "Progenics to Raise Funds - Analyst Blog", "Narrower-than-Expected Loss at VIVUS - Analyst Blog", "Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape", "ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape", "Pipeline Progress at Pluristem - Analyst Blog", "Pharmacyclics Attains 52-Week High - Analyst Blog", "Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day", "Isis Pharma Soars on Positive Data - Analyst Blog", "Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog", "Encouraging Data on Bristol-Myers/Pfizer's Eliquis - Analyst Blog", "XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog", "Bayer Progresses with Stivarga - Analyst Blog", "Raptor Soars on Positive RP103 Data - Analyst Blog", "BioMarin Rises on Favorable CHMP Opinion - Analyst Blog", "The Medicines Co Posts Lower Y/Y Q4 Earnings - Analyst Blog", "Synageva BioPharma Corp. (GEVA) in Focus: Stock Moves 5.1% Higher - Tale of the Tape", "Dynavax Withdraws MAA on Heplisav - Analyst Blog", "Pharmacyclics Beats on Earnings, Revenues in Q4 - Analyst Blog", "Interim Data on Insmed's Arikace - Analyst Blog", "Pipeline Progress at Bayer - Analyst Blog", "MannKind's Q4 Loss Wider than Expected - Analyst Blog", "NPS Pharma Swings to Earnings on Strong Revenues - Analyst Blog", "Strong 2014 Sales Guidance from BioMarin - Analyst Blog", "Pipeline Update at Bayer - Analyst Blog", "Positive Opinion on Isis Pharma's ISIS-TTRRx - Analyst Blog", "Pipeline Progress at Regulus - Analyst Blog", "AVEO/Astellas Terminate Agreement - Analyst Blog", "Acorda Up After Q4 Earnings - Analyst Blog", "Alnylam Widens Q4 Loss - Analyst Blog", "Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape", "Chelsea Therapeutics (CHTP) in Focus: Stock Tumbles 7.5% - Tale of the Tape", "Celgene Plans Stock Split - Analyst Blog", "Actelion's Opsumit Cleared in Switzerland - Analyst Blog", "Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape", "Qiagen to Simplify Next-Generation Sequencing - Analyst Blog", "Pharmacyclics Gains on Imbruvica Label Expansion - Analyst Blog", "Ultragenyx Jumps on Positive Patient Data - Analyst Blog", "Wider-than-Expected Q4 Loss at Incyte - Analyst Blog", "NewLink Genetics (NLNK) Jumps: Stock Rises 8.3% - Tale of the Tape", "Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% - Tale of the Tape", "Gilead Seeks U.S. Approval - Analyst Blog", "What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape", "Earnings Estimates Moving Higher for Alexion (ALXN): Time to Buy? - Tale of the Tape", "Puma Biotech Surges on Favorable Patent Ruling - Analyst Blog", "Loss at Theravance Wider Than Expected - Analyst Blog", "Affymetrix Sees Turnaround Quarter but Earnings Miss - Analyst Blog", "Myriad Genetics Inc. (MYGN) Soars: Stock Adds 15.1% in Session - Tale of the Tape", "InterMune (ITMN) Crumbles: Stock Falls by 6.8% - Tale of the Tape", "Medicines Co. Awarded BARDA Contract - Analyst Blog", "Regeneron Beats on Earnings, Revenues - Analyst Blog", "Earnings Estimates Moving Higher for Alexion (ALXN): Time to Buy? - Tale of the Tape", "Alexion (ALXN) Shares March Higher, Can It Continue? - Tale of the Tape", "LinkedIn, TripAdvisor, Google: Top Manager's Ideas", "Roundtable Top Picks for the Week of Feb. 3rd - Video Blog", "Company news for January 31, 2014 - Corporate Summary", "Alexion Pharmaceuticals, Inc. (ALXN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Earnings Reaction History: Alexion Pharmaceuticals, Inc., 30.0% Follow-Through Indicator, 4.2% Sensitive", "CBS Takes Over #25 Spot From Alexion Pharmaceuticals", "Will Alexion's (ALXN) Earnings Streak End? - Analyst Blog", "Orphan Drug Status for Alexion's Solaris - Analyst Blog", "Biotech Stock Roundup: Sarepta Spikes on Data & Alnylam on Deal - Analyst Blog", "Prospects Bright at Alexion Pharma - Analyst Blog", "Celldex: Some Thoughts On Rindopepimut", "Update on Alexion's Voluntary Recall - Analyst Blog", "A safe way to win with biotech growth", "Alexion Tops on Earnings & Revs in Q4 - Analyst Blog", "Will Alexion's (ALXN) Earnings Streak End? - Analyst Blog", "Cubist Pharma Misses on Earnings and Revenues in Q3 - Analyst Blog", "Another Earnings and Rev Beat from Amgen - Analyst Blog", "Will Alexion's (ALXN) Earnings Streak End? - Analyst Blog", "Illumina Tops Earnings, Ups Guidance - Analyst Blog", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Encouraging Data Published on CELG's Abraxane - Analyst Blog", "Celldex: What's All The Excitement About?", "Positive Data on REGN/Sanofi's Drug - Analyst Blog", "NPS Pharma's Gattex Looks Promising - Analyst Blog", "QIAGEN Aids Genome Sequencing Study - Analyst Blog", "Acorda's Label Expansion Efforts - Analyst Blog", "MannKind Resubmits Afrezza NDA - Analyst Blog", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "Bullish on Gilead's Stribild - Analyst Blog", "Update on Portola's Pipeline - Analyst Blog", "Update on BioDelivery Sciences' Bunavail - Analyst Blog", "Ariad Shares Slip on Clinical Hold - Analyst Blog", "BioMarin to Raise Funds - Analyst Blog", "Encouraging Data on NPS Pharma's Natpara - Analyst Blog", "KYTHERA Proposes Public Offering - Analyst Blog", "Good News for Apricus from Germany - Analyst Blog", "ILMN Expands Prenatal Test Offering - Analyst Blog", "Manufacturing Issues Hit Hospira - Analyst Blog", "Vertex Progresses with Kalydeco - Analyst Blog", "Isis Pharma Gains on Pipeline News - Analyst Blog", "Pipeline Progress at Alexion - Analyst Blog", "Sector Update: Healthcare Stocks Flat Pre-Market; ISIS Reports on Phase 2 Results", "Sector Update: Healthcare", "Encouraging News for Alexion - Analyst Blog", "Celgene's Pipeline Encourages - Analyst Blog", "Biotech Alexion: A Giant In The Tiny Orphan Market", "Six High-Impact Sells - Viking Global Investors", "Voluntary Recall at Alexion - Analyst Blog", "Alnylam Wins Orphan Drug Status - Analyst Blog", "Still Neutral on Cubist Pharma - Analyst Blog", "MannKind to Raise $40M from Deerfield - Analyst Blog", "Good News for Alnylam - Analyst Blog", "Data from Alexion's Soliris Study - Analyst Blog", "Positive Data on MannKind's Afrezza - Analyst Blog", "Wider-than-Expected Loss at MannKind - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,669.95 up 9.84 points", "Market Close Report: NASDAQ Composite index closes at 3,616.47 up 17.33 points", "Moving Average Crossover Alert: Alexion Pharmaceuticals, Inc. (ALXN) - Tale of the Tape", "Earnings Beat at Alexion, View Upped - Analyst Blog", "Year-over-Year Rise in Celgene Earnings - Analyst Blog", "CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares", "Market Close Report: NASDAQ Composite index closes at 3,600.08 up 21.78 points", "Market Close Report: NASDAQ Composite index closes at 3,520.76 up 16.50 points", "Market Close Report: NASDAQ Composite index closes at 3,376.22 up 28.33 points", "Gilead Retained at Neutral - Analyst Blog", "Evenly Poised on Regeneron - Analyst Blog", "Theravance's Vibativ Expanded in the US - Analyst Blog", "Gilead Presents Idelalisib Data - Analyst Blog", "Will Alexion (ALXN) Beat Earnings Estimates This Quarter? - Analyst Blog", "Amgen's Oncology Drug Meets Primary Endpoint - Analyst Blog", "Encouraging Data on Alexion's Soliris - Analyst Blog", "Label Expanded for CELG's Revlimid - Analyst Blog", "Encouraging data from Bristol-Myers - Analyst Blog", "Celgene Presents Data at ASCO - Analyst Blog", "CHMP Backs Celgene's Pomalyst - Analyst Blog", "Amgen Xgeva Label Expanded - Analyst Blog", "Omeros Files CTA for aHUS Candidate - Analyst Blog", "Amgen-Astellas Collaborate - Analyst Blog", "Encouraging Data from Alkermes - Analyst Blog", "EU Approval for Bayer/JNJ's Xarelto - Analyst Blog", "Priority FDA Review for Celgene's Abraxane - Analyst Blog", "Positive Data on Bayer Candidate - Analyst Blog", "Alkermes Reports Earnings for Q4 - Analyst Blog", "Biogen Delays EU Launch of Tecfidera - Analyst Blog", "Bayer Files Riociguat in Japan - Analyst Blog", "Biogen's Hemophilia BLA Accepted - Analyst Blog", "Bayer's Xofigo Cleared in the US - Analyst Blog", "Earnings Beat at Alexion, Ups View - Analyst Blog", "Omeros' OMS721 Files for Orphan Drug Status - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,239.17 down -28.35 points", "Bad News for Alexion, Shares Down - Analyst Blog", "Yet Another Acquisition for Bayer - Analyst Blog", "Alexion Pharma Upgraded to Outperform - Analyst Blog", "Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy", "Market Close Report: NASDAQ Composite index closes at 3,182.03 up 12.29 points", "Market Close Report: NASDAQ Composite index closes at 3,131.49 down -32.92 points", "Positive Data from BMRN's PKU-016 - Analyst Blog", "Update on Peregrine's Bavituximab - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,213.59 up 21.56 points", "Moving Averages Indicate These Sector ETFs Could be Stretched", "Pre-Market Earnings Report for February 14, 2013 : PEP, GM, APA, ABX, DTV, CVE, PPL, ALXN, SLF, WM, REGN, ECA", "Market Close Report: NASDAQ Composite index closes at 3,153.67 up 10.49 points", "Market Close Report: NASDAQ Composite index closes at 3,112.26 up 92.75 points", "Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)", "Time to Consider Pure Growth and Value ETFs? - ETF News And Commentary", "Alexion Pharma Evenly Poised - Analyst Blog", "Positive Data on CYTK's Tirasemtiv - Analyst Blog", "Alexion 4Q Tops on Both Lines - Analyst Blog", "Don't Stay Married to the Old Leaders; Target New Leadership", "IBD Chairman William O'Neil: Supercycle Bull May Arrive", "Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)", "Strong Quarter at Alexion - Analyst Blog", "Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)", "Top Funds Favor Health Care, Retail In Recent Buys ALXN CTRX", "Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM", "Reshuffling The Lineup For The Health Care Model", "Alexion Beats; Raises Guidance - Analyst Blog", "Pre-Market Earnings Report for July 25, 2012 : BMY, BA, ALXN, ARMH, ARG, ATI, AOL, BKU, AVX, ALR, MT, ATMI", "Top-Performing Funds Add Shares Of Health Care Stocks", "Alexion Presents New Data - Analyst Blog", "Weekly Top Insider Sells: GOOG, YHOO, ALXN, and CTL", "After Hours Most Active for May 24, 2012 : EP, KMI, ALXN, S, XRX, GLW, WMB, QQQ, ORCL, FB, TEVA, TIBX", "Alexion Downgraded to Neutral - Analyst Blog", "Top-Performing Funds Latch On To Biotech And Discount Retail Stocks", "Zacks Bull and Bear of the Day Highlights: Alexion Pharmaceuticals, CSN, CBS, News Corporation and Comcast - Press Releases", "Alexion Pharmaceuticals (ALXN) - Bull of the Day", "Alexion is an Outperformer - Analyst Blog", "ETFs For Momentum Stocks (FBT, PNQI, HDGE)", "Risk-Reward Balanced at Alexion - Analyst Blog", "Alexion Exits 2011 on a Strong Note - Analyst Blog", "Alexion Takes Over Enobia Pharma - Analyst Blog", "Alexion Beats, Raises Outlook - Analyst Blog", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "Should Traders Fade Strength in Europe?", "Black Friday Buying and Nasdaq Bargains", "Top Five Companies Worth a Second Look in 2012", "Momentum Ideas: Top 7 Rallies to Keep on Your Radar", "Opening View: DJIA, SPX Cautiously Higher as Wall Street Eyes Euro Zone, Earnings", "VIX Index: Top 10 Debt-Free Stocks to Protect Your Portfolio From Extreme Volatility", "Alexion Cut to Neutral - Analyst Blog", "Medical Breakthrough: Successful Stem Cell Transplant in Sweden", "Options Ideas: 24 Healthcare Stocks With Bullish Options Sentiment", "12 Takeover Targets Seeing Worsening Analyst Sentiment", "Two Stocks for the E-Reading Revolution", "Healthcare Takeovers Targets: Express Scripts Buys Medco"], "Elapsed Time": ["2 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "JUN 17, 2020", "JUN 12, 2020", "JUN 10, 2020", "JUN 8, 2020", "JUN 2, 2020", "2 DAYS AGO", "JUN 2, 2020", "JUN 2, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 28, 2020", "JUN 2, 2020", "MAY 28, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 24, 2020", "MAY 21, 2020", "MAY 21, 2020", "MAY 19, 2020", "MAY 28, 2020", "MAY 17, 2020", "MAY 15, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 17, 2020", "MAY 8, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 8, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 2, 2020", "MAY 1, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 26, 2020", "APR 20, 2020", "MAY 5, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 19, 2020", "APR 15, 2020", "APR 11, 2020", "APR 10, 2020", "APR 9, 2020", "APR 9, 2020", "APR 6, 2020", "APR 19, 2020", "APR 19, 2020", "MAR 26, 2020", "MAR 25, 2020", "MAR 22, 2020", "MAR 19, 2020", "MAR 16, 2020", "MAR 16, 2020", "MAR 27, 2020", "MAR 15, 2020", "MAR 13, 2020", "MAR 6, 2020", "MAR 5, 2020", "MAR 3, 2020", "FEB 27, 2020", "FEB 26, 2020", "MAR 15, 2020", "FEB 16, 2020", "FEB 16, 2020", "FEB 11, 2020", "FEB 6, 2020", "FEB 3, 2020", "FEB 3, 2020", "JAN 30, 2020", "FEB 16, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 28, 2020", "JAN 27, 2020", "JAN 30, 2020", "JAN 19, 2020", "JAN 19, 2020", "JAN 15, 2020", "JAN 14, 2020", "JAN 14, 2020", "JAN 10, 2020", "JAN 9, 2020", "JAN 22, 2020", "JAN 7, 2020", "JAN 7, 2020", "JAN 7, 2020", "JAN 5, 2020", "JAN 2, 2020", "DEC 27, 2019", "DEC 27, 2019", "JAN 7, 2020", "DEC 20, 2019", "DEC 20, 2019", "DEC 18, 2019", "DEC 15, 2019", "DEC 14, 2019", "DEC 6, 2019", "DEC 6, 2019", "DEC 25, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 2, 2019", "NOV 25, 2019", "NOV 25, 2019", "DEC 6, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 2, 2019", "NOV 25, 2019", "NOV 25, 2019", "OCT 25, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 26, 2019", "OCT 23, 2019", "OCT 22, 2019", "OCT 19, 2019", "OCT 16, 2019", "OCT 16, 2019", "OCT 16, 2019", "OCT 14, 2019", "OCT 23, 2019", "OCT 11, 2019", "OCT 11, 2019", "OCT 10, 2019", "OCT 8, 2019", "SEP 27, 2019", "SEP 26, 2019", "SEP 25, 2019", "OCT 14, 2019", "SEP 19, 2019", "SEP 18, 2019", "SEP 17, 2019", "SEP 17, 2019", "SEP 10, 2019", "SEP 6, 2019", "SEP 6, 2019", "SEP 24, 2019", "SEP 3, 2019", "SEP 3, 2019", "AUG 30, 2019", "AUG 30, 2019", "AUG 30, 2019", "AUG 30, 2019", "AUG 28, 2019", "SEP 5, 2019", "AUG 26, 2019", "AUG 26, 2019", "AUG 25, 2019", "AUG 24, 2019", "AUG 23, 2019", "AUG 23, 2019", "AUG 20, 2019", "AUG 26, 2019", "AUG 11, 2019", "AUG 8, 2019", "AUG 2, 2019", "JUL 29, 2019", "JUL 26, 2019", "JUL 26, 2019", "JUL 25, 2019", "AUG 12, 2019", "JUL 24, 2019", "JUL 24, 2019", "JUL 24, 2019", "JUL 24, 2019", "JUL 23, 2019", "JUL 14, 2019", "JUL 14, 2019", "JUL 24, 2019", "JUL 8, 2019", "JUL 1, 2019", "JUN 30, 2019", "JUN 27, 2019", "JUN 26, 2019", "JUN 20, 2019", "JUN 16, 2019", "JUL 8, 2019", "JUL 8, 2019", "JUN 5, 2019", "JUN 4, 2019", "MAY 31, 2019", "MAY 30, 2019", "MAY 28, 2019", "MAY 26, 2019", "JUN 13, 2019", "JUN 13, 2019", "MAY 23, 2019", "MAY 19, 2019", "APR 30, 2019", "APR 25, 2019", "APR 25, 2019", "APR 25, 2019", "MAY 24, 2019", "MAY 23, 2019", "MAY 23, 2019", "MAY 19, 2019", "APR 30, 2019", "APR 25, 2019", "APR 25, 2019", "APR 25, 2019", "MAY 24, 2019", "APR 18, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 25, 2019", "APR 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 13, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 1, 2019", "JAN 31, 2019", "JAN 31, 2019", "JAN 29, 2019", "JAN 28, 2019", "FEB 4, 2019", "JAN 28, 2019", "JAN 28, 2019", "JAN 15, 2019", "JAN 11, 2019", "JAN 8, 2019", "JAN 8, 2019", "DEC 27, 2018", "JAN 28, 2019", "DEC 24, 2018", "DEC 24, 2018", "DEC 22, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 27, 2018", "DEC 21, 2018", "DEC 20, 2018", "DEC 19, 2018", "DEC 19, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 20, 2018", "DEC 11, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 7, 2018", "DEC 14, 2018", "DEC 12, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 3, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 27, 2018", "DEC 5, 2018", "DEC 4, 2018", "DEC 4, 2018", "DEC 3, 2018", "DEC 3, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 27, 2018", "NOV 27, 2018", "NOV 27, 2018", "NOV 26, 2018", "NOV 21, 2018", "NOV 20, 2018", "NOV 20, 2018", "NOV 19, 2018", "NOV 19, 2018", "NOV 15, 2018", "NOV 6, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 2, 2018", "NOV 1, 2018", "OCT 31, 2018", "OCT 31, 2018", "NOV 6, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 11, 2018", "OCT 3, 2018", "OCT 3, 2018", "OCT 2, 2018", "OCT 22, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 27, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 26, 2018", "OCT 2, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 24, 2018", "SEP 24, 2018", "SEP 24, 2018", "SEP 26, 2018", "SEP 19, 2018", "AUG 22, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 20, 2018", "AUG 16, 2018", "AUG 13, 2018", "SEP 20, 2018", "AUG 10, 2018", "AUG 8, 2018", "AUG 2, 2018", "AUG 1, 2018", "AUG 1, 2018", "JUL 26, 2018", "JUL 26, 2018", "AUG 10, 2018", "AUG 10, 2018", "AUG 8, 2018", "JUL 23, 2018", "JUL 23, 2018", "JUL 19, 2018", "JUL 18, 2018", "JUL 17, 2018", "JUL 26, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 17, 2018", "JUL 16, 2018", "JUL 16, 2018", "JUL 12, 2018", "JUL 11, 2018", "JUL 17, 2018", "JUL 17, 2018", "JUL 17, 2018", "JUL 17, 2018", "JUN 20, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUL 9, 2018", "JUN 12, 2018", "JUN 12, 2018", "JUN 12, 2018", "MAY 30, 2018", "MAY 29, 2018", "MAY 28, 2018", "MAY 25, 2018", "JUN 13, 2018", "MAY 25, 2018", "MAY 14, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 8, 2018", "MAY 3, 2018", "MAY 2, 2018", "MAY 25, 2018", "APR 27, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "MAY 1, 2018", "APR 26, 2018", "APR 26, 2018", "APR 25, 2018", "APR 24, 2018", "APR 24, 2018", "APR 23, 2018", "APR 23, 2018", "APR 26, 2018", "APR 20, 2018", "APR 18, 2018", "APR 13, 2018", "APR 12, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "APR 20, 2018", "APR 20, 2018", "APR 18, 2018", "APR 13, 2018", "MAR 26, 2018", "MAR 21, 2018", "MAR 16, 2018", "MAR 15, 2018", "APR 11, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 5, 2018", "FEB 28, 2018", "FEB 23, 2018", "MAR 15, 2018", "FEB 16, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 14, 2018", "FEB 12, 2018", "FEB 12, 2018", "FEB 12, 2018", "FEB 20, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 10, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 2, 2018", "FEB 1, 2018", "FEB 1, 2018", "JAN 31, 2018", "JAN 31, 2018", "FEB 6, 2018", "JAN 30, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 30, 2018", "JAN 17, 2018", "JAN 12, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 22, 2018", "JAN 3, 2018", "JAN 2, 2018", "DEC 27, 2017", "DEC 26, 2017", "DEC 26, 2017", "DEC 20, 2017", "DEC 20, 2017", "JAN 4, 2018", "JAN 3, 2018", "DEC 11, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 19, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 8, 2017", "DEC 4, 2017", "NOV 28, 2017", "NOV 28, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 15, 2017", "NOV 15, 2017", "DEC 5, 2017", "NOV 7, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 3, 2017", "OCT 31, 2017", "OCT 29, 2017", "OCT 26, 2017", "NOV 8, 2017", "NOV 7, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 3, 2017", "OCT 25, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 25, 2017", "OCT 18, 2017", "OCT 17, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 11, 2017", "OCT 11, 2017", "OCT 5, 2017", "OCT 3, 2017", "OCT 2, 2017", "SEP 28, 2017", "OCT 13, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 25, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 26, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 22, 2017", "SEP 20, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 15, 2017", "SEP 15, 2017", "SEP 18, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 14, 2017", "SEP 12, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 7, 2017", "SEP 12, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 7, 2017", "SEP 6, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 31, 2017", "SEP 5, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 25, 2017", "AUG 30, 2017", "AUG 24, 2017", "AUG 24, 2017", "AUG 23, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 24, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 21, 2017", "AUG 21, 2017", "AUG 18, 2017", "AUG 17, 2017", "AUG 17, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 21, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 11, 2017", "AUG 17, 2017", "AUG 11, 2017", "AUG 10, 2017", "AUG 10, 2017", "AUG 9, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 11, 2017", "AUG 1, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "AUG 2, 2017", "JUL 24, 2017", "JUL 24, 2017", "JUL 21, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 25, 2017", "JUL 13, 2017", "JUL 11, 2017", "JUL 10, 2017", "JUL 9, 2017", "JUL 7, 2017", "JUL 6, 2017", "JUL 5, 2017", "JUL 17, 2017", "JUL 3, 2017", "JUN 30, 2017", "JUN 28, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 26, 2017", "JUN 23, 2017", "JUL 3, 2017", "JUN 19, 2017", "JUN 17, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 21, 2017", "JUN 19, 2017", "JUN 17, 2017", "JUN 16, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 9, 2017", "JUN 7, 2017", "JUN 3, 2017", "JUN 1, 2017", "MAY 30, 2017", "MAY 25, 2017", "MAY 25, 2017", "JUN 12, 2017", "MAY 24, 2017", "MAY 24, 2017", "MAY 24, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 24, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 21, 2017", "MAY 17, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 10, 2017", "MAY 10, 2017", "MAY 8, 2017", "MAY 5, 2017", "MAY 17, 2017", "APR 28, 2017", "APR 27, 2017", "APR 27, 2017", "APR 27, 2017", "APR 27, 2017", "APR 26, 2017", "APR 24, 2017", "MAY 4, 2017", "APR 21, 2017", "APR 20, 2017", "APR 19, 2017", "APR 19, 2017", "APR 18, 2017", "APR 16, 2017", "APR 13, 2017", "APR 21, 2017", "APR 21, 2017", "APR 4, 2017", "APR 3, 2017", "MAR 29, 2017", "MAR 28, 2017", "MAR 24, 2017", "MAR 23, 2017", "APR 13, 2017", "MAR 22, 2017", "MAR 21, 2017", "MAR 20, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 23, 2017", "MAR 13, 2017", "MAR 13, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 8, 2017", "MAR 7, 2017", "FEB 28, 2017", "MAR 17, 2017", "MAR 13, 2017", "MAR 13, 2017", "MAR 10, 2017", "FEB 20, 2017", "FEB 17, 2017", "FEB 16, 2017", "FEB 16, 2017", "FEB 27, 2017", "FEB 15, 2017", "FEB 14, 2017", "FEB 10, 2017", "FEB 6, 2017", "FEB 2, 2017", "JAN 31, 2017", "JAN 19, 2017", "FEB 15, 2017", "JAN 12, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 9, 2017", "JAN 18, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 4, 2017", "JAN 9, 2017", "DEC 28, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 22, 2016", "DEC 22, 2016", "DEC 21, 2016", "DEC 21, 2016", "JAN 4, 2017", "DEC 20, 2016", "DEC 19, 2016", "DEC 19, 2016", "DEC 19, 2016", "DEC 16, 2016", "DEC 16, 2016", "DEC 15, 2016", "DEC 21, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 14, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "NOV 29, 2016", "NOV 29, 2016", "NOV 29, 2016", "NOV 23, 2016", "NOV 22, 2016", "NOV 15, 2016", "NOV 14, 2016", "DEC 9, 2016", "NOV 11, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 11, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 1, 2016", "OCT 31, 2016", "NOV 4, 2016", "OCT 31, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 24, 2016", "OCT 31, 2016", "OCT 20, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 11, 2016", "OCT 7, 2016", "OCT 4, 2016", "SEP 28, 2016", "OCT 20, 2016", "SEP 23, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 12, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 1, 2016", "SEP 23, 2016", "SEP 23, 2016", "SEP 20, 2016", "AUG 22, 2016", "AUG 15, 2016", "AUG 12, 2016", "AUG 11, 2016", "AUG 31, 2016", "AUG 30, 2016", "AUG 24, 2016", "AUG 22, 2016", "AUG 22, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 27, 2016", "AUG 5, 2016", "JUL 23, 2016", "JUL 21, 2016", "JUL 19, 2016", "JUL 14, 2016", "JUL 13, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 26, 2016", "JUN 29, 2016", "JUN 28, 2016", "JUN 27, 2016", "JUN 27, 2016", "JUN 24, 2016", "JUN 23, 2016", "JUN 22, 2016", "JUN 29, 2016", "JUN 16, 2016", "JUN 15, 2016", "JUN 13, 2016", "JUN 10, 2016", "JUN 8, 2016", "JUN 8, 2016", "JUN 7, 2016", "JUN 16, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 2, 2016", "JUN 7, 2016", "MAY 27, 2016", "MAY 24, 2016", "MAY 24, 2016", "MAY 17, 2016", "MAY 9, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 31, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 26, 2016", "APR 26, 2016", "APR 21, 2016", "APR 13, 2016", "MAY 2, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 26, 2016", "APR 26, 2016", "MAR 18, 2016", "MAR 18, 2016", "APR 9, 2016", "APR 7, 2016", "APR 6, 2016", "MAR 8, 2016", "MAR 3, 2016", "MAR 2, 2016", "FEB 29, 2016", "FEB 25, 2016", "MAR 11, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 5, 2016", "FEB 4, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 19, 2016", "FEB 1, 2016", "FEB 1, 2016", "JAN 21, 2016", "JAN 15, 2016", "JAN 7, 2016", "JAN 7, 2016", "JAN 3, 2016", "FEB 2, 2016", "DEC 22, 2015", "DEC 13, 2015", "DEC 10, 2015", "DEC 9, 2015", "DEC 8, 2015", "DEC 8, 2015", "DEC 8, 2015", "DEC 28, 2015", "DEC 2, 2015", "NOV 22, 2015", "NOV 18, 2015", "NOV 16, 2015", "NOV 13, 2015", "NOV 11, 2015", "NOV 6, 2015", "DEC 3, 2015", "NOV 1, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 28, 2015", "OCT 27, 2015", "OCT 27, 2015", "NOV 3, 2015", "OCT 25, 2015", "OCT 20, 2015", "OCT 18, 2015", "OCT 14, 2015", "OCT 14, 2015", "OCT 13, 2015", "OCT 13, 2015", "OCT 26, 2015", "SEP 19, 2015", "SEP 18, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 9, 2015", "SEP 7, 2015", "SEP 3, 2015", "SEP 28, 2015", "AUG 21, 2015", "AUG 19, 2015", "AUG 19, 2015", "AUG 19, 2015", "AUG 18, 2015", "AUG 15, 2015", "AUG 4, 2015", "AUG 24, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 24, 2015", "JUL 31, 2015", "JUL 22, 2015", "JUL 21, 2015", "JUL 10, 2015", "JUL 9, 2015", "JUL 8, 2015", "JUL 7, 2015", "JUL 5, 2015", "JUL 23, 2015", "JUN 30, 2015", "JUN 29, 2015", "JUN 15, 2015", "JUN 12, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 9, 2015", "JUL 1, 2015", "JUN 5, 2015", "JUN 3, 2015", "JUN 3, 2015", "JUN 2, 2015", "MAY 29, 2015", "MAY 27, 2015", "MAY 26, 2015", "JUN 9, 2015", "MAY 13, 2015", "MAY 11, 2015", "MAY 10, 2015", "MAY 10, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 6, 2015", "MAY 20, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 6, 2015", "MAY 5, 2015", "MAY 6, 2015", "APR 23, 2015", "APR 23, 2015", "APR 22, 2015", "APR 21, 2015", "APR 15, 2015", "APR 13, 2015", "APR 11, 2015", "APR 28, 2015", "APR 7, 2015", "APR 4, 2015", "MAR 30, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 19, 2015", "MAR 18, 2015", "APR 10, 2015", "MAR 13, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "FEB 26, 2015", "FEB 26, 2015", "MAR 16, 2015", "FEB 6, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 29, 2015", "JAN 29, 2015", "JAN 29, 2015", "JAN 29, 2015", "FEB 10, 2015", "JAN 29, 2015", "JAN 29, 2015", "JAN 29, 2015", "JAN 29, 2015", "JAN 28, 2015", "JAN 27, 2015", "JAN 27, 2015", "JAN 29, 2015", "JAN 23, 2015", "JAN 23, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 27, 2015", "JAN 23, 2015", "JAN 23, 2015", "JAN 22, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 19, 2015", "JAN 19, 2015", "JAN 16, 2015", "JAN 16, 2015", "JAN 21, 2015", "JAN 15, 2015", "JAN 15, 2015", "JAN 15, 2015", "JAN 14, 2015", "JAN 14, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 15, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 11, 2015", "JAN 9, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 12, 2015", "DEC 31, 2014", "DEC 24, 2014", "DEC 21, 2014", "DEC 17, 2014", "DEC 17, 2014", "DEC 16, 2014", "DEC 15, 2014", "JAN 7, 2015", "DEC 3, 2014", "DEC 3, 2014", "DEC 1, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 26, 2014", "NOV 19, 2014", "DEC 8, 2014", "NOV 6, 2014", "NOV 5, 2014", "NOV 4, 2014", "NOV 4, 2014", "OCT 29, 2014", "OCT 26, 2014", "OCT 24, 2014", "NOV 10, 2014", "OCT 21, 2014", "OCT 16, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 13, 2014", "OCT 11, 2014", "OCT 8, 2014", "OCT 22, 2014", "OCT 6, 2014", "OCT 2, 2014", "SEP 24, 2014", "SEP 22, 2014", "SEP 18, 2014", "SEP 17, 2014", "SEP 9, 2014", "OCT 6, 2014", "SEP 2, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 28, 2014", "AUG 27, 2014", "AUG 20, 2014", "AUG 19, 2014", "SEP 4, 2014", "AUG 8, 2014", "AUG 7, 2014", "AUG 6, 2014", "AUG 5, 2014", "AUG 4, 2014", "AUG 4, 2014", "AUG 1, 2014", "AUG 8, 2014", "JUL 28, 2014", "JUL 28, 2014", "JUL 24, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 23, 2014", "JUL 22, 2014", "JUL 30, 2014", "JUL 28, 2014", "JUL 28, 2014", "JUL 8, 2014", "JUN 27, 2014", "JUN 23, 2014", "JUN 20, 2014", "JUN 20, 2014", "JUL 21, 2014", "JUN 19, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 16, 2014", "JUN 13, 2014", "JUN 19, 2014", "JUN 13, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 13, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 9, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 11, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 4, 2014", "JUN 4, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 5, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 28, 2014", "MAY 27, 2014", "MAY 23, 2014", "JUN 2, 2014", "MAY 23, 2014", "MAY 22, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 20, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 16, 2014", "MAY 15, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 20, 2014", "MAY 13, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 9, 2014", "MAY 13, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 8, 2014", "MAY 8, 2014", "MAY 8, 2014", "MAY 9, 2014", "MAY 8, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 6, 2014", "MAY 8, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 5, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 2, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 28, 2014", "APR 30, 2014", "APR 24, 2014", "APR 24, 2014", "APR 24, 2014", "APR 23, 2014", "APR 23, 2014", "APR 22, 2014", "APR 22, 2014", "APR 25, 2014", "APR 24, 2014", "APR 16, 2014", "APR 15, 2014", "APR 15, 2014", "APR 14, 2014", "APR 14, 2014", "APR 22, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 10, 2014", "APR 10, 2014", "APR 14, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 10, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 7, 2014", "APR 7, 2014", "APR 4, 2014", "APR 8, 2014", "APR 4, 2014", "APR 4, 2014", "APR 3, 2014", "APR 3, 2014", "APR 3, 2014", "APR 3, 2014", "APR 1, 2014", "APR 4, 2014", "APR 1, 2014", "APR 1, 2014", "APR 1, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 31, 2014", "APR 1, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 31, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 27, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 24, 2014", "MAR 26, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 19, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 17, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 17, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 14, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 11, 2014", "MAR 12, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 11, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 7, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 5, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "FEB 28, 2014", "MAR 3, 2014", "FEB 28, 2014", "FEB 27, 2014", "FEB 27, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 25, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 25, 2014", "FEB 24, 2014", "FEB 25, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 21, 2014", "FEB 21, 2014", "FEB 21, 2014", "FEB 21, 2014", "FEB 20, 2014", "FEB 20, 2014", "FEB 20, 2014", "FEB 21, 2014", "FEB 20, 2014", "FEB 20, 2014", "FEB 19, 2014", "FEB 19, 2014", "FEB 19, 2014", "FEB 19, 2014", "FEB 18, 2014", "FEB 20, 2014", "FEB 18, 2014", "FEB 18, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 18, 2014", "FEB 13, 2014", "FEB 13, 2014", "FEB 13, 2014", "FEB 13, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 13, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 7, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 6, 2014", "FEB 11, 2014", "FEB 10, 2014", "FEB 5, 2014", "FEB 4, 2014", "FEB 3, 2014", "JAN 31, 2014", "JAN 31, 2014", "JAN 30, 2014", "FEB 5, 2014", "JAN 28, 2014", "JAN 22, 2014", "JAN 22, 2014", "JAN 16, 2014", "DEC 19, 2013", "DEC 16, 2013", "DEC 2, 2013", "JAN 30, 2014", "JAN 28, 2014", "OCT 23, 2013", "OCT 23, 2013", "OCT 22, 2013", "OCT 22, 2013", "OCT 21, 2013", "OCT 17, 2013", "OCT 30, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 15, 2013", "OCT 15, 2013", "OCT 17, 2013", "OCT 14, 2013", "OCT 11, 2013", "OCT 10, 2013", "OCT 8, 2013", "OCT 8, 2013", "OCT 8, 2013", "OCT 8, 2013", "OCT 15, 2013", "OCT 7, 2013", "OCT 7, 2013", "SEP 24, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 16, 2013", "OCT 7, 2013", "SEP 13, 2013", "AUG 26, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 19, 2013", "AUG 19, 2013", "SEP 13, 2013", "AUG 16, 2013", "AUG 13, 2013", "AUG 12, 2013", "JUL 30, 2013", "JUL 29, 2013", "JUL 25, 2013", "JUL 25, 2013", "AUG 19, 2013", "JUL 12, 2013", "JUL 10, 2013", "JUN 26, 2013", "JUN 25, 2013", "JUN 25, 2013", "JUN 24, 2013", "JUN 19, 2013", "JUL 22, 2013", "JUN 13, 2013", "JUN 10, 2013", "JUN 7, 2013", "JUN 5, 2013", "JUN 5, 2013", "JUN 3, 2013", "JUN 17, 2013", "MAY 29, 2013", "MAY 29, 2013", "MAY 29, 2013", "MAY 28, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 31, 2013", "MAY 21, 2013", "MAY 20, 2013", "MAY 16, 2013", "APR 25, 2013", "APR 18, 2013", "APR 1, 2013", "APR 1, 2013", "MAY 21, 2013", "MAR 15, 2013", "MAR 14, 2013", "MAR 4, 2013", "FEB 21, 2013", "FEB 20, 2013", "FEB 20, 2013", "FEB 19, 2013", "MAR 25, 2013", "FEB 13, 2013", "JAN 23, 2013", "JAN 2, 2013", "DEC 12, 2012", "DEC 4, 2012", "DEC 3, 2012", "NOV 27, 2012", "FEB 14, 2013", "NOV 2, 2012", "OCT 30, 2012", "OCT 25, 2012", "OCT 24, 2012", "OCT 15, 2012", "OCT 2, 2012", "SEP 3, 2012", "NOV 19, 2012", "JUL 25, 2012", "JUL 24, 2012", "JUL 3, 2012", "JUN 19, 2012", "JUN 4, 2012", "MAY 24, 2012", "MAY 17, 2012", "AUG 2, 2012", "APR 19, 2012", "APR 19, 2012", "APR 17, 2012", "APR 10, 2012", "FEB 21, 2012", "FEB 10, 2012", "FEB 8, 2012", "APR 26, 2012", "DEC 20, 2011", "NOV 29, 2011", "NOV 25, 2011", "NOV 15, 2011", "NOV 3, 2011", "OCT 20, 2011", "AUG 3, 2011", "DEC 27, 2011", "JUL 8, 2011", "JUN 7, 2011", "JAN 20, 2011", "OCT 22, 2010", "JUL 22, 2011"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/alexion%3A-subcutaneous-ultomiris-shows-pk-based-non-inferiority-in-phase-3-study-2020-06-24", "https://www.nasdaq.com/articles/alexion-pharma-to-present-at-bank-of-america-virtual-conference-webcast-at-2%3A00-pm-et-2020", "https://www.nasdaq.com/articles/alexion-pharma-to-present-at-bofa-virtual-napa-biotech-conference-webcast-at-2%3A00-pm-et", "https://www.nasdaq.com/articles/got-%242000-smart-investors-are-buying-these-stocks-hand-over-fist.-2020-06-17", "https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2020-06-12", "https://www.nasdaq.com/articles/got-%241000-these-value-stocks-are-begging-to-be-bought.-2020-06-10", "https://www.nasdaq.com/articles/bbhs-underlying-holdings-could-mean-11-gain-potential-2020-06-08", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-healthcare-technology-communications-2020-06-02", "https://www.nasdaq.com/articles/alexion%3A-subcutaneous-ultomiris-shows-pk-based-non-inferiority-in-phase-3-study-2020-06-24", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-virgin-galactic-baozun-hollyfrontier-2020-06-02", "https://www.nasdaq.com/articles/3-top-stocks-that-will-make-you-richer-in-june-and-beyond-2020-06-02", "https://www.nasdaq.com/articles/thursday-sector-leaders%3A-utilities-healthcare-2020-05-28", "https://www.nasdaq.com/articles/nasdaq-today%3A-why-alexion-and-workday-stock-are-soaring-2020-05-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-arca-biopharma-aerpio-pharma-triumph-group-2020-05-28", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-khc-alxn-fdx-2020-05-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-blue-hat-arca-biopharma-aerpio-pharma-2020-05-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-raytheon-planet-fitness-lands-end-2020-06-02", "https://www.nasdaq.com/articles/stock-alert%3A-alexion-pharma-up-7-2020-05-28", "https://www.nasdaq.com/articles/heres-why-argenx-stock-is-soaring-today-2020-05-26", "https://www.nasdaq.com/articles/ibb-ilmn-sgen-alxn%3A-etf-inflow-alert-2020-05-26", "https://www.nasdaq.com/articles/is-arrowhead-pharmaceuticals-a-buy-2020-05-24", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-l-brands-akorn-aurora-cannabis-2020-05-21", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-akorn-l-brands-aurora-cannabis-2020-05-21", "https://www.nasdaq.com/articles/3-healthcare-stocks-with-sustainable-competitive-advantages-2020-05-19", "https://www.nasdaq.com/articles/sp-500-movers%3A-hpq-dltr-2020-05-28", "https://www.nasdaq.com/articles/why-gileads-remdesivir-might-not-be-the-mega-moneymaker-some-think-it-will-be-2020-05-17", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-ilmn-alxn-incy-2020-05-15", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-helius-medical-datadog-novavax-2020-05-12", "https://www.nasdaq.com/articles/alxn-makes-bullish-cross-above-critical-moving-average-2020-05-12", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-datadog-novavax-cymabay-therapeutics-2020-05-12", "https://www.nasdaq.com/articles/activist-investor-elliott-pushes-alexion-pharma-to-sell-itself-2020-05-12", "https://www.nasdaq.com/articles/elliott-again-pushes-alexion-pharma-to-explore-a-sale-2020-05-12", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-5-17-2020-2020-05-17", "https://www.nasdaq.com/articles/analysts-anticipate-iyh-will-reach-%24237-2020-05-08", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-beats-earnings-estimates-but-cuts-guidance-2020-05-06", "https://www.nasdaq.com/articles/alexion-pharma-updates-2020-financial-guidance-quick-facts-2020-05-06", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-q1-adjusted-earnings-beat-estimates-2020-05-06", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oil-and-gas-stocks-banks-tesla-tankers-2020-05-05", "https://www.nasdaq.com/articles/why-portola-pharmaceuticals-is-skyrocketing-today-2020-05-05", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-5-8-2020-2020-05-08", "https://www.nasdaq.com/articles/alexion-will-buy-portola-pharmaceuticals-for-%241.4-billion-2020-05-05", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-swks-2020-05-05", "https://www.nasdaq.com/articles/stock-alert%3A-alexion-pharma-loses-5-after-portola-acquisition-news-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05", "https://www.nasdaq.com/articles/alexion-diversifies-treatment-portfolio-with-%241.41-bln-portola-deal-2020-05-05", "https://www.nasdaq.com/articles/alexion-pharma-to-acquire-portola-quick-facts-2020-05-05", "https://www.nasdaq.com/articles/alexion-to-buy-portola-pharmaceuticals-in-%241.41-bln-deal-2020-05-05-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05-0", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-alexion-pharmaceuticals-2020-05-02", "https://www.nasdaq.com/articles/alexion-pharma%3A-chmp-adopts-positive-opinion-for-ultomiris-2020-05-01", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-ftcs-nem-ttwo-alxn-2020-04-27", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-27", "https://www.nasdaq.com/articles/have-%24300-then-open-a-position-in-these-top-stocks-2020-04-27", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-26", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-to-initiate-phase-3-study-for-ultomiris-as-a-potential-coronavirus", "https://www.nasdaq.com/articles/alexion-to-buy-portola-pharmaceuticals-in-%241.41-bln-deal-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dupont-occidental-petroleum-safe-t-group-2020-04-20", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-shares-cross-above-200-dma-2020-04-20", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-wdc-nflx-2020-04-20", "https://www.nasdaq.com/articles/alexion-to-study-rare-blood-disorder-drug-in-severe-covid-19-patients-2020-04-20-0", "https://www.nasdaq.com/articles/alexion-to-study-rare-blood-disorder-drug-in-severe-covid-19-patients-2020-04-20", "https://www.nasdaq.com/articles/alexion-pharma-to-launch-clinical-trial-to-evaluate-ultomiris-quick-facts-2020-04-20", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-healthcare-technology-communications-2020-04-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/2-top-small-cap-stocks-to-buy-right-now-2020-04-15", "https://www.nasdaq.com/articles/3-value-stocks-to-buy-with-your-%241200-stimulus-check-that-can-make-you-rich-2020-04-11", "https://www.nasdaq.com/articles/is-alexion-pharmaceuticals-a-buy-2020-04-10", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-energy-healthcare-2020-04-09", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-rem-fbt-2020-04-09", "https://www.nasdaq.com/articles/analysts-anticipate-24-gains-ahead-for-the-holdings-of-bbh-2020-04-06", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/3-dirt-cheap-healthcare-stocks-to-buy-right-now-2020-03-27", "https://www.nasdaq.com/articles/should-you-buy-these-3-dirt-cheap-stocks-2020-03-26", "https://www.nasdaq.com/articles/5-healthcare-stocks-that-havent-been-this-cheap-in-at-least-10-years-2020-03-25", "https://www.nasdaq.com/articles/coronavirus-stock-market-crash%3A-3-stocks-you-need-to-own-2020-03-22", "https://www.nasdaq.com/articles/3-no-brainer-coronavirus-bear-market-buys-2020-03-19", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ual-ntap-2020-03-16", "https://www.nasdaq.com/articles/have-%241000-then-buy-these-top-stocks-right-now-2020-03-16", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-november-20th-2020-03-27", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/first-week-of-alxn-may-1st-options-trading-2020-03-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-06-2020%3A-stim-opk-alxn-jnj-pfe-abt-mrk-amgn-2020-03-06", "https://www.nasdaq.com/articles/the-implied-analyst-12-month-target-for-sphb-2020-03-05", "https://www.nasdaq.com/articles/alexion-pharma-to-present-at-cowen-health-care-conference-webcast-at-9%3A20-am-et-2020-03-03", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-alxn-2020-02-27", "https://www.nasdaq.com/articles/first-week-of-alxn-april-17th-options-trading-2020-02-26", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-11-2020-2020-02-11", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-2-6-2020-2020-02-06", "https://www.nasdaq.com/articles/is-apellis-pharmaceuticals-a-buy-2020-02-03", "https://www.nasdaq.com/articles/add-up-the-pieces%3A-ius-could-be-worth-%2430-2020-02-03", "https://www.nasdaq.com/articles/relative-strength-alert-for-alexion-pharmaceuticals-2020-01-30", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q4-2019-earnings-call-transcript-2020-01-30", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-right-now-2020-01-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-guides-fy20-below-analysts-estimates-quick-facts-2020-01-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-q4-adjusted-earnings-beat-estimates-2020-01-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-q4-19-earnings-conference-call-at-7%3A30-am-et-2020-01-30", "https://www.nasdaq.com/articles/5-strong-buy-biotech-stocks-to-buy-for-2020-2020-01-28", "https://www.nasdaq.com/articles/health-care-sector-update-for-01-27-2020%3A-ino-alxn-achn-rdy-jnj-pfe-abt-mrk-amgn-2020-01", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-alxn-jpm-tpr-2020-01-30", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/2-biotechs-battling-immune-diseases-2020-01-19", "https://www.nasdaq.com/articles/3-healthcare-stocks-that-are-coming-back-to-life-2020-01-15", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-aal-2020-01-14", "https://www.nasdaq.com/articles/alexion-pharma-to-present-at-j.p-morgan-conference-webcast-at-10%3A30-am-et-2020-01-14", "https://www.nasdaq.com/articles/11-sp-500-stocks-that-could-soar-20-or-more-in-2020-2020-01-10", "https://www.nasdaq.com/articles/why-has-vertex-pharmaceuticals-stock-gained-30-in-the-last-quarter-2020-01-10", "https://www.nasdaq.com/articles/6-industries-that-are-historically-cheap-even-with-the-stock-market-at-an-all-time-high", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-alxn-antm-qcom-2020-01-07", "https://www.nasdaq.com/articles/apellis-lead-drug-tops-alexions-blockbuster-soliris-in-a-pivotal-late-stage-study-2020-01", "https://www.nasdaq.com/articles/these-3-healthcare-stocks-are-set-to-soar-in-2020-says-cowen-2020-01-07", "https://www.nasdaq.com/articles/4-no-brainer-large-cap-stocks-to-own-in-2020-2020-01-05", "https://www.nasdaq.com/articles/look-under-the-hood%3A-pjp-has-11-upside-2020-01-02", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-august-2020-2019-12-27", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-12-27-2019-2019-12-27", "https://www.nasdaq.com/articles/heres-why-apellis-pharmaceuticals-stock-jumped-as-much-as-40.7-today-2020-01-07", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-is-falling-today-2019-12-20", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-myl-2019-12-20", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-alexion-pharmaceuticals-2019-12-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-benjamin-graham-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-2019-12-14", "https://www.nasdaq.com/articles/friday-sector-leaders%3A-energy-healthcare-2019-12-06", "https://www.nasdaq.com/articles/fridays-etf-with-unusual-volume%3A-iwy-2019-12-06", "https://www.nasdaq.com/articles/3-biotech-stocks-to-buy-as-the-sector-heats-up-2019-12-25", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-energy-healthcare-2019-12-05", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-hd-shw-alxn-2019-12-05", "https://www.nasdaq.com/articles/sp-500-movers%3A-alxn-tsco-2019-12-05", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-dltr-2019-12-05", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-pjp-targets-%2470-2019-12-02", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-alxn-dpz-lmt-2019-11-25", "https://www.nasdaq.com/articles/billionaire-ray-dalio-snaps-up-these-3-strong-buy-stocks-2019-11-25", "https://www.nasdaq.com/articles/alexion-rejects-elliott-recommendation-quick-facts-2019-12-06", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-energy-healthcare-2019-12-05", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-hd-shw-alxn-2019-12-05", "https://www.nasdaq.com/articles/sp-500-movers%3A-alxn-tsco-2019-12-05", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-dltr-2019-12-05", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-pjp-targets-%2470-2019-12-02", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-alxn-dpz-lmt-2019-11-25", "https://www.nasdaq.com/articles/billionaire-ray-dalio-snaps-up-these-3-strong-buy-stocks-2019-11-25", "https://www.nasdaq.com/articles/3-healthcare-stocks-with-heightened-expectations-2019-10-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-23-2019%3A-pdlialxntmohexohexo.to-2019-10-23", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-adi-mmm-alxn-2019-10-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-23-2019%3A-alxntmohexo-2019-10-23", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q3-2019-earnings-call-transcript-2019-10-23", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-txn-alxn-2019-10-23", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-q3-19-earnings-conference-call-at-8%3A00-am-et-2019-10-23", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-q3-adjusted-earnings-beat-estimates-2019-10-23", "https://www.nasdaq.com/articles/first-week-of-december-20th-options-trading-for-alexion-pharmaceuticals-alxn-2019-10-22", "https://www.nasdaq.com/articles/bridgebio-calls-off-its-acquisition-offer-for-eidos-therapeutics-2019-10-19", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-tech-data-and-first-majestic-silver-jumped-today-2019-10-16", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-stock-is-skyrocketing-today-2019-10-16", "https://www.nasdaq.com/articles/alexion-pharma-to-acquire-achillion-pharma-for-about-%24930-mln-cash-2019-10-16", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-healthcare-financial-2019-10-14", "https://www.nasdaq.com/articles/alexion-pharma-raises-2019-outlook-2019-10-23", "https://www.nasdaq.com/articles/will-the-pace-of-ma-pick-up-following-the-biotech-sectors-pounding-2019-10-11", "https://www.nasdaq.com/articles/mito-empowered-fprx-cuts-another-70-jobs-second-death-in-legionnaires-outbreak-2019-10-11", "https://www.nasdaq.com/articles/heres-why-stealth-biotherapeutics-rocketed-higher-today-2019-10-10", "https://www.nasdaq.com/articles/oversold-conditions-for-alexion-pharmaceuticals-alxn-2019-10-08", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-october-2019-2019-09-27", "https://www.nasdaq.com/articles/november-8th-options-now-available-for-alexion-pharmaceuticals-alxn-2019-09-26", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-stock-is-jumping-today-2019-09-25", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-alxn-chrw-algn-2019-10-14", "https://www.nasdaq.com/articles/thursday-sector-leaders%3A-healthcare-utilities-2019-09-19", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-adbe-klac-2019-09-18", "https://www.nasdaq.com/articles/pbe-gild-alxn-incy%3A-large-outflows-detected-at-etf-2019-09-17", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-january-2022-2019-09-17", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-meli-alxn-2019-09-10", "https://www.nasdaq.com/articles/friday-sector-leaders%3A-services-healthcare-2019-09-06", "https://www.nasdaq.com/articles/alxn-september-2020-options-begin-trading-2019-09-06", "https://www.nasdaq.com/articles/first-week-of-alxn-may-2020-options-trading-2019-09-24", "https://www.nasdaq.com/articles/october-11th-options-now-available-for-alexion-pharmaceuticals-alxn-2019-09-03", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-wynn-lrcx-2019-09-03", "https://www.nasdaq.com/articles/why-american-outdoor-brands-innovative-industrial-properties-and-alexion-pharmaceuticals", "https://www.nasdaq.com/articles/friday-sector-laggards%3A-services-healthcare-2019-08-30", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-gs-cost-alxn-2019-08-30", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ulta-tsla-2019-08-30", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-adsk-incy-2019-08-28", "https://www.nasdaq.com/articles/heres-why-alexion-pharmaceuticals-dropped-11-in-august-2019-09-05", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-october-4th-2019-08-26", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-amd-2019-08-26", "https://www.nasdaq.com/articles/should-amgen-finally-buy-alexion-pharmaceuticals-2019-08-25", "https://www.nasdaq.com/articles/3-reasons-why-amgen-could-actually-acquire-alexion-2019-08-24", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-23-2019%3A-alxn-seel-gsk-jnj-pfe-abt-mrk-amgn-2019-08-23", "https://www.nasdaq.com/articles/alxn-takeover-rumors-amgns-jasmine-blooms-clsd-sees-the-writing-on-the-wall-2019-08-23", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-october-18th-2019-08-20", "https://www.nasdaq.com/articles/celgenes-%2413.4-billion-deal-with-amgen-is-a-win-win-win-2019-08-26", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-alexion-pharmaceuticals-2019-08-11", "https://www.nasdaq.com/articles/momenta-continues-its-transition-2019-08-08", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-ntap-ibm-alxn-2019-08-02", "https://www.nasdaq.com/articles/we-did-the-math-sphb-can-go-to-%2449-2019-07-29", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-alxn-2019-07-26", "https://www.nasdaq.com/articles/alexion-gets-positive-opinion-from-chmp-for-soliris-for-treatment-of-nmosd-2019-07-26", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-alxn-uhs-vlo-2019-07-25", "https://www.nasdaq.com/articles/alxn-september-27th-options-begin-trading-2019-08-12", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q2-2019-earnings-call-transcript-2019-07-24", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-txn-2019-07-24", "https://www.nasdaq.com/articles/alexion-boosts-fy19-outlook-quick-facts-2019-07-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-q2-adjusted-earnings-beat-estimates-2019-07-24", "https://www.nasdaq.com/articles/first-week-of-alxn-september-20th-options-trading-2019-07-23", "https://www.nasdaq.com/articles/3-biotech-stocks-that-could-double-your-money-2019-07-14", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-for-the-2nd-half-of-2019-2019-07-14", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-tops-expectations-in-q2-2019-07-24", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-august-23rd-2019-07-08", "https://www.nasdaq.com/articles/how-to-invest-in-biotech-stocks-2019-07-02", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-add-to-your-watchlist-2019-06-30", "https://www.nasdaq.com/articles/look-under-the-hood%3A-mgc-has-10-upside-2019-06-27", "https://www.nasdaq.com/articles/first-week-of-alxn-february-2020-options-trading-2019-06-26", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-alxn-cvs-xom-2019-06-20", "https://www.nasdaq.com/articles/3-cheap-drug-stocks-you-can-buy-right-now-2019-06-16", "https://www.nasdaq.com/articles/monday-sector-laggards%3A-healthcare-technology-communications-2019-07-08", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-for-august-23rd-2019-07-08", "https://www.nasdaq.com/articles/10-stocks-to-buy-that-could-be-takeover-targets-2019-06-05", "https://www.nasdaq.com/articles/3-drug-stocks-could-win-key-fda-approvals-june-2019-06-04", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-enters-oversold-territory-alxn-2019-05-31", "https://www.nasdaq.com/articles/11-biotech-stocks-put-your-radar-soon-2019-05-30", "https://www.nasdaq.com/articles/first-week-july-19th-options-trading-alexion-pharmaceuticals-alxn-2019-05-28", "https://www.nasdaq.com/articles/3-big-biotech-stocks-warren-buffett-might-2019-05-26", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-healthcare-utilities-2019-06-13", "https://www.nasdaq.com/articles/alxn-makes-notable-cross-below-critical-moving-average-2019-05-23", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2019-05-23", "https://www.nasdaq.com/articles/top-5-new-drug-launches-2019-and-biotech-stocks-could-win-big-2019-05-19", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-alxn-2019-04-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q1-2019-earnings-call-transcript-2019-04-25", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-fires-all-cylinders-q1-2019-04-25", "https://www.nasdaq.com/articles/alexion-pharma-raises-2018-guidance-q1-profit-beats-estimates-quick-facts-2019-04-25", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-june-2019-2019-05-24", "https://www.nasdaq.com/articles/alxn-makes-notable-cross-below-critical-moving-average-2019-05-23", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2019-05-23", "https://www.nasdaq.com/articles/top-5-new-drug-launches-2019-and-biotech-stocks-could-win-big-2019-05-19", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-alxn-2019-04-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q1-2019-earnings-call-transcript-2019-04-25", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-fires-all-cylinders-q1-2019-04-25", "https://www.nasdaq.com/articles/alexion-pharma-raises-2018-guidance-q1-profit-beats-estimates-quick-facts-2019-04-25", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-june-2019-2019-05-24", "https://www.nasdaq.com/articles/alxn-crosses-below-key-moving-average-level-2019-04-18", "https://www.nasdaq.com/articles/wednesday-sector-laggards-healthcare-materials-2019-04-17", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-alxn-swks-abt-2019-04-17", "https://www.nasdaq.com/articles/interesting-alxn-put-and-call-options-may-31st-2019-04-17", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-799608-down-415-points-2019-04-17", "https://www.nasdaq.com/articles/wednesday-sector-laggards-healthcare-materials-2019-04-17-0", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-alxn-swks-abt-2019-04-17-0", "https://www.nasdaq.com/articles/ra-pharmaceuticals-closes-end-of-phase-2-interaction-with-fda-2019-04-10", "https://www.nasdaq.com/articles/drugmakers-pay-123-million-resolve-us-charity-kickback-probe-2019-04-04", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q4-shares-up-2019-02-04", "https://www.nasdaq.com/articles/economic-earnings-data-deluge-2019-02-04", "https://www.nasdaq.com/articles/q4-earnings-soldier-gamely-googl-clx-more-2019-02-04", "https://www.nasdaq.com/articles/us-stocks-move-papa-johns-ultimate-software-match-aemetis-evolus-2019-02-04", "https://www.nasdaq.com/articles/heres-why-alexion-pharmaceuticals-gained-263-january-2019-02-04", "https://www.nasdaq.com/articles/alexion-alxn-tops-q4-earnings-and-revenues-beat-estimates-2019-02-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-disney-eli-lilly-u.s.-bancorp-prudential-and-alexion", "https://www.nasdaq.com/articles/earnings-reaction-history-alexion-pharmaceuticals-inc-364-follow-through-indicator-52", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-q4-2018-earnings-conference-call-transcript-2019-02-04", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-4-2019-syy-alxn-clx-amg-bsac-saia-mtsc-jout-ufi-lpg", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q4-earnings%3A-whats-in-the-cards-2019-01-31", "https://www.nasdaq.com/articles/close-update-stocks-extend-fed-fueled-rally-end-january-sizable-gains-2019-01-31", "https://www.nasdaq.com/articles/alexions-ultomiris-meets-primary-endpoint-in-ahus-study-2019-01-29", "https://www.nasdaq.com/articles/first-week-alxn-march-15th-options-trading-2019-01-28", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-q4-18-earnings-conference-call-800-am-et-2019-02-04", "https://www.nasdaq.com/articles/health-care-sector-update-01282019-abbvalxntrvnaray-2019-01-28", "https://www.nasdaq.com/articles/health-care-sector-update-01282019-alxntrvnaray-2019-01-28", "https://www.nasdaq.com/articles/new-drugs-approved-december-2019-01-15", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-stock-starting-shine-again-2019-01-11", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-stock-fell-21-december-2019-01-08", "https://www.nasdaq.com/articles/4-biotechs-are-potential-buyouts-post-celgene-deal-2019-01-08", "https://www.nasdaq.com/articles/february-2019-options-now-available-alexion-pharmaceuticals-alxn-2018-12-27", "https://www.nasdaq.com/articles/alexion-pharma-says-phase-3-study-ultomiris-meets-primary-objective-2019-01-28", "https://www.nasdaq.com/articles/alexions-ultomiris-gets-early-fda-nod-for-rare-blood-disorder-2018-12-24", "https://www.nasdaq.com/articles/acorda-gets-fda-approval-for-parkinsons-disease-drug-inbrija-2018-12-24", "https://www.nasdaq.com/articles/alexion-pharma-announces-fda-approval-ultomiris-2018-12-22", "https://www.nasdaq.com/articles/alexion-wins-early-us-approval-rare-blood-disorder-drug-2018-12-21", "https://www.nasdaq.com/articles/us-fda-approves-alexion-pharmas-rare-blood-disorder-drug-2018-12-21", "https://www.nasdaq.com/articles/us-fda-approves-alexion-pharmas-blood-disorder-drug-2018-12-21", "https://www.nasdaq.com/articles/agenus-stock-up-23-on-immuno-oncology-deal-with-gilead-2018-12-21", "https://www.nasdaq.com/articles/alexions-alxn-soliris-drives-growth-amid-pricing-pressure-2018-12-27", "https://www.nasdaq.com/articles/market-close-report-nasdaq-trading-volume-joins-top-ten-ranking-year-nasdaq-composite-7", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-enters-oversold-territory-2018-12-20", "https://www.nasdaq.com/articles/vertexs-vrtx-3rd-study-on-pain-drug-meets-primary-endpoint-2018-12-19", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-becomes-oversold-alxn-2018-12-19", "https://www.nasdaq.com/articles/achillion-reports-positive-interim-data-on-factor-d-inhibitors-2018-12-18", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-cratering-again-today-2018-12-18", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-ibm-azo-alxn-2018-12-18", "https://www.nasdaq.com/articles/allakos-allk-catches-eye%3A-stock-jumps-6.5-2018-12-21", "https://www.nasdaq.com/articles/market-close-report-nasdaq-trading-volume-joins-top-ten-ranking-year-nasdaq-composite-7", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/abeona-therapeutics-abeo-in-focus%3A-stock-moves-5.5-higher-2018-12-11", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-6.9-higher-2018-12-10", "https://www.nasdaq.com/articles/5-top-drugbiotech-merger-acquisition-targets-2019-2018-12-10", "https://www.nasdaq.com/articles/heres-why-ra-pharmaceuticals-inc-soaring-today-2018-12-10", "https://www.nasdaq.com/articles/biogen-biib-in-licenses-als-candidate-biib067-from-ionis-2018-12-07", "https://www.nasdaq.com/articles/amag-to-acquire-ciraparantag-maker-perosphere-pharmaceuticals-2018-12-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-alexion-pharmaceuticals-regeneron", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/fda-committee-to-review-amgens-amgn-osteoporosis-candidate-2018-12-03", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-rises-8.9-2018-12-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-adbe-2018-11-28", "https://www.nasdaq.com/articles/aileron-inks-collaboration-deal-with-pfizer-for-cancer-combo-2018-11-28", "https://www.nasdaq.com/articles/eyenovia-initiates-phase-iii-study-for-mydriasis-candidate-2018-11-27", "https://www.nasdaq.com/articles/inovio-ino-to-receive-milestone-payment-from-astrazeneca-2018-12-05", "https://www.nasdaq.com/articles/global-blood-therapeutics-voxelotor-on-faster-approval-path-2018-12-04", "https://www.nasdaq.com/articles/amgens-bite-immunotherapies-show-promise-in-early-studies-2018-12-04", "https://www.nasdaq.com/articles/fda-committee-to-review-amgens-amgn-osteoporosis-candidate-2018-12-03", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-rises-8.9-2018-12-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-adbe-2018-11-28", "https://www.nasdaq.com/articles/aileron-inks-collaboration-deal-with-pfizer-for-cancer-combo-2018-11-28", "https://www.nasdaq.com/articles/eyenovia-initiates-phase-iii-study-for-mydriasis-candidate-2018-11-27", "https://www.nasdaq.com/articles/rocket-pharmaceuticals-rckt-in-focus%3A-stock-moves-7.2-higher-2018-11-27", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-alxn-2018-11-27", "https://www.nasdaq.com/articles/keryx-kerx-looks-good%3A-stock-adds-7.2-in-session-2018-11-26", "https://www.nasdaq.com/articles/10-stocks-are-screaming-buys-right-now-2018-11-21", "https://www.nasdaq.com/articles/emergents-ebs-zika-vaccine-candidate-meets-study-endpoint-2018-11-20", "https://www.nasdaq.com/articles/fortress-biotech-fbio-in-focus%3A-stock-moves-6.5-higher-2018-11-20", "https://www.nasdaq.com/articles/amgens-blincyto-gets-positive-chmp-opinion-for-line-extension-2018-11-19", "https://www.nasdaq.com/articles/seattle-genetics-sgen-looks-good%3A-stock-adds-5.6-in-session-2018-11-19", "https://www.nasdaq.com/articles/acorda-down-more-than-30-in-the-past-3-months%3A-heres-why-2018-11-15", "https://www.nasdaq.com/articles/health-care-sector-update-11062018-xncrmormylavns-2018-11-06", "https://www.nasdaq.com/articles/pacira-pcrx-q3-earnings-and-revenues-surpass-estimates-2018-11-05", "https://www.nasdaq.com/articles/puma-biotech-pbyi-q3-loss-narrows-nerlynx-pulls-stock-down-2018-11-05", "https://www.nasdaq.com/articles/alxn-crosses-above-key-moving-average-level-2018-11-02", "https://www.nasdaq.com/articles/biotech-etfs-in-focus-on-string-of-q3-earnings-beat-2018-11-01", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-sees-hammer-chart-pattern%3A-time-to-buy-2018-10-31", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-amgen-vertex-impress-in-q3-drna-soars-on-lly-deal-2018-10", "https://www.nasdaq.com/articles/is-alexion-pharmaceuticals-alxn-stock-outpacing-its-medical-peers-this-year-2018-11-06", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-tops-q3-earnings-estimates-2018-10-24", "https://www.nasdaq.com/articles/earnings-reaction-history-alexion-pharmaceuticals-inc-333-follow-through-indicator-44", "https://www.nasdaq.com/articles/health-care-sector-update-10242018-mdttmolhalxn-2018-10-24", "https://www.nasdaq.com/articles/health-care-sector-update-10242018-bgnetmoalxnlh-2018-10-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-q3-2018-earnings-conference-call-transcript-2018-10-24", "https://www.nasdaq.com/articles/biotech-stocks-earnings-lineup-for-oct-24%3A-vrtx-alxn-srpt-2018-10-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-24-2018-t-ba-tmo-ups-gd-noc-bsx-nsc-itw-alxn-siri-aph", "https://www.nasdaq.com/articles/health-care-sector-update-10242018-lh-alxn-tmo-jnj-pfe-abt-mrk-amgn-2018-10-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-tops-q3-earnings-estimates-2018-10-24", "https://www.nasdaq.com/articles/earnings-reaction-history-alexion-pharmaceuticals-inc-333-follow-through-indicator-44", "https://www.nasdaq.com/articles/health-care-sector-update-10242018-mdttmolhalxn-2018-10-24", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-alxn-2018-10-11", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs-2018-10-03", "https://www.nasdaq.com/articles/3-biotech-stocks-virtual-monopolies-2018-10-03", "https://www.nasdaq.com/articles/word-on-the-street%3A-3-stocks-for-a-killer-q4-2018-10-02", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-whats-in-the-cards-2018-10-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-nvda-2018-09-28", "https://www.nasdaq.com/articles/alexion-alxn-to-acquire-biotech-syntimmune-for-%241.2-billion-2018-09-27", "https://www.nasdaq.com/articles/company-news-for-sep-27-2018-2018-09-27", "https://www.nasdaq.com/articles/sp-500-movers-ctas-scg-2018-09-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctas-alxn-2018-09-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-soliris-successful-respite-for-sarepta-amrn-soars-2018-09-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-799037-down-1710-points-2018-09-26", "https://www.nasdaq.com/articles/5-top-healthcare-mutual-funds-to-buy-in-october-2018-10-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-nvda-2018-09-28", "https://www.nasdaq.com/articles/health-care-sector-update-09262018-alxntlryfirevanab-2018-09-26", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-surges%3A-stock-moves-5.3-higher-2018-09-25", "https://www.nasdaq.com/articles/alexions-soliris-successful-in-phase-iii-study-for-nmosd-2018-09-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-cmcsa-alxn-2018-09-24", "https://www.nasdaq.com/articles/sp-500-movers-cmcsa-ew-2018-09-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-799325-629-points-2018-09-24", "https://www.nasdaq.com/articles/health-care-sector-update-09262018-sykalxntlryfirevanab-2018-09-26", "https://www.nasdaq.com/articles/10-stocks-are-screaming-buys-right-now-2018-09-19", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-label-expansion-of-regenerons-eylea-vertexs-kalydeco-2018-08-22", "https://www.nasdaq.com/articles/alexions-bla-for-alxn1210-gets-priority-review-from-fda-2018-08-21", "https://www.nasdaq.com/articles/health-care-sector-update-08202018-amrx-alxn-alsn-thc-lci-2018-08-20", "https://www.nasdaq.com/articles/health-care-sector-update-08202018-aslnalxn-2018-08-20", "https://www.nasdaq.com/articles/qqxts-underlying-holdings-imply-13-gain-potential-2018-08-16", "https://www.nasdaq.com/articles/top-analyst-reports-mastercard-abbvie-twenty-first-century-fox-more-2018-08-13", "https://www.nasdaq.com/articles/notable-thursday-option-activity-cvx-alxn-foxa-2018-09-20", "https://www.nasdaq.com/articles/biotech-etfs-focus-string-q2-earnings-beat-2018-08-10", "https://www.nasdaq.com/articles/oversold-conditions-alexion-pharmaceuticals-alxn-2018-08-08", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-insight-conocophillips-vale-alexion-and-archer", "https://www.nasdaq.com/articles/5-stocks-trading-near-52-week-high-more-upside-store-2018-08-01-0", "https://www.nasdaq.com/articles/5-stocks-trading-near-52-week-high-with-more-upside-in-store-2018-08-01", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q2-guidance-up-2018-07-26", "https://www.nasdaq.com/articles/alexion-alxn-tops-q2-earnings-and-revenues-beat-estimates-2018-07-26", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-breaks-below-200-day-moving-average-notable-alxn-2018-08-10", "https://www.nasdaq.com/articles/biotech-etfs-focus-string-q2-earnings-beat-2018-08-10", "https://www.nasdaq.com/articles/6-stocks-buy-trade-war-protection-2018-07-25", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-07-23", "https://www.nasdaq.com/articles/amgen-amgn-to-report-q2-earnings%3A-will-it-beat-again-2018-07-23", "https://www.nasdaq.com/articles/karyopharm-initiates-nda-submission-process-for-selinexor-2018-07-19", "https://www.nasdaq.com/articles/jj-jnj-faces-%244.69-billion-verdict-in-talc-case-revised-2018-07-18", "https://www.nasdaq.com/articles/jjs-jnj-q2-earnings-beat-on-higher-cancer-drug-sales-2018-07-17", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-beats-q2-earnings-and-revenue-estimates-2018-07-26", "https://www.nasdaq.com/articles/drug-stocks-to-report-earnings-on-jul-26%3A-amgn-alxn-more-2018-07-25", "https://www.nasdaq.com/articles/6-stocks-buy-trade-war-protection-2018-07-25", "https://www.nasdaq.com/articles/jjs-jnj-phase-iii-study-for-invokana-halted-earlier-2018-07-17", "https://www.nasdaq.com/articles/how-pieces-add-bbh-headed-146-2018-07-16", "https://www.nasdaq.com/articles/pfizers-xtandi-gets-fda-nod-for-expanded-patient-population-2018-07-16", "https://www.nasdaq.com/articles/alxn-august-31st-options-begin-trading-2018-07-12", "https://www.nasdaq.com/articles/achillions-3rd-factor-d-inhibitor-enters-clinical-studies-2018-07-11", "https://www.nasdaq.com/articles/jj-jnj-ordered-to-pay-%244.69-billion-in-talc-lawsuit-revised-2018-07-17", "https://www.nasdaq.com/articles/roches-flu-drug-meets-primary-endpoint-in-phase-iii-study-2018-07-17", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn%3A-moving-average-crossover-alert-2018-07-17", "https://www.nasdaq.com/articles/jjs-jnj-phase-iii-study-for-invokana-halted-earlier-2018-07-17", "https://www.nasdaq.com/articles/alexion-alxn-submits-application-for-alxn1210-with-fda-2018-06-20", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-breaks-above-200-day-moving-average-bullish-alxn-2018-06-15", "https://www.nasdaq.com/articles/analysts-anticipate-iyh-will-reach-205-2018-06-14", "https://www.nasdaq.com/articles/10-stocks-that-are-screaming-buys-right-now-2018-07-09", "https://www.nasdaq.com/articles/10-stocks-that-are-screaming-buys-right-now-2018-06-12", "https://www.nasdaq.com/articles/alexion-complement-pharma-tie-up-to-treat-neuro-disorders-2018-06-12", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-chtr-alxn-fbhs-2018-06-12", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-epclusas-china-approval-bmrn-palynziqs-fda-nod-2018-05-30", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-alxn-blk-azo-2018-05-29", "https://www.nasdaq.com/articles/why-is-alexion-alxn-down-3.5-since-its-last-earnings-report-2018-05-28", "https://www.nasdaq.com/articles/health-care-sector-update-05252018-evfm-rmti-alxn-2018-05-25", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-axon-soars-amgen-drugs-get-fda-ec-nod-2018-06-13", "https://www.nasdaq.com/articles/health-care-sector-update-05252018-alxnrmti-2018-05-25", "https://www.nasdaq.com/articles/look-under-hood-qqxt-has-16-upside-2018-05-14", "https://www.nasdaq.com/articles/10-stocks-are-screaming-buys-right-now-2018-05-09", "https://www.nasdaq.com/articles/7-money-making-stocks-buy-now-2018-05-08", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-alxn-usat-fdx-2018-05-08", "https://www.nasdaq.com/articles/achillion-achn-posts-wider-than-expected-q1-loss-names-ceo-2018-05-03", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-vrtx-post-solid-results-gild-disappoints-in-q1-2018-05-02", "https://www.nasdaq.com/articles/health-care-sector-update-05252018-bmrnrmtialxnevfm-2018-05-25", "https://www.nasdaq.com/articles/strength-seen-in-alexion-pharmaceuticals-alxn%3A-stock-soars-14.5-2018-04-27", "https://www.nasdaq.com/articles/7-stocks-goldman-sachs-thinks-are-set-to-rip-higher-2018-04-26", "https://www.nasdaq.com/articles/us-stocks-edge-higher-positive-economic-data-tech-gains-2018-04-26", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q1-guidance-up-2018-04-26", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-and-sales-beat-estimates-2018-04-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-711868-11494-points-2018-04-26", "https://www.nasdaq.com/articles/why-dominos-pizza-advanced-micro-devices-and-alexion-pharmaceuticals-jumped-today-2018-04", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-05-01", "https://www.nasdaq.com/articles/health-care-sector-update-04262018-alxnaxsmabbvbmy-2018-04-26", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-ma-alxn-mhk-2018-04-26", "https://www.nasdaq.com/articles/drug-stock-q1-earnings-due-on-apr-26%3A-abbv-alxn-bmy-vrtx-2018-04-25", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biomarin-bmrn-in-q1-earnings-2018-04-24", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-alxn-might-surprise-this-earnings-season-2018-04-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-alxn-sees-hammer-chart-pattern%3A-time-to-buy-2018-04-23", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-04-23", "https://www.nasdaq.com/articles/heres-why-alexion-pharmaceuticals-surging-today-2018-04-26", "https://www.nasdaq.com/articles/whats-in-store-for-biogen-biib-this-earnings-season-2018-04-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alks-up-cldx-down-alxn-to-acquire-wilson-therapeutics-2018-04-18", "https://www.nasdaq.com/articles/pharma-ma-active-week-4-potential-buyout-targets-2018-04-13", "https://www.nasdaq.com/articles/alexion-alxn-to-acquire-wilson-therapeutics-for-%24855m-2018-04-12", "https://www.nasdaq.com/articles/add-parts-spyx-could-be-worth-74-2018-04-12", "https://www.nasdaq.com/articles/health-care-sector-update-04112018-alxn-hsdt-biol-txmd-2018-04-11", "https://www.nasdaq.com/articles/health-care-sector-update-04112018-cbayalxntxmdbiol-2018-04-11", "https://www.nasdaq.com/articles/amgen-amgn-to-report-q1-earnings%3A-is-a-beat-in-the-cards-2018-04-20", "https://www.nasdaq.com/articles/whats-in-store-for-biogen-biib-this-earnings-season-2018-04-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alks-up-cldx-down-alxn-to-acquire-wilson-therapeutics-2018-04-18", "https://www.nasdaq.com/articles/pharma-ma-active-week-4-potential-buyout-targets-2018-04-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-fb-msft-2018-03-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-arna-up-on-study-data-prta-teams-up-with-celgene-2018-03-21", "https://www.nasdaq.com/articles/alexion-alxn-gains-on-positive-date-from-lead-candidate-2018-03-16", "https://www.nasdaq.com/articles/us-stocks-extend-gains-amid-strong-earnings-reports-rising-oil-prices-2018-03-15", "https://www.nasdaq.com/articles/health-care-sector-update-04112018-alxntxmdbiol-2018-04-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-meli-alxn-2018-03-15", "https://www.nasdaq.com/articles/morning-movers-sears-soars-dollar-general-gains-alexion-rallies-2018-03-15", "https://www.nasdaq.com/articles/pre-market-most-active-mar-15-2018-alxn-pti-aqua-baba-sbgl-qqq-hgv-eric-mu-hmy-xt-dg-2018", "https://www.nasdaq.com/articles/health-care-sector-update-03152018-rcusalxnsnybivvablxsldb-2018-03-15", "https://www.nasdaq.com/articles/notable-thursday-option-activity-alxn-wyn-mon-2018-03-15", "https://www.nasdaq.com/articles/health-care-sector-update-03152018-alxnsnybivvablxsldb-2018-03-15", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-inc-stock-soaring-today-2018-03-15", "https://www.nasdaq.com/articles/sp-500-movers-qrvo-alxn-2018-03-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-meli-alxn-2018-03-15", "https://www.nasdaq.com/articles/morning-movers-sears-soars-dollar-general-gains-alexion-rallies-2018-03-15", "https://www.nasdaq.com/articles/pre-market-most-active-mar-15-2018-alxn-pti-aqua-baba-sbgl-qqq-hgv-eric-mu-hmy-xt-dg-2018", "https://www.nasdaq.com/articles/omeros-corporation-buy-dip-2018-03-05", "https://www.nasdaq.com/articles/ibb-regn-vrtx-alxn-large-outflows-detected-etf-2018-02-28", "https://www.nasdaq.com/articles/achillion-achn-q4-loss-widens-plans-job-cuts-to-save-cost-2018-02-23", "https://www.nasdaq.com/articles/health-care-sector-update-03152018-alxn-2018-03-15", "https://www.nasdaq.com/articles/after-hours-most-active-feb-16-2018-p-ge-alxn-bac-twtr-dakt-tlrd-foxa-s-mu-car-qqq-2018-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-caterpillar-union-pacific-alexion-and-sanofi", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-amtd-alxn-noc-2018-02-15", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-3155-points-week-rising-4th-straight-day-2018-02-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-ulta-meli-2018-02-12", "https://www.nasdaq.com/articles/sp-500-movers-ulta-csra-2018-02-12", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-698196-10747-points-2018-02-12", "https://www.nasdaq.com/articles/3-strong-buy-stocks-with-big-revenue-drivers-2018-02-20", "https://www.nasdaq.com/articles/alexions-alxn-earnings-and-sales-beat-estimates-in-q4-2018-02-08", "https://www.nasdaq.com/articles/teva-tumbles-twitter-soars-market-seeks-direction-2018-02-08", "https://www.nasdaq.com/articles/alexion-alxn-tops-q4-earnings-and-revenues-beat-estimates-2018-02-08", "https://www.nasdaq.com/articles/earnings-reaction-history-alexion-pharmaceuticals-inc-364-follow-through-indicator-32", "https://www.nasdaq.com/articles/regn-vs.-alxn%3A-which-stock-is-poised-for-better-q4-earnings-2018-02-07", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-alexion-pharmaceuticals-alxn-2018-02-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-8-2018-pm-cvs-tmus-bce-regn-tri-yum-alxn-k-tsn-tu-wltw", "https://www.nasdaq.com/articles/3-etfs-to-watch-on-biotech-earnings-2018-02-10", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-02-05", "https://www.nasdaq.com/articles/whats-in-the-cards-for-teva-teva-this-earnings-season-2018-02-05", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-glaxo-gsk-this-earnings-season-2018-02-02", "https://www.nasdaq.com/articles/allergan-agn-to-report-q4-earnings%3A-whats-in-the-cards-2018-02-01", "https://www.nasdaq.com/articles/will-gilead-gild-disappoint-investors-in-q4-earnings-2018-02-01", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-q4-earnings-exceed-expectations-2018-01-31", "https://www.nasdaq.com/articles/whats-in-the-cards-for-gw-pharma-gwph-in-q1-earnings-2018-01-31", "https://www.nasdaq.com/articles/5-biotech-stocks-set-to-trump-estimates-this-earnings-season-2018-02-06", "https://www.nasdaq.com/articles/can-merck-mrk-deliver-a-positive-surprise-in-q4-earnings-2018-01-30", "https://www.nasdaq.com/articles/vertex-vrtx-to-report-q4-earnings%3A-whats-in-the-cards-2018-01-29", "https://www.nasdaq.com/articles/will-amgen-amgn-benefit-from-growth-drugs-in-q4-earnings-2018-01-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alexion-pharmaceuticals-celgene-abbvie-and-merck-2018", "https://www.nasdaq.com/articles/will-these-4-large-cap-drug-stocks-be-big-winners-earnings-season-2018-01-22-0", "https://www.nasdaq.com/articles/whats-in-the-cards-for-varian-medical-var-in-q1-earnings-2018-01-22", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biogen-biib-this-earnings-season-2018-01-22", "https://www.nasdaq.com/articles/alxn-makes-notable-cross-below-critical-moving-average-2018-01-30", "https://www.nasdaq.com/articles/news-explains-halozyme-therapeutics-double-digit-drop-today-2018-01-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-amgen-exelixis-alexion-and-vertex-2018-01-12", "https://www.nasdaq.com/articles/alxn-march-2nd-options-begin-trading-2018-01-11", "https://www.nasdaq.com/articles/can-biotech-keep-last-years-momentum-alive-in-2018-2018-01-11", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2018-01-08", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-151-2018-01-08", "https://www.nasdaq.com/articles/10-strong-buy-stocks-2017s-best-analysts-2018-01-08", "https://www.nasdaq.com/articles/will-these-4-large-cap-drug-stocks-be-big-winners-earnings-season-2018-01-22", "https://www.nasdaq.com/articles/will-these-2-large-cap-biotechs-be-on-investor-radar-in-18-2018-01-03", "https://www.nasdaq.com/articles/why-these-2-biotechs-could-outperform-amid-hyper-competition-2018-01-02", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-japan-2017-12-27", "https://www.nasdaq.com/articles/health-care-sector-update-12262017-ptla-alxn-abbv-zsan-rdy-nvs-2017-12-26", "https://www.nasdaq.com/articles/morning-movers-apple-sinks-under-armour-slips-alexion-rises-2017-12-26", "https://www.nasdaq.com/articles/first-week-august-2018-options-trading-alexion-pharmaceuticals-alxn-2017-12-20", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-clementia-pharmaceuticals-inc-aetna-inc-universal-health", "https://www.nasdaq.com/articles/omeros-inks-agreement-with-fda-for-oms721-phase-iii-trial-2018-01-04", "https://www.nasdaq.com/articles/alexion-alxn-in-focus%3A-stock-moves-7.2-higher-2017-12-11", "https://www.nasdaq.com/articles/4-drug-biotech-stocks-that-could-be-buyout-targets-in-2018-2017-12-11", "https://www.nasdaq.com/articles/why-biotech-could-see-30-upside-second-quarter-2017-12-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-alxn-2017-12-08", "https://www.nasdaq.com/articles/sp-500-movers-coo-alxn-2017-12-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-684008-2724-points-2017-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12082017-vtgnalxncoo-2017-12-08", "https://www.nasdaq.com/articles/achillions-renal-disease-candidate-gets-orphan-drug-status-2017-12-19", "https://www.nasdaq.com/articles/5-cheap-biotech-stocks-snag-bounce-2017-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12082017-alxnsagecoo-2017-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12072017-myo-entl-syk-alxn-halo-2017-12-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctrp-viab-2017-12-07", "https://www.nasdaq.com/articles/sp-500-movers-hrb-viab-2017-12-07", "https://www.nasdaq.com/articles/analysts-predict-22-upside-pbe-2017-12-07", "https://www.nasdaq.com/articles/health-care-sector-update-12072017-scmpentlsykalxn-2017-12-07", "https://www.nasdaq.com/articles/friday-sector-leaders-energy-healthcare-2017-12-08", "https://www.nasdaq.com/articles/why-ra-pharmaceuticals-inc-got-hammered-today-2017-12-04", "https://www.nasdaq.com/articles/why-omeros-corporation-best-buy-biotech-right-now-2017-11-28", "https://www.nasdaq.com/articles/alexion-alxn-down-14.6-since-earnings-report%3A-can-it-rebound-2017-11-28", "https://www.nasdaq.com/articles/notable-monday-option-activity-ual-fb-alxn-2017-11-20", "https://www.nasdaq.com/articles/biotechs-trading-lower-in-q4-on-macro-uncertainty-tepid-q3-2017-11-17", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-alexion-pharmaceuticals-inc.-alliance-data-systems", "https://www.nasdaq.com/articles/achillion-achn-shares-down-as-jj-announces-stake-sale-2017-11-15", "https://www.nasdaq.com/articles/why-alexion-pharmacteuicals-sank-89-november-2017-12-05", "https://www.nasdaq.com/articles/clear-cut-reason-alexion-pharmaceuticals-tanked-15-october-2017-11-07", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-156-2017-11-06", "https://www.nasdaq.com/articles/achillion-achn-q3-loss-narrows-pipeline-expansion-in-focus-2017-11-03", "https://www.nasdaq.com/articles/health-care-sector-update-11032017-alxn-2017-11-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-qcom-mdlz-2017-10-31", "https://www.nasdaq.com/articles/3-etfs-to-watch-on-biotech-earnings-2017-10-29", "https://www.nasdaq.com/articles/oversold-conditions-alexion-pharmaceuticals-alxn-2017-10-26", "https://www.nasdaq.com/articles/tech-tumbles-and-oil-boils-2017-11-08", "https://www.nasdaq.com/articles/clear-cut-reason-alexion-pharmaceuticals-tanked-15-october-2017-11-07", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-156-2017-11-06", "https://www.nasdaq.com/articles/achillion-achn-q3-loss-narrows-pipeline-expansion-in-focus-2017-11-03", "https://www.nasdaq.com/articles/drug-stock-q3-earnings-roster-for-oct-26%3A-gild-bmy-more-2017-10-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q3-earnings-gileads-car-t-drug-gets-fda-nod-2017-10-25", "https://www.nasdaq.com/articles/alexion-rises-best-case-scenario-fda-approval-muscle-disease-2017-10-24", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-10-24", "https://www.nasdaq.com/articles/celgene-results-called-alarming-alexion-bristol-mixed-2017-10-26", "https://www.nasdaq.com/articles/alexion-alxn-tops-q3-earnings-sales-miss-shares-up-2017-10-26", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-getting-battered-too-hard-for-comfort-2017-10-26", "https://www.nasdaq.com/articles/alexion-alxn-tops-q3-earnings-lags-sales-2017-view-up-2017-10-26", "https://www.nasdaq.com/articles/drug-stock-q3-earnings-roster-for-oct-26%3A-gild-bmy-more-2017-10-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-exelixis-soars-priority-review-fda-panel-supports-spark-drug-2017-10", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-acn-nvda-alxn-2017-10-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-has-2017-10-24", "https://www.nasdaq.com/articles/morning-movers-more-cuts-geand-more-earnings-you-can-shake-stick-2017-10-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-trying-close-key-technical-measure-2017-10-11", "https://www.nasdaq.com/articles/seeking-alpha-editors-picks-daily-october-11-2017-2017-10-11", "https://www.nasdaq.com/articles/analysts-predict-10-upside-holdings-qqq-2017-10-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-flexion-therapeutics-alexion-pharmaceuticals-ptc", "https://www.nasdaq.com/articles/3-biotech-and-pharma-stocks-key-fda-catalysts-october-2017-10-02", "https://www.nasdaq.com/articles/clovis-oncology-scores-relative-strength-rating-upgrade-2017-09-28", "https://www.nasdaq.com/articles/rhenman-partners-asset-management-ab-buys-arena-pharmaceuticals-inc-vertex-2017-10-13", "https://www.nasdaq.com/articles/intercept-icpt-provides-safety-guidelines-for-ocaliva-2017-09-27", "https://www.nasdaq.com/articles/stocks-watch-prothena-sees-relative-strength-rating-jump-81-2017-09-27", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating-2017-09-27", "https://www.nasdaq.com/articles/acceleron-pharma-reaches-80-plus-relative-strength-rating-benchmark-2017-09-27", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-innoviva-2017-09-27", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-alxn-mon-cme-2017-09-27", "https://www.nasdaq.com/articles/infinity-bristol-myers-adds-tnbc-patients-to-clinical-deal-2017-09-26", "https://www.nasdaq.com/articles/4-strong-buy-stocks-from-best-performing-analysts-2017-09-27", "https://www.nasdaq.com/articles/global-blood-therapeutic-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-09-26", "https://www.nasdaq.com/articles/acceleron-pharma-trying-close-key-technical-measure-2017-09-26", "https://www.nasdaq.com/articles/acorda-therapeutics-getting-closer-key-technical-measure-2017-09-26", "https://www.nasdaq.com/articles/abbvie-bristol-myers-inks-deal-to-develop-therapeutic-cancer-2017-09-25", "https://www.nasdaq.com/articles/the-medicines-co.-continues-to-focus-on-pipeline-development-2017-09-22", "https://www.nasdaq.com/articles/bayer-bayry-focuses-on-pipeline-development-acquisitions-2017-09-22", "https://www.nasdaq.com/articles/dr.-reddys-laboratories-rdy-surges%3A-stock-moves-5.7-higher-2017-09-22", "https://www.nasdaq.com/articles/3-biotech-stocks-major-catalysts-october-2017-09-26", "https://www.nasdaq.com/articles/alnylam-sanofis-rnai-drug-meets-endpoint-in-study-stock-up-2017-09-21", "https://www.nasdaq.com/articles/karyopharms-liposarcoma-candidate-superior-in-phase-ii-study-2017-09-21", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-adds-51.7-in-session-2017-09-21", "https://www.nasdaq.com/articles/ardsley-advisory-partners-buys-alexion-pharmaceuticals-inc-new-residential-investment-corp", "https://www.nasdaq.com/articles/akari-therapeutics-aktx-stock-skyrocketing-over-60-today-heres-why-2017-09-21", "https://www.nasdaq.com/articles/teva-nuvelution-to-speed-up-development-of-austedo-in-us-2017-09-20", "https://www.nasdaq.com/articles/epizyme-epzm-looks-good%3A-stock-adds-7.8-in-session-2017-09-20", "https://www.nasdaq.com/articles/werner-enterprises-cott-akari-therapeutics-and-alexion-highlighted-as-zacks-bull-and-bear", "https://www.nasdaq.com/articles/proqrs-genetic-disorder-candidate-gets-orphan-drug-status-2017-09-20", "https://www.nasdaq.com/articles/alkermes-aristada-shows-better-results-to-treat-schizophrenia-2017-09-19", "https://www.nasdaq.com/articles/pluristems-ischemia-candidate-gets-fast-track-designation-2017-09-19", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-10.5-higher-2017-09-19", "https://www.nasdaq.com/articles/axovant-sciences-ltd.-axon-jumps%3A-stock-rises-7.2-2017-09-19", "https://www.nasdaq.com/articles/glaxos-triple-therapy-copd-inhaler-gets-chmp-nod-in-the-eu-2017-09-18", "https://www.nasdaq.com/articles/jjs-jnj-psoriasis-drug-guselkumab-gets-chmp-nod-in-eu-2017-09-18", "https://www.nasdaq.com/articles/novartis-poised-to-grow-on-oncology-portfolio-biosimilars-2017-09-20", "https://www.nasdaq.com/articles/proqrs-genetic-disorder-candidate-gets-orphan-drug-status-2017-09-20", "https://www.nasdaq.com/articles/alkermes-aristada-shows-better-results-to-treat-schizophrenia-2017-09-19", "https://www.nasdaq.com/articles/pluristems-ischemia-candidate-gets-fast-track-designation-2017-09-19", "https://www.nasdaq.com/articles/synthetic-biologics-syn-in-focus%3A-stock-moves-7.7-higher-2017-09-18", "https://www.nasdaq.com/articles/ibb-biib-regn-alxn-etf-inflow-alert-2017-09-15", "https://www.nasdaq.com/articles/pfizer-xtandi-succeeds-in-early-stage-prostate-cancer-study-2017-09-15", "https://www.nasdaq.com/articles/strength-seen-in-halozyme-therapeutics-halo%3A-stock-soars-21.2-2017-09-15", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-alxn-could-beat-earnings-estimates-again-2017-09-18", "https://www.nasdaq.com/articles/alexion-alxn-reports-interim-results-for-soliris-study-2017-09-14", "https://www.nasdaq.com/articles/4-biotech-stocks-that-show-promise-on-sustainable-growth-2017-09-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-cut-jobs-streamline-operations-kura-cancer-data-2017-09-13", "https://www.nasdaq.com/articles/roche-rhhby-announces-data-on-respiratory-drug-esbriet-2017-09-13", "https://www.nasdaq.com/articles/alexion-to-restructure-operations-to-lower-headcount-by-20-2017-09-13", "https://www.nasdaq.com/articles/achillions-hcv-partnership-with-jj-terminated-stock-falls-2017-09-12", "https://www.nasdaq.com/articles/astrazenecas-asthma-candidate-shows-promising-results-2017-09-12", "https://www.nasdaq.com/articles/glaxos-shingles-candidate-gets-positive-fda-committee-vote-2017-09-14", "https://www.nasdaq.com/articles/pfizer-lung-cancer-drugs-overall-survival-data-unfavorable-2017-09-12", "https://www.nasdaq.com/articles/5-top-ranked-biotech-stocks-buy-right-now-2017-09-11", "https://www.nasdaq.com/articles/astrazenecas-lung-cancer-study-data-promising-shares-spike-2017-09-11", "https://www.nasdaq.com/articles/regeneron-sanofis-dupixent-asthma-study-meets-endpoints-2017-09-11", "https://www.nasdaq.com/articles/lilly-to-cut-3500-jobs-to-invest-in-new-drugs-and-growth-2017-09-08", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-08", "https://www.nasdaq.com/articles/astrazenecas-copd-candidate-duaklir-reports-positive-data-2017-09-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-payx-2017-09-12", "https://www.nasdaq.com/articles/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-2017-09-06", "https://www.nasdaq.com/articles/cellect-biotechnology-apop-soars%3A-stock-adds-10.2-in-session-2017-09-06", "https://www.nasdaq.com/articles/proqrs-qrx-421-gets-orphan-drug-designation-from-fda-and-ema-2017-09-06", "https://www.nasdaq.com/articles/vivus-gives-rights-to-alvogen-in-korea-for-anti-obesity-drug-2017-09-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-activision-blizzard-intuit", "https://www.nasdaq.com/articles/morning-movers-us-steel-jumps-merrill-upgrade-united-technologies-drops-rockwell-collins", "https://www.nasdaq.com/articles/biotech-stocks-back-favor-will-rally-continue-2017-09-05", "https://www.nasdaq.com/articles/aerie-initiates-phase-iii-study-for-ophthalmic-drug-roclatan-2017-09-07", "https://www.nasdaq.com/articles/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-2017-09-06", "https://www.nasdaq.com/articles/amgen-gets-eu-nod-to-expand-hyperparathyroidism-drug-label-2017-09-01", "https://www.nasdaq.com/articles/5-winning-stocks-beat-september-blues-2017-09-01", "https://www.nasdaq.com/articles/amags-filing-for-ferahemes-label-expansion-accepted-by-fda-2017-09-01", "https://www.nasdaq.com/articles/teva-austedo-gets-fda-nod-for-label-expansion-in-dyskinesia-2017-08-31", "https://www.nasdaq.com/articles/roches-rhhby-actemra-gets-fda-nod-for-label-expansion-2017-08-31", "https://www.nasdaq.com/articles/how-parts-add-qqq-headed-158-2017-08-31", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-05", "https://www.nasdaq.com/articles/xbi-exel-alxn-vrtx-etf-inflow-alert-2017-08-30", "https://www.nasdaq.com/articles/juno-therapeutics-juno-soars%3A-stock-adds-20.1-in-session-2017-08-30", "https://www.nasdaq.com/articles/advanced-accelerator-gets-action-date-for-lutathera-from-fda-2017-08-29", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-gets-canadian-nod-2017-08-29", "https://www.nasdaq.com/articles/kamada-kmda-gets-fda-approval-for-rabies-vaccine-2017-08-28", "https://www.nasdaq.com/articles/traders-buy-calls-alexion-pharma-2017-08-28", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-combo-gets-priority-review-in-u.s.-2017-08-25", "https://www.nasdaq.com/articles/biomarins-pegvaliase-bla-granted-priority-review-by-the-fda-2017-08-30", "https://www.nasdaq.com/articles/intra-cellular-itci-soars%3A-stock-adds-27.7-in-session-2017-08-24", "https://www.nasdaq.com/articles/paratek-pharmaceuticals-inc.-prtk-catches-eye%3A-stock-up-27.3-2017-08-24", "https://www.nasdaq.com/articles/immunomedics-immu-catches-eye%3A-stock-up-5.1-2017-08-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-label-expansion-alexion-biib-facing-drug-price-probe-2017-08-23", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-exel-alxn-vrtx-2017-08-22", "https://www.nasdaq.com/articles/immunomedics-progress-in-phase-ii-cancer-study-encouraging-2017-08-22", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-centene", "https://www.nasdaq.com/articles/array-biopharma-arry-looks-good%3A-stock-adds-5.9-in-session-2017-08-24", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-europe-2017-08-22", "https://www.nasdaq.com/articles/intec-pharma-ntec-catches-eye%3A-stock-adds-9.8-in-session-2017-08-22", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-adamas-adms-2017-08-21", "https://www.nasdaq.com/articles/mirati-therapeutics-mrtx-rises%3A-stock-moves-10.9-higher-2017-08-21", "https://www.nasdaq.com/articles/horizon-pharma-hznp-soars%3A-stock-adds-10.5-in-session-2017-08-18", "https://www.nasdaq.com/articles/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-0", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-granted-priority-review-by-fda-2017-08-17", "https://www.nasdaq.com/articles/4-biotech-stocks-add-your-portfolio-post-q2-earnings-2017-08-22", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-europe-2017-08-22", "https://www.nasdaq.com/articles/intec-pharma-ntec-catches-eye%3A-stock-adds-9.8-in-session-2017-08-22", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-adamas-adms-2017-08-21", "https://www.nasdaq.com/articles/regeneron-vs-alexion-which-stock-better-pick-post-q2-earnings-2017-08-14", "https://www.nasdaq.com/articles/3-strong-buy-biotech-stocks-you-should-watch-2017-08-14", "https://www.nasdaq.com/articles/editas-medicine-edit-looks-good%3A-stock-moves-up-11.3-2017-08-14", "https://www.nasdaq.com/articles/xbi-exel-alxn-clvs-etf-outflow-alert-2017-08-11", "https://www.nasdaq.com/articles/novo-nordisks-semaglutide-shows-remarkable-results-in-study-2017-08-17", "https://www.nasdaq.com/articles/implied-volatility-surging-for-alexion-pharmaceuticals-alxn-stock-options-2017-08-11", "https://www.nasdaq.com/articles/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-2017-08-10", "https://www.nasdaq.com/articles/geron-gern-q2-loss-narrows-sales-miss-estimates-stock-up-2017-08-10", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-shooting-25-higher-today-2017-08-09", "https://www.nasdaq.com/articles/forget-bayer-buy-these-3-drug-stocks-instead-2017-08-08", "https://www.nasdaq.com/articles/dynavax-technologies-dvax-catches-eye%3A-stock-adds-11.2-in-session-2017-08-08", "https://www.nasdaq.com/articles/key-reason-alexion-pharmaceuticals-inc-vaulted-13-higher-july-2017-08-08", "https://www.nasdaq.com/articles/forget-teva-teva-buy-these-4-drug-stocks-instead-2017-08-11", "https://www.nasdaq.com/articles/3-etfs-to-watch-out-for-on-biotech-earnings-2017-08-01", "https://www.nasdaq.com/articles/alexion-alxn-tops-q2-earnings-revenues-ups-2017-view-2017-07-27", "https://www.nasdaq.com/articles/alexion-alxn-tops-q2-earnings-sales-shares-2017-07-27", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-etf-outflow-alert-2017-07-26", "https://www.nasdaq.com/articles/biotech-stocks-jul27-q2-earnings-roster%3A-bmy-celg-alxn-2017-07-26", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-alxn-might-surprise-this-earnings-season-2017-07-26", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-hbi-ea-alxn-2017-07-26", "https://www.nasdaq.com/articles/new-strong-buy-stocks-august-2nd-2017-08-02", "https://www.nasdaq.com/articles/whats-in-the-cards-for-exelixis-exel-in-q2-earnings-2017-07-24", "https://www.nasdaq.com/articles/is-celgene-celg-poised-for-a-beat-this-earnings-season-2017-07-24", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-alexion-pharmaceuticals-alxn-stock-2017-07-21", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2017-07-20", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-07-20", "https://www.nasdaq.com/articles/is-gilead-gild-poised-for-a-beat-this-earnings-season-2017-07-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-boosted-cf-data-fda-nod-gilead-puma-drugs-2017-07-19", "https://www.nasdaq.com/articles/can-intercept-icpt-beat-estimates-this-earnings-season-2017-07-25", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-large-inflows-detected-etf-2017-07-13", "https://www.nasdaq.com/articles/5-top-multibagger-biotech-stocks-buy-2nd-half-2017-07-11", "https://www.nasdaq.com/articles/spiros-segalas-commentary-alexion-pharmaceuticals-2017-07-10", "https://www.nasdaq.com/articles/3-stocks-huge-business-advantages-2017-07-09", "https://www.nasdaq.com/articles/alexion-reportedly-being-investigated-by-hhs-shares-slip-2017-07-07", "https://www.nasdaq.com/articles/3-hot-biotech-stocks-ready-sectors-next-breakout-2017-07-06", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-clvs-exel-alxn-2017-07-05", "https://www.nasdaq.com/articles/wall-streets-5-hottest-biotech-stocks-right-now-2017-07-17", "https://www.nasdaq.com/articles/3-best-performing-stocks-june-2017-07-03", "https://www.nasdaq.com/articles/analysts-anticipate-qqq-will-reach-151-2017-06-30", "https://www.nasdaq.com/articles/2-fastest-growing-biotech-stocks-2017-06-28", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2017-06-27", "https://www.nasdaq.com/articles/heres-why-ra-pharmaceuticals-inc-tumbled-much-32-today-2017-06-27", "https://www.nasdaq.com/articles/3-top-stocks-sale-summer-2017-06-26", "https://www.nasdaq.com/articles/top-stock-reports-oracle-allergan-abbott-2017-06-23", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-shouldnt-buy-vertex-pharmaceuticals-2017-07-03", "https://www.nasdaq.com/articles/monday-619-insider-buying-report-alxn-akam-2017-06-19", "https://www.nasdaq.com/articles/weekly-top-insider-buys-highlight-week-june-16-2017-06-17", "https://www.nasdaq.com/articles/baker-bros-advisors-lp-buys-incyte-corp-avexis-inc-la-jolla-pharmaceutical-co-sells-abbvie", "https://www.nasdaq.com/articles/company-news-for-june-15-2017-2017-06-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-management-changes-biogen-alexion-gild-files-hiv-drug-2017-06-15", "https://www.nasdaq.com/articles/biogen-loses-top-executive-again-cfo-clancy-to-join-alexion-2017-06-14", "https://www.nasdaq.com/articles/omeros-omer-lead-candidate-gets-breakthrough-designation-2017-06-14", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-alxn-2017-06-21", "https://www.nasdaq.com/articles/monday-619-insider-buying-report-alxn-akam-2017-06-19", "https://www.nasdaq.com/articles/weekly-top-insider-buys-highlight-week-june-16-2017-06-17", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-wednesday%3A-ford-motor-company-f-alexion-pharmaceuticals-inc.-alxn-and", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2017-06-14", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-619489-down-2548-points-2017-06-14", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-strp-alxn-scco-2017-06-14", "https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-utilities-2017-06-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-alxn-2017-06-14", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-pbe-qgen-ions-alxn-2017-06-09", "https://www.nasdaq.com/articles/5-top-stocks-june-2017-06-07", "https://www.nasdaq.com/articles/3-stocks-vertex-pharmaceuticals-return-potential-2017-06-03", "https://www.nasdaq.com/articles/why-is-alexion-alxn-down-23-since-the-last-earnings-report-2017-06-01", "https://www.nasdaq.com/articles/how-pieces-add-eqal-targets-31-2017-05-30", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-620526-2017-05", "https://www.nasdaq.com/articles/after-hours-most-active-may-25-2017-hpe-ko-ozrk-jnpr-msft-xom-dfs-alxn-bmy-ctsh-jd-cmcsa", "https://www.nasdaq.com/articles/9-biotech-stats-will-blow-you-away-2017-06-12", "https://www.nasdaq.com/articles/company-news-for-may-24-2017-2017-05-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-regeneron-ra-drug-amgen-hit-study-data-2017-05-24", "https://www.nasdaq.com/articles/back-2400-already-2017-05-24", "https://www.nasdaq.com/articles/heres-why-alexion-pharma-alxn-stock-sinking-today-2017-05-23", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-now-oversold-alxn-2017-05-23", "https://www.nasdaq.com/articles/mid-day-market-update-kirklands-drops-after-weak-q1-results-helios-and-matheson-analytics", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-alxn-googl-mgrc-2017-05-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-intu-2017-05-24", "https://www.nasdaq.com/articles/pre-market-most-active-may-23-2017-vips-tsu-sc-nok-epc-momo-ttwo-aeg-eric-qqq-tlt-alxn", "https://www.nasdaq.com/articles/why-herbalife-alexion-pharmaceuticals-and-brown-forman-slumped-today-2017-05-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-613871-509-points-2017-05-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-americas-car-mart-rises-earnings-beat-alexion-shares-drop-2017", "https://www.nasdaq.com/articles/health-care-sector-update-05232017-alxn-etrm-cers-jnj-nvs-2017-05-23", "https://www.nasdaq.com/articles/stocks-fell-3-year-lows-week-may-19-2017-05-21", "https://www.nasdaq.com/articles/heres-why-omeros-corporation-surging-again-today-2017-05-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-xlnx-mnst-2017-05-23", "https://www.nasdaq.com/articles/pre-market-most-active-may-23-2017-vips-tsu-sc-nok-epc-momo-ttwo-aeg-eric-qqq-tlt-alxn", "https://www.nasdaq.com/articles/why-herbalife-alexion-pharmaceuticals-and-brown-forman-slumped-today-2017-05-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-biomarin-report-q1-kite-down-patient-death-2017-05-10", "https://www.nasdaq.com/articles/what-are-we-waiting-2017-05-10", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-services-2017-05-08", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-regeneron-edwards-lifesciences-alexion", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-inks-deal-boost-pipeline-sangamo-soars-pfizer-deal-2017-05-17", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2017-04-28", "https://www.nasdaq.com/articles/alxn-makes-bullish-cross-above-critical-moving-average-2017-04-27", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-revenues-ups-17-view-2017-04-27", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-sales-shares-up-2017-04-27", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-oih-2017-04-27", "https://www.nasdaq.com/articles/stocks-give-encore-performance-2017-04-26", "https://www.nasdaq.com/articles/why-akari-therapetuics-plc-falling-today-2017-04-24", "https://www.nasdaq.com/articles/5-healthcare-innovators-im-still-buying-2017-05-04", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-consumer-products-2017-04-21", "https://www.nasdaq.com/articles/peek-under-hood-iyh-has-11-upside-2017-04-20", "https://www.nasdaq.com/articles/3-beaten-healthcare-stocks-are-they-bargains-2017-04-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-oncomed-2017-04-19", "https://www.nasdaq.com/articles/7-most-expensive-prescription-drugs-world-2017-04-18", "https://www.nasdaq.com/articles/3-big-reasons-be-bullish-biotech-stocks-2017-04-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-lila-alxn-2017-04-13", "https://www.nasdaq.com/articles/alexion-alxn-q1-earnings%3A-can-the-stock-pull-a-surprise-2017-04-21", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-consumer-products-2017-04-21", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-slid-99-march-why-2017-04-04", "https://www.nasdaq.com/articles/3-top-growth-stocks-priced-bargain-spring-2017-04-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-study-2017-03-29", "https://www.nasdaq.com/articles/heres-why-omeros-corporation-stock-climbed-higher-today-2017-03-28", "https://www.nasdaq.com/articles/omeros-power-pipeline-2017-03-24", "https://www.nasdaq.com/articles/alexion-alxn-files-for-soliris-label-expansion-in-japan-2017-03-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-580515-down-3101-points-2017-04-13", "https://www.nasdaq.com/articles/commit-buy-alexion-pharmaceuticals-75-earn-51-using-options-2017-03-22", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-enters-oversold-territory-alxn-2017-03-21", "https://www.nasdaq.com/articles/look-under-hood-bbh-has-12-upside-2017-03-20", "https://www.nasdaq.com/articles/midday-update-market-indices-flat-set-close-week-higher-2017-03-17", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-tiffany-earnings-top-estimates-2017-03-17", "https://www.nasdaq.com/articles/futures-cautiously-higher-ahead-production-data-2017-03-17", "https://www.nasdaq.com/articles/alexion-alxn-licenses-artubus-technology-for-rare-diseases-2017-03-17", "https://www.nasdaq.com/articles/health-care-sector-update-03232017-alxn-2017-03-23", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-alxn-antm-pn-2017-03-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsco-ctrp-2017-03-13", "https://www.nasdaq.com/articles/alexions-sbla-for-soliris-receives-fda-acknowledgement-2017-03-10", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-ca-inc.-ca-autodesk-inc.-adsk-and-alexion-pharmaceuticals", "https://www.nasdaq.com/articles/alxn-crosses-below-key-moving-average-level-2017-03-08", "https://www.nasdaq.com/articles/right-time-invest-biotech-stocks-2017-03-07", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-lineup-for-mar-1%3A-myl-kerx-more-2017-02-28", "https://www.nasdaq.com/articles/close-update-stocks-limp-fridays-close-hang-slim-gains-week-2017-03-17", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-alxn-antm-pn-2017-03-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsco-ctrp-2017-03-13", "https://www.nasdaq.com/articles/forget-alexion-buy-these-4-biotech-stocks-instead-2017-02-20", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-lineup-for-feb-21%3A-irwd-mnta-exas-2017-02-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-khc-2017-02-17", "https://www.nasdaq.com/articles/alexion-alxn-q4-earnings-in-line-sales-rise-y-y-2017-02-16", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q4-earnings-and-revenues-2017-02-16", "https://www.nasdaq.com/articles/ibb-regn-ilmn-alxn-large-outflows-detected-etf-2017-02-27", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-16-2017-chtr-duk-pcg-wm-alxn-zts-mgm-lh-aee-eca-scg", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-ups-alxn-pep-2017-02-14", "https://www.nasdaq.com/articles/alexion-alxn-q4-earnings%3A-can-the-stock-pull-a-surprise-2017-02-10", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2017-02-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-tsco-2017-02-02", "https://www.nasdaq.com/articles/alxn-crosses-above-key-moving-average-level-2017-01-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-procter-gamble-micron-macys-and-alexion-2017", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-slated-for-feb-16%3A-alxn-zts-more-2017-02-15", "https://www.nasdaq.com/articles/deja-vu-drug-stocks-trump-slams-drug-pricing-again-2017-01-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-isrg-2017-01-11", "https://www.nasdaq.com/articles/alexion-alxn-files-for-label-expansion-of-soliris-in-u.s.-eu-2017-01-11", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-556365-2017-01", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-regn-alxn-incy-2017-01-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-ebay-ilmn-2017-01-10", "https://www.nasdaq.com/articles/heres-why-alexion-pharmaceuticals-inc-stock-gave-36-2016-2017-01-09", "https://www.nasdaq.com/articles/4-top-biotech-mutual-funds-for-2017-2017-01-18", "https://www.nasdaq.com/articles/company-news-for-january-06-2017-2017-01-06", "https://www.nasdaq.com/articles/alxn-crosses-above-key-moving-average-level-2017-01-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-wba-alxn-2017-01-05", "https://www.nasdaq.com/articles/sp-500-movers-kss-alxn-2017-01-05", "https://www.nasdaq.com/articles/alexion-alxn-stock-up-on-10q-filing-2016-view-retained-2017-01-05", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-548794-2017-01", "https://www.nasdaq.com/articles/alexion-alxn%3A-will-the-stock-continue-to-suffer-in-2017-2017-01-04", "https://www.nasdaq.com/articles/alexion-blood-disorder-drug-gets-orphan-designation-in-u.s.-2017-01-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alexion-pharmaceuticals-celgene-incyte-eli-lilly", "https://www.nasdaq.com/articles/nasdaq-100-movers-wdc-nvda-2016-12-27", "https://www.nasdaq.com/articles/forget-alexion-alxn-buy-these-3-biotech-stocks-instead-2016-12-27", "https://www.nasdaq.com/articles/are-these-3-stocks-biggest-comeback-opportunities-2017-2016-12-22", "https://www.nasdaq.com/articles/alexion-soliris-fails-in-phase-ii-iii-delayed-graft-function-study-2016-12-22", "https://www.nasdaq.com/articles/bad-news-bashes-biotech-investors-again-2016-12-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-conatus-soars-novartis-deal-early-fda-nod-clovis-drug-2016-12-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-inotek-plunges-pipeline-setback-kite-files-ind-study-initiation-2017", "https://www.nasdaq.com/articles/agree-purchase-alexion-pharmaceuticals-75-earn-99-using-options-2016-12-20", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-regn-myl-alxn-2016-12-19", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-545744-2028-points-2016-12-19", "https://www.nasdaq.com/articles/alexion-investors-want-answers-2016-12-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-alxn-2016-12-16", "https://www.nasdaq.com/articles/sp-500-movers-jwn-alxn-2016-12-16", "https://www.nasdaq.com/articles/we-did-math-pbe-can-go-52-2016-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-12212016-alxngildmrusincymack-2016-12-21", "https://www.nasdaq.com/articles/worst-yet-come-alexion-pharmaceuticals-2016-12-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-myl-2016-12-13", "https://www.nasdaq.com/articles/alexion-slips-to-52-week-low-as-ceo-cfo-quit-amid-probe-2016-12-13", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-546383-2016-12", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-over-3-ophthotech-shares-tumble-after-failed-phase-3-trial", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-incs-shareholders-lost-3-billion-today-2016-12-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-regn-2016-12-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-ophthotech-slumps-fovista-results-achaogen-skyrockets-data-2016-12", "https://www.nasdaq.com/articles/worst-yet-come-alexion-pharmaceuticals-2016-12-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-myl-2016-12-13", "https://www.nasdaq.com/articles/alexion-slips-to-52-week-low-as-ceo-cfo-quit-amid-probe-2016-12-13", "https://www.nasdaq.com/articles/health-care-sector-update-12122016-alxnaznhonakaoopht-2016-12-12", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-spyg-2016-12-12", "https://www.nasdaq.com/articles/mid-afternoon-market-update-achaogen-surges-positive-phase-3-results-alexion-shares-slide", "https://www.nasdaq.com/articles/sp-500-movers-alxn-regn-2016-12-12", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-turn-higher-nivalis-therapeutics-shares-tumble-after", "https://www.nasdaq.com/articles/why-thor-industries-alexion-pharmaceuticals-and-berry-plastics-jumped-today-2016-11-29", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-537992-1111-points-2016-11-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-stops-ampyra-pswd-development-crl-spectrums-qapzola-2016-11", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-you-can-buy-right-now-2016-11-22", "https://www.nasdaq.com/articles/ibb-regn-alxn-vrtx-etf-inflow-alert-2016-11-15", "https://www.nasdaq.com/articles/alexion-alxn-offers-long-term-phase-iii-data-on-kanuma-2016-11-14", "https://www.nasdaq.com/articles/alxn-makes-bullish-cross-above-critical-moving-average-2016-12-09", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-523711-2831-points-2016-11-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-ionis-soars-spinraza-data-regenerons-q3-results-mixed-2016-11-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-november-8th-2016-11-08", "https://www.nasdaq.com/articles/biotech-etfs-slumping-on-q3-results-2016-11-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-lvnta-biib-2016-11-07", "https://www.nasdaq.com/articles/sp-500-movers-nem-syy-2016-11-07", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-516617-11980-points-2016-11-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-nvda-2016-11-11", "https://www.nasdaq.com/articles/spy-etf-tests-key-level-every-sp-sector-posts-weekly-loss-2016-11-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-symc-alxn-2016-11-04", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-bbh-2016-11-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-enbrel-sales-regenerons-sarilumab-faces-delay-2016-11-03", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-november-2nd-2016-11-02", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-nov-2-agn-zts-more-2016-11-01", "https://www.nasdaq.com/articles/3-big-stock-charts%3A-conocophillips-cop-western-digital-corp-wdc-and-alexion", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ofg-alxn-scty-2016-11-04", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-518914-down-96-points-2016-10-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-orly-wdc-2016-10-27", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q2-earnings-beats-revenues-2016-10-27", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-521597-down-3430-points-2016-10-27", "https://www.nasdaq.com/articles/alexion-alxn-q3-earnings-lag-revenues-tops-lifts-view-2016-10-27", "https://www.nasdaq.com/articles/drug-stock-q3-earnings-roster-for-oct-27%3A-amgn-bmy-more-2016-10-26", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2016-10-24", "https://www.nasdaq.com/articles/genetic-stocks-to-watch-for-earnings-on-nov-1%3A-gild-more-2016-10-31", "https://www.nasdaq.com/articles/alexion-alxn-q3-earnings%3A-can-the-stock-pull-a-surprise-2016-10-20", "https://www.nasdaq.com/articles/math-shows-qus-can-go-69-2016-10-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-wdc-ulta-2016-10-13", "https://www.nasdaq.com/articles/alexion-presents-new-long-term-phase-iii-data-on-kanuma-2016-10-11", "https://www.nasdaq.com/articles/health-care-sector-update-10072016-celg-2016-10-07", "https://www.nasdaq.com/articles/3-growth-stocks-buy-october-2016-10-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgens-kyprolis-disappoints-array-cancer-data-2016-09-28", "https://www.nasdaq.com/articles/alexion-graft-versus-host-disease-drug-wins-orphan-status-2016-10-20", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-530575-down-3377-points-2016-09-23", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2016-09-20", "https://www.nasdaq.com/articles/commit-buy-alexion-pharmaceuticals-85-earn-67-using-options-2016-09-20", "https://www.nasdaq.com/articles/look-under-hood-ivv-has-11-upside-2016-09-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsco-wba-2016-09-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-colucid-soars-migraine-data-dynavax-drug-fda-panel-meeting-cancelled", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-patent-infringement-lawsuit-enbrel-biosimilar-approved-2016", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-bmrn-2016-09-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-530575-down-3377-points-2016-09-23", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2016-09-20", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-22nd-2016-08-22-0", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-15th-2016-08-15", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-cranks-out-data-2016-08-12", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-qqxt-2016-08-11", "https://www.nasdaq.com/articles/5-growth-stocks-buy-september-2016-08-31", "https://www.nasdaq.com/articles/alexions-gvhd-candidate-gets-orphan-drug-status-in-the-eu-2016-08-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-medivation-pfizer-clovis-priority-review-2016-08-24", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-22nd-2016-08-22", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-22nd-2016-08-22-0", "https://www.nasdaq.com/articles/alexion-alxn-beats-on-q2-earnings-and-revenues-2016-07-28", "https://www.nasdaq.com/articles/watch-for-drug-stocks-earnings-on-jul-28%3A-bmy-celg-more-2016-07-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-q2-results-impress-gilead-hcv-franchise-under-pressure-2016", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-5th-2016-08-05", "https://www.nasdaq.com/articles/i-just-bought-these-4-fast-growing-biotech-stocks-2016-07-23", "https://www.nasdaq.com/articles/sorry-you-cant-buy-hot-biotech-least-not-directly-2016-07-21", "https://www.nasdaq.com/articles/earnings-estimates-these-3-biotech-giants-should-be-heading-lower-heres-why-2016-07-19", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-inc-stock-sank-235-june-2016-07-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-and-out-clinical-hold-amgen-biosimilar-gets-panel-backing-2016", "https://www.nasdaq.com/articles/brexit-shouldnt-have-much-if-any-effect-sector-2016-07-07", "https://www.nasdaq.com/articles/health-care-sector-update-07072016-alxn-2016-07-07", "https://www.nasdaq.com/articles/alexion-alxn-q2-earnings%3A-stock-likely-to-disappoint-2016-07-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-gets-fda-nod-hcv-drug-regulus-hit-clinical-hold-2016-06-29", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2016-06-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-cmcsa-2016-06-27", "https://www.nasdaq.com/articles/how-does-brexit-impact-healthcare-stocks-2016-06-27", "https://www.nasdaq.com/articles/2-biotech-stocks-wont-pay-dividend-anytime-soon-and-1-should-2016-06-24", "https://www.nasdaq.com/articles/how-former-market-darling-became-undervalued-stock-2016-06-23", "https://www.nasdaq.com/articles/3-value-stocks-near-52-week-lows-worth-buying-2016-06-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-endp-stx-2016-06-29", "https://www.nasdaq.com/articles/3-underdog-stocks-were-watching-2016-06-16", "https://www.nasdaq.com/articles/weeks-43-biggest-stock-upgrades-and-downgrades-2016-06-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ishares-nasdaq-biotechnology-biogen-alexion-pharma", "https://www.nasdaq.com/articles/4-stocks-crushed-biotechnology-etf-ibb-week-2016-06-10", "https://www.nasdaq.com/articles/company-news-for-june-08-2016-2016-06-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-slips-ms-results-asco-data-focus-2016-06-08", "https://www.nasdaq.com/articles/ibb-ishares-nasdaq-biotechnology-index-etf-still-buy-2016-06-07", "https://www.nasdaq.com/articles/stock-market-news-for-june-16-2016-2016-06-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-wdc-2016-06-07", "https://www.nasdaq.com/articles/sp-500-movers-biib-wdc-2016-06-07", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-tuesday%3A-alexion-pharmaceuticals-inc.-alxn-verizon-communications-inc", "https://www.nasdaq.com/articles/stocks-mixed-after-dow-flirts-with-18000-2016-06-07", "https://www.nasdaq.com/articles/tuesday-sector-laggards-healthcare-utilities-2016-06-07", "https://www.nasdaq.com/articles/why-alexion-pharmacetuicals-inc-dropping-today-2016-06-07", "https://www.nasdaq.com/articles/alexions-alxn-rare-disorder-drug-gets-eu-orphan-status-2016-06-02", "https://www.nasdaq.com/articles/alexions-soliris-misses-phase-iii-primary-efficacy-endpoint-2016-06-07", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-june-2016-05-27", "https://www.nasdaq.com/articles/41-trades-make-may-ends-2016-05-24", "https://www.nasdaq.com/articles/baron-funds-comments-alexion-pharmaceuticals-2016-05-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-stx-2016-05-17", "https://www.nasdaq.com/articles/analysts-expect-19-upside-qqxt-2016-05-09", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-incs-double-digit-earnings-fall-2016-05-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-sbac-alxn-2016-05-03", "https://www.nasdaq.com/articles/these-billionaires-just-made-killing-celator-heres-what-else-theyve-been-buying-2016-05-31", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q1-earnings-and-revenues-2016-04-28", "https://www.nasdaq.com/articles/alexion-alxn-lags-q1-earnings-revenues-revises-view-2016-04-28", "https://www.nasdaq.com/articles/4-biotech-stocks-reporting-apr-28-amgn-gild-alxn-celg-2016-04-27", "https://www.nasdaq.com/articles/alexion-alxn-q1-earnings%3A-whats-in-store-for-the-stock-2016-04-26", "https://www.nasdaq.com/articles/tuesday-sector-laggards-healthcare-utilities-2016-04-26", "https://www.nasdaq.com/articles/ibb-regn-ilmn-alxn-etf-outflow-alert-2016-04-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-advisory-panels-say-yes-intercept-no-clovis-2016-04-13", "https://www.nasdaq.com/articles/biotech-etfs-sink-on-mixed-q1-results-2016-05-02", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q1-earnings-and-revenues-2016-04-28", "https://www.nasdaq.com/articles/alexion-alxn-lags-q1-earnings-revenues-revises-view-2016-04-28", "https://www.nasdaq.com/articles/4-biotech-stocks-reporting-apr-28-amgn-gild-alxn-celg-2016-04-27", "https://www.nasdaq.com/articles/alexion-alxn-q1-earnings%3A-whats-in-store-for-the-stock-2016-04-26", "https://www.nasdaq.com/articles/tuesday-sector-laggards-healthcare-utilities-2016-04-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-atvi-adbe-2016-03-18", "https://www.nasdaq.com/articles/do-you-own-any-these-top-sector-funds-2016-03-18", "https://www.nasdaq.com/articles/9-drugs-cost-medicare-fortune-2016-04-09", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-spxt-2016-04-07", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2016-04-06", "https://www.nasdaq.com/articles/why-omeros-corporation-dropped-12-february-2016-03-08", "https://www.nasdaq.com/articles/these-3-biotechs-are-growing-fast-which-best-buy-today-2016-03-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-hiv-drug-approved-baxalta-immuno-oncology-deal-2016-03-02", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-5-charts-2016-02-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-ptct-plunges-rtf-fda-radius-shoots-amgen-data-2016-02-25", "https://www.nasdaq.com/articles/upstart-biggest-threat-alexion-pharmaceuticals-2016-03-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-alexion-cti-biopharma-biocryst-and-sarepta", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-regeneron-miss-estimates-setback-cti-biopharma-2016-02-10", "https://www.nasdaq.com/articles/biotech-etfs-slide-as-stocks-report-mixed-q4-results-2016-02-09", "https://www.nasdaq.com/articles/key-takeaways-alexion-pharmaceuticals-incs-earnings-release-2016-02-05", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-in-focus%3A-stock-rises-6.3-2016-02-04", "https://www.nasdaq.com/articles/alexion-misses-on-earnings-and-revenues-in-q4-gives-view-2016-02-03", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q4-earnings-and-revenues-2016-02-03", "https://www.nasdaq.com/articles/2-reasons-alexion-pharmaceuticals-stock-could-rise-2016-02-19", "https://www.nasdaq.com/articles/is-alexion-alxn-likely-to-disappoint-this-earnings-season-2016-02-01", "https://www.nasdaq.com/articles/will-2016-be-alexion-pharmaceuticals-incs-best-year-yet-2016-02-01", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-stock-bargain-or-rip-2016-01-21", "https://www.nasdaq.com/articles/why-ultragenyx-pharmaceuticals-skyrocketed-2015-2016-01-15", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2016-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-01072016-gsk-alxn-2016-01-07", "https://www.nasdaq.com/articles/weekly-cfo-sales-highlight-hr-block-dish-network-alexion-pharmaceuticals-2016-01-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-3-2016-mrk-cmcsa-mdlz-gm-so-adp-alxn-bdx-exc-etn-mpc", "https://www.nasdaq.com/articles/best-3-biotech-stocks-2016-2015-12-22", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-tyson-foods-alexion-pharmaceuticals-gilead-sciences-2015-12-13", "https://www.nasdaq.com/articles/weekly-insider-sells-highlights-cdw-twitter-pg-alexion-pharmaceuticals-2015-12-10", "https://www.nasdaq.com/articles/alexion-alxn-gains-after-kanuma-receives-fda-approval-2015-12-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-spls-alxn-2015-12-08", "https://www.nasdaq.com/articles/sp-500-movers-hrb-azo-2015-12-08", "https://www.nasdaq.com/articles/instant-analysis-alexion-pharmaceuticals-inc-wins-important-fda-approval-2015-12-08", "https://www.nasdaq.com/articles/5-best-performing-nasdaq-stocks-of-2015-2015-12-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-repros-tanks-crl-abbvie-multiple-myeloma-drug-approved-2015-12-02", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2015-11-22", "https://www.nasdaq.com/articles/alxn-crosses-above-key-moving-average-level-2015-11-18", "https://www.nasdaq.com/articles/these-biotech-stocks-may-start-paying-dividends-2016-2015-11-16", "https://www.nasdaq.com/articles/jim-simons-largest-adds-3rd-quarter-2015-11-13", "https://www.nasdaq.com/articles/duo-catalysts-sends-alexion-pharmaceuticals-13-higher-october-2015-11-11", "https://www.nasdaq.com/articles/biotech-sees-better-than-expected-earnings%3A-etfs-in-focus-2015-11-06", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-regn-biib-alxn-2015-12-03", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-november-2015-11-01", "https://www.nasdaq.com/articles/alexion-beats-on-earnings-in-q3-but-misses-on-revenues-2015-10-29", "https://www.nasdaq.com/articles/health-care-sector-update-10292015-reva-alxn-2015-10-29", "https://www.nasdaq.com/articles/alexion-alxn-beats-on-q3-earnings-revises-outlook-2015-10-29", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-29-2015-mo-ma-cop-epd-twc-mck-amt-alxn-aet-cme-px-apd", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-what-to-expect-2015-10-27", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-alxn-2015-10-27", "https://www.nasdaq.com/articles/5-exciting-biotech-stocks-to-buy-on-november-upswing-2015-11-03", "https://www.nasdaq.com/articles/3-top-stocks-buy-your-kidsgrandkids-2015-10-25", "https://www.nasdaq.com/articles/ultragenyx-rare-reports-positive-interim-data-on-ux007-2015-10-20", "https://www.nasdaq.com/articles/3-biotechs-growing-faster-apple-2015-10-18", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-now-2015-10-14", "https://www.nasdaq.com/articles/stock-market-news-for-october-14-2015-2015-10-14", "https://www.nasdaq.com/articles/health-care-sector-update-10132015-lly-ccl-alxn-2015-10-13", "https://www.nasdaq.com/articles/alexion-alxn-presents-positive-5-year-data-on-strensiq-2015-10-13", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-nabs-approval-wall-street-not-impressed-2015-10-26", "https://www.nasdaq.com/articles/3-triple-digit-biotech-stocks-are-worth-every-penny-2015-09-19", "https://www.nasdaq.com/articles/3-biotech-stocks-can-upgrade-your-portfolio-2015-09-18", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2015-09-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-tetraphase-geron-alexion-and-acadia-2015-09-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-biosimilar-competition-amgen-tetraphase-hit-disappointing-data-2015", "https://www.nasdaq.com/articles/alexions-kanuma-fda-action-date-delayed-by-three-months-2015-09-07", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-scores-2-regulatory-wins-2015-09-03", "https://www.nasdaq.com/articles/stock-market-news-for-september-28-2015-2015-09-28", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-alexion-pharmaceuticals-alxn-2015-08", "https://www.nasdaq.com/articles/baron-funds-comments-alexion-pharmaceuticals-inc-2015-08-19", "https://www.nasdaq.com/articles/drugmakers-incredible-run-looks-far-done-2015-08-19", "https://www.nasdaq.com/articles/omeros-reveals-positive-data-on-oms721-from-phase-ii-2015-08-19", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-18th-2015-08-18", "https://www.nasdaq.com/articles/5-most-expensive-drugs-world-2015-2015-08-15", "https://www.nasdaq.com/articles/mixed-biotech-earnings-put-these-etfs-in-focus-etf-news-and-commentary-2015-08-04", "https://www.nasdaq.com/articles/oversold-conditions-alexion-pharmaceuticals-alxn-2015-08-24", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-rsp-cb-celg-alxn-2015-07-30", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q2-earnings-revises-outlook-tale-of-the-tape-2015-07-30", "https://www.nasdaq.com/articles/alexion-misses-on-earnings-in-q2-2015-outlook-revised-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-down-tecfidera-issues-regenerons-praluent-gets-fda-nod", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-30-2015-pg-mdlz-cop-cl-epd-twc-oxy-teva-alxn-adp-ci-vlo", "https://www.nasdaq.com/articles/will-rising-costs-hurt-alexion-alxn-earnings-in-q2-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/biotech-ipo-boom-gaining-thrust-nantkwest-debut-2015-07-24", "https://www.nasdaq.com/articles/health-care-sector-update-07312015-alxn-nlnk-uhs-2015-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-pcsk9-inhibitor-first-gain-approval-exelixis-positive-data", "https://www.nasdaq.com/articles/qld-alxn-aal-amgn-etf-outflow-alert-2015-07-21", "https://www.nasdaq.com/articles/how-rare-disease-drugmaker-alexion-pharmaceuticals-found-its-groove-june-2015-07-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vertex-biogen-applied-genetic-gilead-and-alexion-press", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-cf-drug-approved-biogen-strikes-deal-gene-therapy-analyst", "https://www.nasdaq.com/articles/alexion-hypophosphatasia-drug-strensiq-approved-in-japan-analyst-blog-2015-07-07", "https://www.nasdaq.com/articles/competitive-advantage-best-biotech-stocks-2015-07-05", "https://www.nasdaq.com/articles/alxn-september-4th-options-begin-trading-2015-07-23", "https://www.nasdaq.com/articles/andreas-halvorsen-increases-stake-esperion-therapeutics-2015-06-30", "https://www.nasdaq.com/articles/alexions-strensiq-and-kanuma-get-positive-chmp-opinions-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-avgo-2015-06-15", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-12th-tale-of-the-tape-2015-06-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-panel-recommends-regenerons-praluent-sage-gains-data-analyst", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-nflx-2015-06-10", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2015-06-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-celgene-immunotherapy-deal-biomarinsarepta-dmd-drugs-progress", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-5th-tale-of-the-tape-2015-06-05", "https://www.nasdaq.com/articles/it-too-late-invest-health-care-2015-06-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-immunogen-soars-asco-data-amgen-collaborates-roche-analyst-blog-2015", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-2nd-tale-of-the-tape-2015-06-02", "https://www.nasdaq.com/articles/qld-alxn-aal-adi-etf-outflow-alert-2015-05-29", "https://www.nasdaq.com/articles/synageva-biopharma-files-for-kanumas-approval-in-japan-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-may-26th-tale-of-the-tape-2015-05-26", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-9th-tale-of-the-tape-2015-06-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-buy-synageva-fda-panel-backs-vertexs-orkambi-analyst-blog", "https://www.nasdaq.com/articles/etfs-in-focus-on-impressive-q1-biotech-earnings-etf-news-and-commentary-2015-05-11", "https://www.nasdaq.com/articles/will-suitors-line-buy-these-biotech-stocks-next-2015-05-10", "https://www.nasdaq.com/articles/investors-just-doubled-their-money-stock-2015-05-10", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc.-alxn-in-focus%3A-stock-jumps-5.1-tale-of-the-tape-2015-05-08", "https://www.nasdaq.com/articles/alexion-to-buy-synageva-for-%248.4b%3A-alexion-down-synageva-up-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/midday-update-yellen-spooks-wall-street-comments-stock-valuations-2015-05-06", "https://www.nasdaq.com/articles/why-im-buying-sarepta-therapeutics-stock-2015-05-20", "https://www.nasdaq.com/articles/sp-500-movers-alxn-wu-2015-05-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-expd-2015-05-06", "https://www.nasdaq.com/articles/futures-rebound-gains-europe-billion-dollar-biotech-deal-2015-05-06", "https://www.nasdaq.com/articles/close-update-stocks-lower-yellen-valuation-warning-2015-05-06", "https://www.nasdaq.com/articles/health-care-sector-update-05062015-fatejunogevaalxnardx-2015-05-06", "https://www.nasdaq.com/articles/health-care-sector-update-05062015-ptbi-geva-ardx-alxn-2015-05-06", "https://www.nasdaq.com/articles/etf-preview-broad-market-etfs-gain-line-futures-crude-oil-biotech-funds-among-most-active", "https://www.nasdaq.com/articles/why-shares-synageva-biopharma-corp-skyrocketed-today-2015-05-06", "https://www.nasdaq.com/articles/alexion-misses-q1-earnings-estimates-keeps-2015-outlook-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q1-earnings-maintains-outlook-tale-of-the-tape-2015-04-23", "https://www.nasdaq.com/articles/qld-alxn-aal-adi-large-outflows-detected-etf-2015-04-22", "https://www.nasdaq.com/articles/will-alexions-alxn-soliris-drive-q1-earnings-beat-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-favorable-briefing-documents-mdcos-kengreal-alexion-soliris-label", "https://www.nasdaq.com/articles/alexion-up-as-soliris-gains-eu-nod-for-label-updates-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/10-largest-companies-market-cap-biotech-2015-04-11", "https://www.nasdaq.com/articles/10-most-profitable-businesses-biotech-2015-04-28", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-ftc-2015-04-07", "https://www.nasdaq.com/articles/following-gilead-sciences-inc-which-biotech-will-pay-dividend-next-2015-04-04", "https://www.nasdaq.com/articles/proshares-ultra-qqq-experiences-big-outflow-2015-03-30", "https://www.nasdaq.com/articles/stock-market-news-for-march-26-2015-market-news-2015-03-26", "https://www.nasdaq.com/articles/alxn-makes-notable-cross-below-critical-moving-average-2015-03-25", "https://www.nasdaq.com/articles/can-biotech-stock-go-good-great-2015-03-19", "https://www.nasdaq.com/articles/commit-buy-alexion-pharmaceuticals-145-earn-11-using-options-2015-03-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctxs-nflx-2015-04-10", "https://www.nasdaq.com/articles/affymetrix-hits-52-week-high-on-stellar-q4-positive-outlook-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/sp-500-analyst-moves-alxn-2015-03-02", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-takes-over-13-spot-tyson-foods-2015-03-02", "https://www.nasdaq.com/articles/insiders-buy-holdings-fbt-etf-2015-03-02", "https://www.nasdaq.com/articles/alexions-soliris-label-may-be-updated-upon-ec-approval-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/tqqq-atvi-akam-alxn-etf-outflow-alert-2015-02-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-avgo-2015-02-26", "https://www.nasdaq.com/articles/3-biotech-stocks-wall-street-loves-2015-03-16", "https://www.nasdaq.com/articles/gilead-amgen-q4-earnings-weak-outlook-affect-biotech-etfs-etf-news-and-commentary-2015-02", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-jumps%3A-stock-rises-5.8-tale-of-the-tape-2015-01-30", "https://www.nasdaq.com/articles/qiagen-qgen-disappoints-with-q4-earnings-revenue-miss-analyst-blog-2015-01-30", "https://www.nasdaq.com/articles/celgene-q4-earnings-revenues-in-line-revlimid-sales-up-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/vertex-posts-wider-4q-loss-affirms-kalydeco-outlook-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2015-01-29", "https://www.nasdaq.com/articles/health-care-sector-update-01292015-abt-cah-alxn-2015-01-29", "https://www.nasdaq.com/articles/stock-market-news-for-february-10-2015-market-news-2015-02-10", "https://www.nasdaq.com/articles/alexion-alxn-misses-on-q4-earnings-appoints-new-ceo-tale-of-the-tape-2015-01-29", "https://www.nasdaq.com/articles/incytes-phase-iii-response-data-on-jakafi-published-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/alexion-misses-on-q4-earnings-2015-outlook-disappoints-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/salix-financial-results-need-correcting%3A-audit-committee-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/amgen-beats-q4-earnings-revenues-maintains-outlook-analyst-blog-2015-01-28", "https://www.nasdaq.com/articles/gilead-includes-pan-genotypic-agent-in-hcv-licensing-deals-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/the-medicines-co.-gets-chmp-recommendation-for-3-drugs-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/pluristem-therapeutics-psti-in-focus%3A-stock-surges-20.4-tale-of-the-tape-2015-01-29", "https://www.nasdaq.com/articles/minerva-neurosciences-gains-on-positive-data-on-min-202-analyst-blog-2015-01-23", "https://www.nasdaq.com/articles/sanofis-cerdelga-cleared-in-the-eu-for-gaucher-disease-analyst-blog-2015-01-23", "https://www.nasdaq.com/articles/kite-pharma-kite-in-focus%3A-stock-tumbles-9.2-tale-of-the-tape-2015-01-22", "https://www.nasdaq.com/articles/keryx-biopharmaceuticals-kerx-in-focus%3A-stock-falls-by-6.8-tale-of-the-tape-2015-01-22", "https://www.nasdaq.com/articles/biomarin-to-raise-funds-to-finance-prosensa-acquisition-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/illumina-launches-miseq-fgx-for-forensic-dna-analysis-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/endo-prices-%241.2b-senior-notes-offering-for-auxilium-deal-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/will-alexions-alxn-soliris-drive-q4-earnings-beat-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/minerva-neurosciences-gains-on-positive-data-on-min-202-analyst-blog-2015-01-23", "https://www.nasdaq.com/articles/sanofis-cerdelga-cleared-in-the-eu-for-gaucher-disease-analyst-blog-2015-01-23", "https://www.nasdaq.com/articles/celgene-to-use-zymeworks-azymetric-platform-for-new-drugs-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/affymetrix-hits-52-week-high-on-strong-top-line-growth-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/applied-genetic-technologies-agtc-in-focus%3A-stock-rises-6.6-tale-of-the-tape-2015-01-21", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-in-focus%3A-stock-rises-5.8-tale-of-the-tape-2015-01-21", "https://www.nasdaq.com/articles/alnylam-to-raise-%24450-million-through-issuance-of-shares-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/keryx-to-raise-%24110-million-through-issuance-of-shares-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/arena-pharmaceuticals-to-raise-fund-via-share-issuance-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/merrimack-reveals-additional-data-from-oncology-candidate-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/celgene-to-use-zymeworks-azymetric-platform-for-new-drugs-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/biodelivery-sciences-international-bdsi-in-focus%3A-stock-up-5-tale-of-the-tape-2015-01-19", "https://www.nasdaq.com/articles/celgene-up-as-otezla-gains-eu-approval-for-two-indications-analyst-blog-2015-01-19", "https://www.nasdaq.com/articles/illumina-unveils-3-ngs-systems-modifies-business-strategy-analyst-blog-2015-01-16", "https://www.nasdaq.com/articles/oncomed-starts-expansion-stage-study-for-solid-tumor-drug-analyst-blog-2015-01-16", "https://www.nasdaq.com/articles/state-union-address-investing-idea-precision-medicine-2015-01-21", "https://www.nasdaq.com/articles/illumina-declares-impressive-q4-2014-preliminary-results-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/regado-biosciences-to-merge-with-tobira-therapeutics-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/qiagen-up-on-ce-ivd-mark-for-new-liquid-biopsy-test-kit-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/biomarin-gains-on-vimizim-2014-view-batten-disease-data-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/qiagen-up-on-enzymatics-unit-buy-archerdx-partnership-deal-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/galena-biopharma-gale-jumps%3A-stock-rises-9.1-tale-of-the-tape-2015-01-13", "https://www.nasdaq.com/articles/celgenes-preliminary-results-2015-outlook-encouraging-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/sarepta-starts-dosing-in-duchenne-muscular-dystrophy-study-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/biogen-to-acquire-convergence-expand-pain-pipeline-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/seattle-genetics-bristol-myers-to-study-adcetris-opdivo-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/will-qiagens-qiasymphony-placements-weave-magic-in-2015-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/bristol-myers-opdivo-study-stopped-on-favorable-data-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/regeneron-sanofi-seek-pcsk9-drug-praluent-approval-in-eu-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/emergent-biosolutions-provides-preliminary-2014-results-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/argos-therapeutics-falls-on-disappointing-phase-iib-hiv-data-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/pharmacyclics-reports-preliminary-results-and-2015-outlook-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/qiagen-qgen-launches-next-gen-tb-infection-test-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/affymetrix-affx-expands-genotyping-arrays-product-line-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/3-biotech-stocks-focused-curing-ultra-rare-diseases-2015-01-11", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2015-01-09", "https://www.nasdaq.com/articles/sp-500-movers-adm-mwv-2015-01-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-tsco-2015-01-08", "https://www.nasdaq.com/articles/alexion-reports-disappointing-phase-ii-data-on-soliris-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-remains-in-focus-in-2015-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/alexion-seeks-fda-approval-for-its-hypophosphatasia-drug-analyst-blog-2014-12-31", "https://www.nasdaq.com/articles/sp-500-movers-rig-celg-2014-12-24", "https://www.nasdaq.com/articles/markets-10-best-stocks-2014-12-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-sophiris-cyclacel-plunge-data-chemocentryx-gains-positive-results", "https://www.nasdaq.com/articles/3-companies-growing-faster-mannkind-corporation-2014-12-17", "https://www.nasdaq.com/articles/alexion-announces-new-share-repurchase-program-of-%24500m-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/alexions-soliris-receives-orphan-drug-status-in-japan-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-gmcr-2015-01-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-avanir-be-acquired-japanese-firm-biogen-scores-alzheimers-study", "https://www.nasdaq.com/articles/stock-market-news-for-december-03-2014-market-news-2014-12-03", "https://www.nasdaq.com/articles/valeants-onexton-gel-gets-fda-approval-for-acne-analyst-blog-2014-12-01", "https://www.nasdaq.com/articles/health-care-sector-update-11282014-alxn-nvs-dvax-2014-11-28", "https://www.nasdaq.com/articles/alexions-soliris-gets-final-positive-nice-recommendation-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/alexions-alxn-soliris-gets-orphan-drug-status-in-japan-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/stock-market-news-for-november-19-2014-market-news-2014-11-19", "https://www.nasdaq.com/articles/weekly-insider-sells-highlight-orcl-alxn-wat-xray-2014-12-08", "https://www.nasdaq.com/articles/etf-outlook-first-trust-amex-biotech-index-fund-etf-fbt-2014-11-06", "https://www.nasdaq.com/articles/trend-making-gilead-sciences-inc-worry-2014-11-05", "https://www.nasdaq.com/articles/why-alexion-pharmaceuticals-alxn-could-be-an-impressive-growth-stock-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/top-funds-buy-ulta-beauty-alexion-avago-2014-11-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-beat-raise-quarter-amgen-celgene-alexion-biogen-analyst-blog-2014-10", "https://www.nasdaq.com/articles/5-most-expensive-drugs-world-2014-10-26", "https://www.nasdaq.com/articles/company-news-for-october-24-2014-corporate-summary-2014-10-24", "https://www.nasdaq.com/articles/sarepta-q3-loss-narrower-expected-eteplirsen-focus-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/will-alexion-alxn-earnings-suffer-due-to-higher-costs-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/alexion-alxn-seeks-japanese-approval-for-asfotase-alfa-analyst-blog-2014-10-16", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-lower-pre-bell-2014-10-15", "https://www.nasdaq.com/articles/sector-update-health-care-2014-10-15-1", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-vrtx-2014-10-13", "https://www.nasdaq.com/articles/5-richest-states-america-2014-10-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-sunesis-tanks-study-results-chimerix-ebola-update-analyst-blog-2014", "https://www.nasdaq.com/articles/pre-market-earnings-report-october-23-2014-cmcsa-unp-mmm-celg-lly-oxy-cat-gm-alxn-pcp-rtn", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-in-focus%3A-stock-rises-6.0-tale-of-the-tape-2014-10-06", "https://www.nasdaq.com/articles/proshares-ultrapro-qqq-experiences-big-inflow-2014-10-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-auxilium-acquisition-target-amgen-submits-another-bla-analyst-blog", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-tqqq-atvi-akam-alxn-2014-09-18", "https://www.nasdaq.com/articles/3-hot-ways-play-biotechnology-bonanza-2014-09-17", "https://www.nasdaq.com/articles/alexions-asfotase-alfa-gets-japanese-orphan-drug-status-analyst-blog-2014-09-09", "https://www.nasdaq.com/articles/stock-market-news-for-october-06-2014-market-news-2014-10-06", "https://www.nasdaq.com/articles/ibb-celg-biib-alxn-etf-outflow-alert-2014-09-02", "https://www.nasdaq.com/articles/pfizers-c.-difficile-vaccine-gets-fast-track-status-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/isis-pharmaceuticals-starts-phase-iii-study-on-isis-apociiirx-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/repros-reports-encouraging-late-stage-data-on-androxal-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-biotechs-surge-intermune-acquisition-deal-focus-more-mas-analyst", "https://www.nasdaq.com/articles/biotech-stock-roundup-achillion-scores-mid-stage-study-gileads-sovaldi-remains-focus", "https://www.nasdaq.com/articles/amgen-amgn-reports-encouraging-top-line-data-on-amg-416-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-soliris-wins-nice-backing-for-ahus-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/orexigen-therapeutics-reports-wider-q2-loss-as-costs-mount-analyst-blog-2014-08-08", "https://www.nasdaq.com/articles/nps-pharma-reports-earnings-in-q2-on-strong-gattex-sales-analyst-blog-2014-08-07", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-tqqq-atvi-akam-alxn-2014-08-06", "https://www.nasdaq.com/articles/actavis-beats-q2-earnings-revs-provides-2015-outlook-analyst-blog-2014-08-05", "https://www.nasdaq.com/articles/arena-pharmaceuticals-falls-on-wider-than-expected-q2-loss-analyst-blog-2014-08-04", "https://www.nasdaq.com/articles/alkermes-reports-loss-in-q2-on-higher-costs-revenues-up-analyst-blog-2014-08-04", "https://www.nasdaq.com/articles/dr.-reddys-rdy-q1-earnings-and-revenues-rise-y-y-analyst-blog-2014-08-01", "https://www.nasdaq.com/articles/vivus-reports-narrower-than-expected-loss-on-qsymia-sales-analyst-blog-2014-08-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-mnst-dltr-2014-07-28", "https://www.nasdaq.com/articles/biotech-etf-price-swings-may-signal-need-caution-2014-07-28", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-q2-earnings-in-line-revises-view-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/will-alexion-pharmaceuticals-alxn-miss-this-earnings-season-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-24-2014-mmm-unp-bmy-lly-celg-f-cat-gm-pcp-alxn-pot-rtn", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-tax-inversion-amgen-drug-scores-phase-3-analyst-blog-2014-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-nflx-wynn-2014-07-22", "https://www.nasdaq.com/articles/aegerion-q2-loss-narrower-than-expected-2014-view-retained-analyst-blog-2014-07-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-mnst-dltr-2014-07-28", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-ceo-to-retire-appoints-successor-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/alexion-pharma-looks-life-beyond-its-blockbuster-2014-07-08", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-mtum-2014-06-27", "https://www.nasdaq.com/articles/regenerx-and-lees-pharmaceutical-dry-eye-drug-progresses-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-wfm-dish-2014-06-20", "https://www.nasdaq.com/articles/alnylam-tap-collaborate-for-aat-candidate-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/bluebird-bio-inc.-blue-in-focus%3A-stock-surges-10.24-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/insmed-soars-on-arikayces-breakthrough-designation-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/alexions-soliris-gets-orphan-drug-status-for-new-indication-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/biotech-stock-roundup-hcv-back-focus-idenix-achillion-soar-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/jjs-velcade-in-focus-at-the-european-hematology-association-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-crumbles-on-analyst-worries-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/karyopharm-therapeutics-skyrockets-on-drug-trial-news-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/shire-to-conduct-trials-on-vyvanse-on-fdas-request-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/valeant-launches-hostile-bid-for-allergan-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-new-kalydeco-data-out-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/roches-hpv-test-approved-in-canada-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/encouraging-long-term-data-on-celgenes-otezla-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/bayer-looking-to-expand-eyleas-label-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/allergan-rejects-valeants-proposal-yet-again-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/pdl-biopharma-views-lower-q2-revenues-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/alkermes-progresses-with-its-late-stage-candidate-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/astrazeneca-boosts-pipeline-with-%24232-million-synairgen-deal-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/immunomedics-immu-132-gets-orphan-drug-status-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/valeants-jublia-approved-in-the-u.s.-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/dendreons-ceo-departs-at-critical-juncture-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/agios-initiates-trial-on-ag-348-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/gw-pharma-gets-fast-track-designation-for-epidiolex-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/pipeline-progress-at-glaxosmithkline-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/mannkind-hits-52-week-high-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/nps-pharmas-natpara-likely-to-be-reviewed-in-september-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/positive-phase-iib-data-from-jazz-pharma-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/halozyme-study-clinical-hold-lifted-by-fda-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/positive-data-on-vertex-pharmas-kalydeco-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/bayer-looking-to-expand-adempas-label-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/incyte-gains-on-positive-jakafi-data-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/data-on-bristol-myers-yervoy-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/valeant-relentless-on-acquiring-allergan-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-rost-ilmn-2014-06-05", "https://www.nasdaq.com/articles/valeant-ups-offer-for-allergan-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/intercepts-obeticholic-acid-gets-fast-track-status-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/biomarins-pipeline-advances-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/valeant-selling-product-rights-to-nestle-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/ptc-therapeutics-up-on-positive-chmp-opinion-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/pipeline-progress-at-redhill-biopharma-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/nps-pharma-on-shires-radar-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/sarepta-to-acquire-manufacturing-facility-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/data-on-insmeds-arikayce-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/celgene-inks-licensing-deal-with-aadi-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/intercept-sinks-on-cholesterol-issue-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/dendreon-up-on-provenge-data-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/abbvies-humira-gets-orphan-drug-designation-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/endocyte-merck-withdraw-eu-regulatory-filings-analyst-blog-2014-05-20", "https://www.nasdaq.com/articles/ziopharm-presents-encouraging-data-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/sarepta-to-acquire-manufacturing-facility-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/update-on-glaxos-darapladib-analyst-blog-2014-05-16", "https://www.nasdaq.com/articles/merck-kgaa-beats-on-q1-earnings-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-mannkind-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/repros-q1-loss-in-line-with-expectations-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/osiris-therapeutics-q1-loss-narrower-than-expected-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/glaxo-genmabs-arzerra-disappoints-analyst-blog-2014-05-20", "https://www.nasdaq.com/articles/insys-in-focus-on-subsys-worries-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/alnylam-up-on-narrower-than-expected-q1-loss-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/shares-continue-to-fall-on-emergent-biosolutions-wider-loss-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-orexigen-in-q1-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/dendreon-falls-on-q1-loss-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/spectrum-pharma-up-on-q1-earnings-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-nps-pharma-shares-down-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/abbotts-promising-data-on-radical-platform-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharma-guidance-reiterated-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/xoma-posts-wider-q1-loss-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/anacor-reports-wider-than-expected-q1-loss-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/salix-q1-earnings-boosted-santarus-acquisition-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-aveo-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/avanir-loss-in-line-with-ests-revs-up-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/jj-gilead-hcv-combo-drug-filed-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/medivation-q1-loss-wider-than-expected-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/regeneron-beats-on-earnings-revenues-in-q1-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/split-update-overshadows-wider-q1-loss-at-theravance-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-endocyte-tumbles-merrimack-soars-pipeline-news-analyst-blog-2014-05", "https://www.nasdaq.com/articles/isis-pharmas-q1-loss-widens-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-aegerion-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/acorda-misses-on-earnings-beats-revs-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-disca-gmcr-2014-05-06", "https://www.nasdaq.com/articles/myriad-genetics-drops-despite-earnings-revs-beat-ups-view-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-auxilium-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/vivus-reports-narrower-than-expected-loss-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/marginal-earnings-beat-at-zoetis-view-maintained-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/regeneron-inks-ophthalmology-deal-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/vical-narrows-q1-loss-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-seattle-genetics-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/earnings-beat-at-pharmacyclics-guidance-pulls-down-stock-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-pacira-revs-up-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-auxilium-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/idenixs-q1-loss-widens-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/geron-reports-in-line-q1-loss-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/endocyte-shares-sink-on-dsmb-recommendation-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/acorda-down-on-plumiaz-crl-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/novo-nordisk-beats-earnings-ests-misses-revs-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-incyte-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/celldexs-q1-loss-widens-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/shire-beats-on-earnings-in-q1-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/affymetrix-q1-earnings-beat-ests-by-a-penny-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/3-biotech-beats-this-earnings-season-earnings-esp-2014-05-01", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-alkermes-revenues-slip-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/oncogenex-posts-wider-loss-beats-revenues-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/synagevas-q1-loss-narrower-than-expected-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/crl-for-the-medicines-co.s-cangrelor-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/loss-at-biomarin-narrower-than-expected-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/bristol-myers-beats-earnings-in-q1-misses-on-sales-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/bayer-gains-on-q1-earnings-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-04-29", "https://www.nasdaq.com/articles/oncogenexs-custirsen-misses-primary-endpoint-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/can-affymetrix-affx-surprise-this-earnings-season-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/hyperion-set-to-acquire-andromeda-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/cytokinetics-tirasemtiv-misses-primary-endpoint-analyst-blog-2014-04-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-sovaldi-shines-biogen-alexion-outlook-analyst-blog-2014-04", "https://www.nasdaq.com/articles/emergents-biothrax-gets-orphan-drug-status-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/alexion-posts-strong-earnings-in-q1-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/celgene-earnings-grow-year-over-year-in-q1-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/strong-q1-earnings-at-gilead-on-stellar-sovaldi-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-april-24-2014-vz-mmm-mo-ups-lly-cat-celg-gm-twc-fcx-rtn-alxn", "https://www.nasdaq.com/articles/keep-an-eye-on-these-3-biotech-stocks-earnings-esp-2014-04-22", "https://www.nasdaq.com/articles/alexion-likely-to-keep-earnings-streak-alive-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/company-news-for-april-25-2014-corporate-summary-2014-04-25", "https://www.nasdaq.com/articles/emergents-biothrax-gets-orphan-drug-status-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-pdufa-date-pushed-out-alkermes-impresses-data-analyst-blog", "https://www.nasdaq.com/articles/good-news-for-biomarin-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/fda-nod-for-mercks-grastek-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/gilead-bucks-biotech-trend-thanks-to-sovaldi-news-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/pipeline-progress-at-coronado-biosciences-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/synageva-heading-big-disappointment-2014-04-22", "https://www.nasdaq.com/articles/positive-data-on-biogen-sobis-eloctate-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/rite-aid-rad-jumps%3A-stock-up-8.4-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/celladon-cldn-jumps%3A-stock-up-11.5-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/update-on-biolinerxs-bl-8040-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/encouraging-results-on-gileads-sovaldi-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/sp-500-movers-bbby-hpq-2014-04-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-bbby-chrw-2014-04-10", "https://www.nasdaq.com/articles/positive-results-on-intercept-pharmas-oca-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/halozyme-falls-on-phase-ii-study-halt-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/bristol-myers-seeks-fda-approval-for-hcv-candidates-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/fda-target-date-for-gileads-hcv-candidate-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/mannkind-slips-on-afrezza-approval-delay-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/idenix-pharmaceuticals-idix-jumps%3A-stock-up-12.4-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-in-focus%3A-stock-tumbles-18.3-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/3-top-ranked-biotech-stocks-rebound-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/epo-upholds-alnylams-mcswiggen-patent-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/encouraging-pre-clinical-data-from-celldex-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/intercept-pharma-prices-1m-share-offering-shares-down-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/pipeline-update-from-idenix-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/fda-news-lifts-dyax-slightly-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/momentum-slide-continue-netflix-facebook-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/response-genetics-rgdx-in-focus%3A-stock-up-18.3-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/questcor-pharmaceuticals-qcor-shows-strength%3A-stock-surges-18.7-in-session-tale-of-the", "https://www.nasdaq.com/articles/the-medicines-cos-fibrocaps-under-u.s.-review-analyst-blog-2014-04-04", "https://www.nasdaq.com/articles/glaxo-and-amgen-terminate-agreement-analyst-blog-2014-04-04", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-amgn-biib-alxn-2014-04-03", "https://www.nasdaq.com/articles/acceleron-pharma-xlrn-jumps%3A-stock-up-13.2-tale-of-the-tape-2014-04-03", "https://www.nasdaq.com/articles/bayer-initiates-xofigo-combination-study-analyst-blog-2014-04-03", "https://www.nasdaq.com/articles/encouraging-results-on-gileads-sovaldi-analyst-blog-2014-04-03", "https://www.nasdaq.com/articles/ultragenyx-rare-jumps%3A-stock-rises-7.0-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/weakness-seen-in-kindred-biosciences-kin%3A-stock-tumbles-9.0-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/cara-therapeutics-inc.-cara-worth-watching%3A-stock-surges-12.7-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/momenta-pharmaceuticals-slumps%3A-mnta-falls-16.9-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/exact-sciences-exas-jumps%3A-stock-adds-10.2-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/ec-approves-roche-halozymes-mabthera-sc-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/glaxo-presents-darapladib-data-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/idera-soars-on-phase-ii-drug-data-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/mannkind-down-on-fdas-briefing-document-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/celladon-cldn-jumps%3A-stock-up-5.9-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/gileads-hcv-candidate-under-review-in-the-eu-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/biodelivery-sciences-and-quintiles-sign-deal-for-bunavail-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-inc.-ino-worth-watching%3A-stock-surges-12.7-tale-of-the-tape-2014-03", "https://www.nasdaq.com/articles/insmed-incorporated-saw-its-shares-rise-more-than-7-in-the-session.-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/mei-pharma-inc.-meip-in-focus%3A-stock-up-12.1-tale-of-the-tape-2014-03-28", "https://www.nasdaq.com/articles/integra-lifesciences-introduces-wound-matrix-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/cvs-caremark-receives-fep-contract-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/fda-nod-for-biogens-alprolix-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/china-cord-blood-corporation-co-soars%3A-stock-up-5.7-tale-of-the-tape-2014-03-27", "https://www.nasdaq.com/articles/exelixis-cometriq-approved-in-the-eu-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/insmed-down-on-disappointing-arikayce-results-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/nektar-rises-on-fda-notification-revised-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/retrophin-rtrx-catches-eye%3A-stock-moves-7.9-higher-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-kythera-kyth-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/time-to-focus-on-alexion-alxn-for-strong-earnings-growth-potential-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/bristol-myers-deal-overshadows-q4-loss-at-five-prime-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/update-on-celgenes-product-portfolio-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/iyh-mdt-bax-alxn-etf-outflow-alert-2014-03-25", "https://www.nasdaq.com/articles/astrazenecas-forxiga-approved-in-japan-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/positive-chmp-opinion-for-novo-nordisks-drugs-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/japan-approves-medivation-astellas-xtandi-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-wfm-alxn-2014-03-25", "https://www.nasdaq.com/articles/sp-500-movers-alxn-frx-2014-03-24", "https://www.nasdaq.com/articles/galectin-therapeutics-inc.-galt-in-focus%3A-stock-moves-up-8.84-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/breakthrough-therapy-status-for-pfizers-drug-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-jumps%3A-stock-rises-7.2-tale-of-the-tape-2014-03-24", "https://www.nasdaq.com/articles/gilead-down-on-sovaldi-price-issue-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/are-biotech-stocks-oversold-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/trial-protocol-submission-lifts-heat-biologics-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/sinovac-biotech-sva-soars%3A-stock-rises-17.1-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/strength-seen-in-ziopharm-oncology-ziop%3A-stock-up-11.8-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-symc-2014-03-24", "https://www.nasdaq.com/articles/synta-pharmaceuticals-corp.-snta-catches-eye%3A-stock-jumps-9.5-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/qiagens-quantiferon-tb-test-now-in-china-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/glaxos-mage-a3-candidate-disappoints-again-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/good-news-for-johnson-johnson-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/aveo-regains-av-203-rights-from-biogen-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/favorable-data-for-myriad-genetics-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/positive-data-on-novo-nordisks-n8-gp-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/oncolytics-biotech-oncy-jumps%3A-stock-rises-5-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/prothena-surges-on-clinical-data-hopes-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/palatin-technologies-ptn-worth-watching%3A-stock-soars-15.6-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/synthetic-biologics-inc.-syn-in-focus%3A-stock-up-9.5-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/prothena-prta-jumps%3A-stock-rises-27.5-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/sequenom-sqnm-soars%3A-stock-rises-6.4-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-has-a-bright-short-term-future-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-up-6.1-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/update-from-celgene-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/horizon-pharma-to-buy-vidara-shares-rise-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/oncomeds-q4-loss-narrows-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/fate-reports-in-line-loss-in-q4-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-nvda-2014-03-19", "https://www.nasdaq.com/articles/intrexon-deal-update-overshadows-q4-loss-at-fibrocell-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/strength-seen-in-gtx-gtxi%3A-stock-moves-8.8-higher-tale-of-the-tape-2014-03-19", "https://www.nasdaq.com/articles/nektar-rises-on-fda-notification-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/genomic-health-unveils-oncotype-dx-data-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/prosensa-rises-on-encouraging-data-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/novo-nordisk-extends-diabetes-operations-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/medivation-astellas-seek-xtandi-label-expansion-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/biogen-faces-delay-in-fda-action-date-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/bristol-myers-five-prime-join-forces-shares-up-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/horizon-pharma-hznp-jumps%3A-stock-rises-5.6-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-relypsa-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/idenix-files-lawsuit-vs.-gilead-again-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/glaxo-theravance-update-on-copd-drugs-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/milestone-payment-for-ligand-pharma-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/repros-provides-proellex-update-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/pipeline-update-from-biodelivery-sciences-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/intercept-sees-weakness-in-earnings-result-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/amgen-scores-again-with-pcsk9-inhibitor-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/biogen-to-be-added-to-sp100-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-surges%3A-stock-moves-22.6-higher-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/update-on-glaxos-pipeline-analyst-blog-2014-03-17", "https://www.nasdaq.com/articles/raptor-pharma-posts-wider-than-expected-q4-loss-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/progenics-q4-loss-narrower-than-expected-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/revenues-decline-at-discovery-labs-in-q4-shares-down-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/narrower-than-expected-q4-loss-at-repros-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-soars%3A-stock-adds-9.6-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/aveo-q4-loss-narrower-than-expected-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/update-on-bayers-adempas-analyst-blog-2014-03-17", "https://www.nasdaq.com/articles/fate-therapeutics-prohema-in-phase-ii-study-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/astrazeneca-to-sell-cheshire-research-site-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/acura-pharmaceuticals-inc.-acur-in-focus%3A-stock-moves-7.7-higher-tale-of-the-tape-2014-03", "https://www.nasdaq.com/articles/bright-outlook-at-bayer-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/geron-plunges-on-fda-clinical-hold-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/bright-outlook-at-ligand-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/pdl-biopharma-expects-higher-q1-revenues-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/insmed-insm-looks-good%3A-stock-adds-5.9-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-regeneron-slide-pcsk9-inhibitor-concerns-analyst-blog-2014-03", "https://www.nasdaq.com/articles/enzymotec-ltd.-enzy-in-focus%3A-stock-up-5.2-tale-of-the-tape-2014-03-12", "https://www.nasdaq.com/articles/bayer-amgens-nexavar-fails-in-late-stage-study-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/glaxo-strengthens-indian-presence-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/phase-i-data-on-rexahns-supinoxin-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/chelsea-therapeutics-posts-wider-q4-loss-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/stock-market-news-for-march-11-2014-market-news-2014-03-11", "https://www.nasdaq.com/articles/iwr-act-alxn-dal-large-inflows-detected-etf-2014-03-12", "https://www.nasdaq.com/articles/focus-on-regulus-pipeline-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/kythera-regains-atx-101-from-bayer-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/regado-rises-on-reg1-fast-track-designation-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/alexion-lifts-2014-view-shares-up-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/mid-day-market-update-chiquita-gains-merger-news-cliffs-natural-shares-drop-2014-03-10", "https://www.nasdaq.com/articles/biogen-upgraded-to-strong-buy-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-mcdonalds-comparable-sales-fall-03-2014-03-10", "https://www.nasdaq.com/articles/igi-laboratories-inc.-ig-in-focus%3A-stock-up-11.7-tale-of-the-tape-2014-03-11", "https://www.nasdaq.com/articles/sector-update-health-care-2014-03-10", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-higher-pre-market-alexion-3-fiscal-2014-guidance-2014", "https://www.nasdaq.com/articles/strength-seen-in-ohr-pharmaceutical-inc.-ohrp-stock-shoots-22-tale-of-the-tape-2014-03-10", "https://www.nasdaq.com/articles/mid-afternoon-market-update-3d-printing-names-take-hit-barrons-piece-fuel-cell-names", "https://www.nasdaq.com/articles/mondays-etf-movers-xlv-gxc-2014-03-10", "https://www.nasdaq.com/articles/sp-500-movers-clf-fmc-2014-03-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-vod-alxn-2014-03-10", "https://www.nasdaq.com/articles/emergent-beats-on-earnings-revenues-shares-up-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/spectrum-pharma-posts-lower-y-y-q4-earnings-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-worth-watching%3A-stock-surges-17.1-tale-of-the-tape-2014-03-07", "https://www.nasdaq.com/articles/why-you-need-to-pay-attention-to-kamada-kmda-stock-tale-of-the-tape-2014-03-07", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/oncothyreon-onty-jumps%3A-stock-moves-9.9-higher-tale-of-the-tape-2014-03-06", "https://www.nasdaq.com/articles/osiris-misses-on-q4-earnings-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/regulatory-update-on-cubist-pharmas-tedizolid-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/sangamo-soars-on-positive-data-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-intermune-grabs-headlines-impressive-data-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/pipeline-setback-overshadows-xomas-q4-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/sunesis-snss-jumps%3A-stock-moves-6.8-higher-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/pdl-biopharma-misses-on-q4-earnings-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-rises-7.5-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/ovascience-ovas-in-focus%3A-stock-tanks-9.5-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc.-isis-in-focus%3A-stock-up-8.9-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/update-on-alexions-soliris-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/update-on-bayer-regenerons-eylea-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/theravance-to-split-in-q2-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/celldex-posts-narrower-than-expected-loss-in-q4-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/synageva-4q-loss-narrower-than-expected-loss-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-in-focus%3A-stock-tumbles-10.1-tale-of-the-tape-2014-03-04", "https://www.nasdaq.com/articles/top-mutual-funds-add-health-care-leisure-and-banks-2014-03-04", "https://www.nasdaq.com/articles/isis-pharma-slips-on-wider-than-expected-q4-loss-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/promising-data-on-merck-allergy-drug-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/bayer-up-on-higher-q4-earnings-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/are-these-biotechs-part-of-your-portfolio-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/transition-therapeutics-tthi-jumps%3A-stock-moves-7.6-higher-tale-of-the-tape-2014-03-03", "https://www.nasdaq.com/articles/glaxo-ligand-look-to-expand-promacta-label-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/eu-review-for-the-medicines-co.s-oritavancin-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/biogen-keeps-momentum-going-ms-drug-tecfidera-2014-03-03", "https://www.nasdaq.com/articles/earnings-decline-yoy-at-alkermes-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iwp-act-alxn-cci-2014-03-03", "https://www.nasdaq.com/articles/idenix-q4-loss-narrower-than-expected-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-nektar-guidance-disappoints-analyst-blog-2014-02-27", "https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-revenues-analyst-blog-2014-02-27", "https://www.nasdaq.com/articles/infinity-pharma-rises-on-narrower-than-expected-loss-analyst-blog-2014-02-26", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-up-9.3-tale-of-the-tape-2014-02-26", "https://www.nasdaq.com/articles/fda-clears-astrazenecas-myalept-analyst-blog-2014-02-26", "https://www.nasdaq.com/articles/no-looking-back-for-regenerons-eylea-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/arena-posts-wider-loss-misses-ests-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/idenix-q4-loss-narrower-than-expected-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/standard-review-for-mercks-v503-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/orphan-drug-for-alexions-soliris-in-eu-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/orphan-drug-status-for-xomas-gevokizumab-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/encouraging-news-from-pfizer-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/fda-designation-for-bristol-myers-candidate-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/progenics-to-raise-funds-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-vivus-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/stemline-therapeutics-stml-worth-watching%3A-stock-rises-8.1-tale-of-the-tape-2014-02-24", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-jumps%3A-stock-rises-17.3-tale-of-the-tape-2014-02-24", "https://www.nasdaq.com/articles/pipeline-progress-at-pluristem-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/pharmacyclics-attains-52-week-high-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/bull-day-alexion-pharma-alxn-bull-day-2014-02-24", "https://www.nasdaq.com/articles/isis-pharma-soars-on-positive-data-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/vertex-kalydeco-approved-for-an-additional-indication-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/encouraging-data-on-bristol-myers-pfizers-eliquis-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/xenoports-4q-loss-narrower-than-expected-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/bayer-progresses-with-stivarga-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/raptor-soars-on-positive-rp103-data-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/biomarin-rises-on-favorable-chmp-opinion-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/the-medicines-co-posts-lower-y-y-q4-earnings-analyst-blog-2014-02-20", "https://www.nasdaq.com/articles/synageva-biopharma-corp.-geva-in-focus%3A-stock-moves-5.1-higher-tale-of-the-tape-2014-02-20", "https://www.nasdaq.com/articles/dynavax-withdraws-maa-on-heplisav-analyst-blog-2014-02-20", "https://www.nasdaq.com/articles/pharmacyclics-beats-on-earnings-revenues-in-q4-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/interim-data-on-insmeds-arikace-analyst-blog-2014-02-20", "https://www.nasdaq.com/articles/pipeline-progress-at-bayer-analyst-blog-2014-02-20", "https://www.nasdaq.com/articles/mannkinds-q4-loss-wider-than-expected-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/nps-pharma-swings-to-earnings-on-strong-revenues-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/strong-2014-sales-guidance-from-biomarin-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/pipeline-update-at-bayer-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/positive-opinion-on-isis-pharmas-isis-ttrrx-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/pipeline-progress-at-regulus-analyst-blog-2014-02-20", "https://www.nasdaq.com/articles/aveo-astellas-terminate-agreement-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/acorda-up-after-q4-earnings-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/alnylam-widens-q4-loss-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/strength-seen-in-retrophin-rtrx%3A-stock-soars-49.8-tale-of-the-tape-2014-02-14", "https://www.nasdaq.com/articles/chelsea-therapeutics-chtp-in-focus%3A-stock-tumbles-7.5-tale-of-the-tape-2014-02-14", "https://www.nasdaq.com/articles/celgene-plans-stock-split-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/actelions-opsumit-cleared-in-switzerland-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/acura-pharmaceuticals-inc.-acur-looks-good%3A-stock-adds-5.1-in-session-tale-of-the-tape", "https://www.nasdaq.com/articles/qiagen-to-simplify-next-generation-sequencing-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/pharmacyclics-gains-on-imbruvica-label-expansion-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/ultragenyx-jumps-on-positive-patient-data-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/wider-than-expected-q4-loss-at-incyte-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/newlink-genetics-nlnk-jumps%3A-stock-rises-8.3-tale-of-the-tape-2014-02-11", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-falls%3A-stock-goes-down-5.4-tale-of-the-tape-2014-02-11", "https://www.nasdaq.com/articles/gilead-seeks-u.s.-approval-analyst-blog-2014-02-11", "https://www.nasdaq.com/articles/what-makes-genomic-health-ghdx-a-strong-sell-tale-of-the-tape-2014-02-13", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-alexion-alxn%3A-time-to-buy-tale-of-the-tape-2014-02-10", "https://www.nasdaq.com/articles/puma-biotech-surges-favorable-patent-ruling-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/loss-at-theravance-wider-than-expected-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/affymetrix-sees-turnaround-quarter-but-earnings-miss-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/myriad-genetics-inc.-mygn-soars%3A-stock-adds-15.1-in-session-tale-of-the-tape-2014-02-06", "https://www.nasdaq.com/articles/intermune-itmn-crumbles%3A-stock-falls-by-6.8-tale-of-the-tape-2014-02-06", "https://www.nasdaq.com/articles/medicines-co.-awarded-barda-contract-analyst-blog-2014-02-06", "https://www.nasdaq.com/articles/regeneron-beats-on-earnings-revenues-analyst-blog-2014-02-11", "https://www.nasdaq.com/articles/gilead-beats-on-earnings-revs-sovaldi-off-to-a-flier-analyst-blog-2014-02-05", "https://www.nasdaq.com/articles/alexion-alxn-shares-march-higher-can-it-continue-tale-of-the-tape-2014-02-05", "https://www.nasdaq.com/articles/linkedin-tripadvisor-google-top-managers-ideas-2014-02-04", "https://www.nasdaq.com/articles/roundtable-top-picks-week-feb-3rd-video-blog-2014-02-03", "https://www.nasdaq.com/articles/company-news-for-january-31-2014-corporate-summary-2014-01-31", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-inc-alxn-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/earnings-reaction-history-alexion-pharmaceuticals-inc-300-follow-through-indicator-42", "https://www.nasdaq.com/articles/cbs-takes-over-25-spot-alexion-pharmaceuticals-2014-02-05", "https://www.nasdaq.com/articles/will-alexions-alxn-earnings-streak-end-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/orphan-drug-status-for-alexions-solaris-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-spikes-data-alnylam-deal-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/prospects-bright-at-alexion-pharma-analyst-blog-2014-01-16", "https://www.nasdaq.com/articles/celldex-some-thoughts-rindopepimut-2013-12-19", "https://www.nasdaq.com/articles/update-on-alexions-voluntary-recall-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/safe-way-win-biotech-growth-2013-12-02", "https://www.nasdaq.com/articles/alexion-tops-on-earnings-revs-in-q4-analyst-blog-2014-01-30", "https://www.nasdaq.com/articles/will-alexions-alxn-earnings-streak-end-analyst-blog-2014-01-28", "https://www.nasdaq.com/articles/cubist-pharma-misses-on-earnings-and-revenues-in-q3-analyst-blog-2013-10-23", "https://www.nasdaq.com/articles/another-earnings-and-rev-beat-from-amgen-analyst-blog-2013-10-23", "https://www.nasdaq.com/articles/will-alexions-alxn-earnings-streak-end-analyst-blog-2013-10-22", "https://www.nasdaq.com/articles/illumina-tops-earnings-ups-guidance-analyst-blog-2013-10-22", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-10-21", "https://www.nasdaq.com/articles/encouraging-data-published-on-celgs-abraxane-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/celldex-whats-all-excitement-about-2013-10-30", "https://www.nasdaq.com/articles/positive-data-on-regn-sanofis-drug-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/nps-pharmas-gattex-looks-promising-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/qiagen-aids-genome-sequencing-study-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/acordas-label-expansion-efforts-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/mannkind-resubmits-afrezza-nda-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2013-10-15", "https://www.nasdaq.com/articles/bullish-on-gileads-stribild-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/update-on-portolas-pipeline-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/update-on-biodelivery-sciences-bunavail-analyst-blog-2013-10-11", "https://www.nasdaq.com/articles/ariad-shares-slip-on-clinical-hold-analyst-blog-2013-10-10", "https://www.nasdaq.com/articles/biomarin-to-raise-funds-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/encouraging-data-on-nps-pharmas-natpara-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/kythera-proposes-public-offering-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/good-news-for-apricus-from-germany-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/ilmn-expands-prenatal-test-offering-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/manufacturing-issues-hit-hospira-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/vertex-progresses-with-kalydeco-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/isis-pharma-gains-on-pipeline-news-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/pipeline-progress-at-alexion-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/sector-update-healthcare-stocks-flat-pre-market-isis-reports-phase-2-results-2013-09-23", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-23-0", "https://www.nasdaq.com/articles/encouraging-news-for-alexion-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/celgenes-pipeline-encourages-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/biotech-alexion-giant-tiny-orphan-market-2013-09-13", "https://www.nasdaq.com/articles/six-high-impact-sells-viking-global-investors-2013-08-26", "https://www.nasdaq.com/articles/voluntary-recall-at-alexion-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/alnylam-wins-orphan-drug-status-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/still-neutral-on-cubist-pharma-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/mannkind-to-raise-%2440m-from-deerfield-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/good-news-for-alnylam-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/data-from-alexions-soliris-study-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/positive-data-on-mannkinds-afrezza-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-mannkind-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-366995-984-points-2013-08-12", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-361647-1733-points-2013-07-30", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-alexion-pharmaceuticals-inc.-alxn-tale-of-the-tape-2013-07", "https://www.nasdaq.com/articles/earnings-beat-at-alexion-view-upped-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/year-over-year-rise-in-celgene-earnings-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/ceo-alexion-pharmaceuticals-inc-leonard-bell-sold-140000-shares-2013-08-19", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-360008-2178-points-2013-07-12", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-352076-1650-points-2013-07-10", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-337622-2833-points-2013-06-26", "https://www.nasdaq.com/articles/gilead-retained-at-neutral-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/evenly-poised-on-regeneron-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/theravances-vibativ-expanded-in-the-us-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/gilead-presents-idelalisib-data-analyst-blog-2013-06-19", "https://www.nasdaq.com/articles/will-alexion-alxn-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/amgens-oncology-drug-meets-primary-endpoint-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/encouraging-data-on-alexions-soliris-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/label-expanded-for-celgs-revlimid-analyst-blog-2013-06-07", "https://www.nasdaq.com/articles/encouraging-data-from-bristol-myers-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/celgene-presents-data-at-asco-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/chmp-backs-celgenes-pomalyst-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/amgen-xgeva-label-expanded-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/omeros-files-cta-for-ahus-candidate-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/amgen-astellas-collaborate-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/encouraging-data-from-alkermes-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/eu-approval-for-bayer-jnjs-xarelto-analyst-blog-2013-05-28", "https://www.nasdaq.com/articles/priority-fda-review-for-celgenes-abraxane-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/positive-data-on-bayer-candidate-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/alkermes-reports-earnings-for-q4-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/biogen-delays-eu-launch-of-tecfidera-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/bayer-files-riociguat-in-japan-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/biogens-hemophilia-bla-accepted-analyst-blog-2013-05-20", "https://www.nasdaq.com/articles/bayers-xofigo-cleared-in-the-us-analyst-blog-2013-05-16", "https://www.nasdaq.com/articles/earnings-beat-at-alexion-ups-view-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/omeros-oms721-files-for-orphan-drug-status-analyst-blog-2013-04-18", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-323917-down-2835-points-2013-04-01", "https://www.nasdaq.com/articles/bad-news-for-alexion-shares-down-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/yet-another-acquisition-for-bayer-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/alexion-pharma-upgraded-to-outperform-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-todays-most-compelling-buy-2013-03-14", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-318203-1229-points-2013-03-04", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-313149-down-3292-points-2013-02-21", "https://www.nasdaq.com/articles/positive-data-from-bmrns-pku-016-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/update-on-peregrines-bavituximab-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-321359-2156-points-2013-02-19", "https://www.nasdaq.com/articles/moving-averages-indicate-these-sector-etfs-could-be-stretched-2013-03-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-14-2013-pep-gm-apa-abx-dtv-cve-ppl-alxn-slf-wm-regn", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-315367-1049-points-2013-01-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-311226-9275-points-2013-01-02", "https://www.nasdaq.com/articles/short-interest-swings-biotech-stocks-biib-celg-vvus-2012-12-12", "https://www.nasdaq.com/articles/time-consider-pure-growth-and-value-etfs-etf-news-and-commentary-2012-12-04", "https://www.nasdaq.com/articles/alexion-pharma-evenly-poised-analyst-blog-2012-12-03", "https://www.nasdaq.com/articles/positive-data-on-cytks-tirasemtiv-analyst-blog-2012-11-27", "https://www.nasdaq.com/articles/alexion-4q-tops-on-both-lines-analyst-blog-2013-02-14", "https://www.nasdaq.com/articles/dont-stay-married-old-leaders-target-new-leadership-2012-11-02", "https://www.nasdaq.com/articles/ibd-chairman-william-oneil-supercycle-bull-may-arrive-2012-10-30", "https://www.nasdaq.com/articles/short-interest-swings-biotech-stocks-biib-gild-vvus-2012-10-25", "https://www.nasdaq.com/articles/strong-quarter-at-alexion-analyst-blog-2012-10-24", "https://www.nasdaq.com/articles/short-interest-swings-biotech-stocks-biib-celg-gild-2012-10-15", "https://www.nasdaq.com/articles/top-funds-favor-health-care-retail-recent-buys-alxn-ctrx-2012-10-02", "https://www.nasdaq.com/articles/weekly-top-insider-sells-goog-kss-alxn-and-qcom-2012-09-03", "https://www.nasdaq.com/articles/reshuffling-lineup-health-care-model-2012-11-19", "https://www.nasdaq.com/articles/alexion-beats-raises-guidance-analyst-blog-2012-07-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-25-2012-bmy-ba-alxn-armh-arg-ati-aol-bku-avx-alr-mt-atmi", "https://www.nasdaq.com/articles/top-performing-funds-add-shares-health-care-stocks-2012-07-03", "https://www.nasdaq.com/articles/alexion-presents-new-data-analyst-blog-2012-06-19", "https://www.nasdaq.com/articles/weekly-top-insider-sells-goog-yhoo-alxn-and-ctl-2012-06-04", "https://www.nasdaq.com/articles/after-hours-most-active-may-24-2012-ep-kmi-alxn-s-xrx-glw-wmb-qqq-orcl-fb-teva-tibx-2012", "https://www.nasdaq.com/articles/alexion-downgraded-to-neutral-analyst-blog-2012-05-17", "https://www.nasdaq.com/articles/top-performing-funds-latch-biotech-and-discount-retail-stocks-2012-08-02", "https://www.nasdaq.com/articles/zacks-bull-and-bear-of-the-day-highlights%3A-alexion-pharmaceuticals-csn-cbs-news", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-bull-of-the-day-2012-04-19", "https://www.nasdaq.com/articles/alexion-is-an-outperformer-analyst-blog-2012-04-17", "https://www.nasdaq.com/articles/etfs-momentum-stocks-fbt-pnqi-hdge-2012-04-10", "https://www.nasdaq.com/articles/risk-reward-balanced-at-alexion-analyst-blog-2012-02-21", "https://www.nasdaq.com/articles/alexion-exits-2011-on-a-strong-note-analyst-blog-2012-02-10", "https://www.nasdaq.com/articles/alexion-takes-over-enobia-pharma-analyst-blog-2012-02-08", "https://www.nasdaq.com/articles/alexion-beats-raises-outlook-analyst-blog-2012-04-26", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2011-12-20", "https://www.nasdaq.com/articles/should-traders-fade-strength-europe-2011-11-29", "https://www.nasdaq.com/articles/black-friday-buying-and-nasdaq-bargains-2011-11-25", "https://www.nasdaq.com/articles/top-five-companies-worth-second-look-2012-2011-11-15", "https://www.nasdaq.com/articles/momentum-ideas-top-7-rallies-keep-your-radar-2011-11-03", "https://www.nasdaq.com/articles/opening-view-djia-spx-cautiously-higher-wall-street-eyes-euro-zone-earnings-2011-10-20", "https://www.nasdaq.com/articles/vix-index-top-10-debt-free-stocks-protect-your-portfolio-extreme-volatility-2011-08-03", "https://www.nasdaq.com/articles/alexion-cut-to-neutral-analyst-blog-2011-12-27", "https://www.nasdaq.com/articles/medical-breakthrough-successful-stem-cell-transplant-sweden-2011-07-08", "https://www.nasdaq.com/articles/options-ideas-24-healthcare-stocks-bullish-options-sentiment-2011-06-07", "https://www.nasdaq.com/articles/12-takeover-targets-seeing-worsening-analyst-sentiment-2011-01-20", "https://www.nasdaq.com/articles/two-stocks-e-reading-revolution-2010-10-22", "https://www.nasdaq.com/articles/healthcare-takeovers-targets-express-scripts-buys-medco-2011-07-22"], "Content": []}